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- SUMMARY - 
 
 
Understanding the molecular mechanism regulating angiogenesis is an essential aspect of 
pathology of many diseases. Recent evidences implicate membrane-type 1 matrix metalloprotease 
(MT1-MMP), a potent pericellular enzyme expressed by vascular cells, in inflammation and 
angiogenesis. This work aimed to explore the MT1-MMP’s contribution to inflammatory-induced 
angiogenesis, formation of new vessels from preexisting ones. To accomplish this, we applied 
quantitative proteomic technique named SILAC to TNFα-activated endothelial cells derived from 
wildtype and MT1-MMP null mice to identify the substrate repertoire of this protease and identify 
candidates that might affect capillary sprouting within the inflammatory context. We found that 
TNFα activated endothelial cells and induced expression of several markers characteristic for 
endothelial tip cells, the main effectors of sprouting angiogenesis. Moreover, MT1-MMP 
expression was upregulated after TNFα pulse, accompanied by differences in supernatant 
glycoproteome between wildtype and MT1-MMP null endothelial cells. Glycoproteins identified as 
putative MT1-MMP substrates include key extracellular matrix, matricellular and secreted proteins 
such TSP1, NID1, CYR61, SEM3C or SLIT2 as well as cytokines and growth factors like EGFR 
and CSF1. Bioinformatic analysis revealed a combinatorial MT1-MMP proteolytic program, in 
which combined rather than single substrate processing would determine biological decisions by 
activated endothelial cells, including chemotaxis, cell motility and adhesion, and vasculature 
development. Processing of TSP1, CYR61, NID1 and SEM3C was impaired in MT1-MMP-
deficient animals leading to reduce angiogenic response. The relevance of this MT1-MMP-driven 
proteolytic program was observed in pathology in aberrant angiogenesis related to chronic 
inflammatory disorders as inflammatory bowel disease (IBD). Using an experimental model of 
mouse colitis we showed soluble levels of TSP1 and NID1 were increased and positively correlated 
with MT1-MMP expression. Impaired processing of these substrates was also observed in human 
serum samples from patients with low/moderate activity of ulcerative colitis or Crohn’s disease.  
Taken together, these data illustrate that MT1-MMP is an important regulator of 
inflammatory-induced angiogenic response in endothelial cells and that substrates processed by this 
protease, such as TSP1 and NID1 might be used as a biomarkers for the diagnosis or prognosis of 
chronic inflammatory disorders.  
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- RESUMEN - 
 
Entender los mecanismos moleculares que regulan la angiogénesis es un aspecto esencial 
en la patología de numerosas enfermedades. La metaloproteasa de matriz extracelular de membrana 
tipo 1 (MT1-MMP) es una potente enzima pericelular expresada por las células vasculares. Este 
trabajo ha explorado la contribución de MT1-MMP en la angiogénesis, formación de nuevos vasos 
a partir de vasculatura pre-existente, en el contexto inflamatorio. Para ello, se ha aplicado la técnica 
de proteómica cuantitativa denominada SILAC en células endoteliales derivadas de ratones de 
genotipo silvestre o deficientes en MT1-MMP; estas células endoteliales se han activado con la 
citoquina inflamatoria TNFα con objeto de identificar el repertorio de sustratos de MT1-MMP e 
identificar candidatos que podrían afectar la respuesta angiogénica en inflamación. Hemos 
demostrado que TNFα activaba las células endoteliales e inducía la expresión de varios marcadores 
característicos de células endoteliales líder (tip). El tratamiento con TNFα también aumentaba la 
expresión de la proteasa MT1-MMP en las células endoteliales lo que correlacionaba con 
diferencias en el glicoproteoma del sobrenadante de cultivo de células endoteliales de genotipo 
silvestre versus deficientes en MT1-MMP. Las glicoproteínas identificadas como sustratos 
potenciales de MT1-MMP incluyen proteínas de la matriz extracelular, proteínas matricelulares y 
proteínas secretadas como TSP1, CYR61, NID1, SEM3C o SLIT2 así como citoquinas y factores 
de crecimiento como EGFR y CSF1. El análisis bioinformático de los datos proteómicos ha 
desvelado un programa proteolítico combinatorial, en el cual el procesamiento combinado de 
varios sustratos por MT1-MMP en vez del procesamiento de sustratos individuales es el que 
determina las decisiones biológicas de las células endoteliales activadas tales como quimiotaxis, 
motilidad y adhesión celular, y desarrollo vascular. Hemos confirmado que el procesamiento de 
TSP1, CYR61, NID1 y SEM3C está disminuido tanto en células como en ratones deficientes en 
MT1-MMP lo que correlaciona con una reducción de la respuesta angiogénica. Por último, hemos 
investigado la importancia de este programa proteolítico mediado por MT1-MMP en patologías 
que cursan con angiogénesis inflamatoria, en concreto en enfermedad inflamatoria intestinal. 
Utilizando un modelo de colitis experimental en ratón hemos observado que los niveles solubles en 
suero de los sustratos TSP1 y NID1 aumentan en correlación con la expresión de MT1-MMP a lo 
largo de la severidad de la colitis. Además, en muestras de suero procedentes de pacientes con 
colitis ulcerosa o enfermedad de Crohn con actividad baja/moderada también se observa un 
aumento en los niveles de TSP1 y NID1.  
En conclusión, nuestros datos demuestran la importancia de MT1-MMP como proteasa 
reguladora de la angiogénesis inflamatoria en células endoteliales e indican que sustratos 
procesados por MT1-MMP como TSP1 o NID1 pueden servir como biomarcadores para el 
diagnóstico o pronóstico de enfermedades inflamatorias crónicas.  
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- NON-STANDARD ABBREVIATIONS AND ACRONYMS - 
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- MORPHOGENESIS OF THE VASCULAR SYSTEM - 
 
The vascular network penetrates whole body to supply tissues with nutrients and oxygen 
and provide signaling molecules and immune cells. The mechanism by which blood vessels form 
involves three main processes: VASCULOGENESIS, ANGIOGENESIS (sprouting and intussusception) and 
VASCULAR REMODELLING (Risau 1997). VASCULOGENESIS refers mostly to the embryonic stage when 
the first primitive vascular structures are being formed from endothelial progenitors, although it 
may also occur in cancer (Carmeliet 2003). It is characterized by primitive vascular endothelial 
cells (angioblasts) that migrate to the sites of vascularization, differentiate and form the initial 
vascular plexus (Risau 1995, 1997).  
ANGIOGENESIS is referred to formation of new capillaries from pre-existing ones and is 
driven by highly invasive endothelial cells (ECs), called the tip cells. Once the nascent vascular 
plexus is formed, these specialized endothelial cells proliferate and migrate forming new capillaries 
that branch from existing vessels. Tip cells selection is controlled by the Notch pathway (Hellström 
et al. 2007) and their migration depends on a gradient of VEGF, a master regulator of angiogenesis 
(Gerhardt et al. 2003). Growth of the vascular network is a highly dynamic process with several 
main mechanisms including: (1) sprouting, (2) anastomosis, (3) lumenization and (4) pruning. The 
earliest steps include activation of part of endothelial cells (tip cells), loosening of cell junction 
integrity, basement membrane degradation and invasion of tip cells to initiate first sprout. Once 
filopodia-extending tip cells reach other sprout or nearby vessel they connect (anastomose) 
followed by lumen assembly to create new functional vessel. Subsequent recruitment of mural cells 
and basement membrane deposition stabilize newly formed connections (R. H. Adams and 
Eichmann 2010) and excess of redundant branches is removed (pruning). Term “VASCULAR 
REMODELLING” is commonly used to refer to the later phase of blood vessels formation when vessels 
increase its luminal diameter in response to increased blood flow and acquires identity as artery, 
vein or capillary.  
Angiogenesis occurs at later embryonic and postnatal stages where appears to be the main 
process for the formation of the majority of blood vessels. In adult organism in physiologic 
conditions vasculature is stable, but in situations such as tissue repair or pathological disease 
processes, ECs become again motile and invasive letting the vessels growth and expand (Figure 
1A).  
 
Principal cellular players in angiogenesis 
Several cell types are actively involved in the process of new vessel formation. Endothelial 
cells, together with pericytes form a highly specialized, dynamic interface between the blood and 
the surrounding tissue (Figure 1A). Apart of ECs, fibroblasts, epithelial, mesenchymal or 
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microglial cell can regulate angiogenesis by either releasing pro- or antiangiogenic stimuli or 
providing physical support by enwrapping nascent tubules and promoting their stability (Rymo et 
al. 2011). During vessel formation in retinal development astrocytes apart of secreting VEGF-A, 
the main proangiogenic factor, spread at the vascular front providing a sort of scaffold on which 
ECs migrate (Gerhardt et al. 2003; Stone et al. 1995). Recent studies demonstrate that also 
leukocytes and macrophages are universal players associated with physiologic and pathologic 
angiogenesis acting as suppliers of angiogenic cytokines like M-SCF and placenta growth factor 
(PlGF) or as physical support for branching and anastomosis (Fantin et al. 2010; Y. Kubota et al. 
2009; Luttun et al. 2002; Pipp et al. 2003). Although all these cell types contribute to the correct 
functioning of the vasculature and directly or indirectly participate in angiogenesis, only the 
vascular endothelial cells are thought to be the key players regulating the process of vascular 
network formation. 
 
  
 
Figure 1.   Cell interplay in the vascular system in homeostatic and inflammatory conditions. (A) In 
homeostatic conditions endothelial cells (ECs), vascular smooth muscle cells (VSMCs)/pericytes and 
macrophages promote normal functioning of the vasculature (left). Upon inflammation, macrophages release 
soluble cytokines and growth factors such as TNFα that induces morphological and phenotypic changes in 
ECs, VSMCs and macrophages aimed at resolution of the injury (right). (B) Activated endothelium consists 
of tip cells that lead and guide new sprout, highly proliferative stalk cells and phalanx cells maintaining 
vessel stability.  
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In adults ECs maintain plasticity required for specific morphogenetic responses upon 
proangiogenic stimulus. There are three types of ECs involved in angiogenesis: PHALANX, STALK and 
TIP endothelial cells (Figure 1B). Phalanx cells mostly remain quiescent, resemble cobblestone 
appearance and together with stalk cells are covered by pericytes and basement membrane to 
maintain structural and functional integrity of the vessel (Mazzone et al. 2009). Moreover, stalk 
cells are highly proliferative and provide new ECs for vessel elongation and support lumen 
formation. In contrast, tip cells, located at the distal end of sprouts are motile and polarized with 
multiple protrusions. They are attracted by proangiogenic stimuli, which induce directional 
migration and invasion of surrounding tissue and fuse with neighboring sprouts in process termed 
anastomosis (Geudens and Gerhardt 2011). Tip cells do not have lumen and usually do not 
proliferate; they have also different gene expression profile from stalk and phalanx cells, 
characterized by high levels of VEGFR2 (Gerhardt et al. 2003). The tip/stalk selection is transient 
and reversible with continuous shuffling regulated by VEGFR-Dll4-Notch signaling (Jakobsson et 
al. 2010). At final steps of new vessel formation recruitment of mural cells like pericytes and 
vascular smooth muscle cells stabilize vessel and promote their maturation (Armulik et al. 2005; 
Betsholtz et al. 2005). Vascular pruning and remodeling finish the process of vascular 
morphogenesis and convert these new vessels in stable and quiescent vasculature (Baluk et al. 
2004; Rocha and Adams 2009). 
 
Molecular regulation of angiogenesis 
The master regulator of both physiologic and pathologic vessel growth is VEGF; a mitogen 
specific to ECs but expressed also by many other cell types including macrophages and cancer cells 
(Ferrara 1999; Salgado et al. 2001). The effect of VEGF depends on the presence of specific 
receptors localized on activated endothelium – VEGFR1 on stalk or VEGFR2 and VEGFR3 on tip 
cells {Phng, 2009, Angiogenesis: a team effort coordinated by notch}. Activation of these receptors 
causes increased permeability of blood vessels, activation and migration of endothelium (Figure 1 
and 2). Tip cells migrate towards increased VEGF gradient, whereas stalk cells upregulate 
proliferation in response to high VEGF concentration (De Smet et al. 2009; Gerhardt et al. 2003). 
Moreover VEGF induces filopodia formation through Cdc42 activation (De Smet et al. 2009). 
Other cytokines such as FGF, HGF, IL-8, PDGF and family of CXC chemokines have been also 
classified as direct proangiogenic factors, stimulating degradation of extracellular matrix, EC 
migration and proliferation. Another group of angiogenesis stimulating agents in paracrine way are 
able to stimulate proper ECs to produce and release direct stimulus (Salgado 2001). Among them 
are IL-6, TGF-β, prostaglandins, angiopoietins, G-CSF, GM-CSF, SCF and other (Heidemann 
2003). 
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Despite high local concentration of VEGF or other proangiogenic stimuli, not all ECs will 
acquire tip cell phenotype. This fate selection is strongly controlled by the Notch pathway (Figure 
2) (Eilken and Adams 2010; Phng and Gerhardt 2009; Roca and Adams 2007). VEGF induces high 
expression levels of Delta-like 4 (Dll4), one of the Notch ligands, in tip cells, which in turn activate 
Notch in neighboring stalk cells and suppress the tip phenotype by downregulation of VEGFR2 
and -3 (Benedito et al. 2009; Hellström et al. 2007; Suchting et al. 2007). Stalk cells in contrast 
express high levels of another Notch ligand, Jagged1 (Jag1), a Dll4 antagonist, which induces 
sprouting and inhibit Notch signals in tip cells (R. H. Adams and Eichmann 2010; Benedito et al. 
2009). Balanced signaling between Dll4 and Jag1 maintain dynamic and reversible tip/stalk 
phenotype acquired by vascular endothelial cells. 
 
 
Figure 2.  Tip cell selection is controlled through Notch 
signalling. Tip cells respond to the to high VEGF gradient, 
which induces high expression levels of Dll4, one of the 
Notch ligands, in tip cells, which in turn activate Notch in 
neighboring stalk cells and suppress the tip phenotype by 
downregulation of VEGFR2 and -3 and increased 
proliferation of other EC that will become stalk cells. 
Strong expression of Jagg1 in stalk cell antagonizes Dll4-
mediated activation of Notch on neighboring tip ECs. 
 
 
 
 
 
Inflammation-driven angiogenesis 
In the postnatal life of healthy organisms angiogenesis is not a common phenomenon. 
Proliferation of endothelium is slow and its turnover takes over three years (Denekamp 1984). 
Activation of the angiogenic process requires local change of equilibrium between stimulating and 
inhibitory agents of vascular network growth. In healthy adult individuals the balance between pro- 
and antiangiogenic factors in clearly leaning on the part of the latters (Pepper et al. 1996). 
Inflammatory response can often activate angiogenesis in several ways. First, vessels permeability 
and enhanced leukocyte transmigration to the inflamed tissue, which produce angiogenic factors 
can stimulate vessel growth. Furthermore, released by activated leukocytes/macrophages 
proinflammatory cytokines stimulate VEGF mRNA expression (Ferrara 1999). Second, increased 
blood influx itself can stimulate angiogenesis through shear stress on the endothelium (Schaper and 
Scholz 2003). Finally, hypoxic condition in the inflamed tissue can induce angiogenesis through 
upregulation of VEGF, TNFα or bFGF (Taylor and Sivakumar 2005). Normally angiogenesis that 
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occurs in acute inflammation is beneficial to its resolution, however if angiogenesis persists might 
contribute to induction of chronic inflammatory disease. This pathologic angiogenesis is 
considered an important indicator of pathogenesis in many diseases like connective tissue disorders 
such as psoriasis, rheumatoid arthritis, in gastric disorders (inflammatory bowel disease), 
cardiovascular diseases (artherosclerosis) and neuroinfection, diabetes or cancer (Folkman 1995a, 
1995b). Thus the importance of angiogenesis in chronic inflammatory diseases raised a possibility 
of antiangiogenic therapies. Most of them are based on blocking VEGF or PDGFβ receptors, 
nonetheless only a part of patients may benefit from antiantiogenic therapies, thus there is a raising 
need of successful improvement and search of new targets (Crawford and Ferrara 2009; Potente et 
al. 2011).  
 
 
- MMP FAMILY OF PROTEASES - 
 
Fundamental to the angiogenic process is the ability of endothelial cells to degrade 
extracellular matrix and surrounding blood vessels basement membrane. The family of matrix 
metalloproteases (MMPs) play in this process substantial role principally due to they capability of 
degrading surrounding tissues during initial steps of sprouting; however new functions for this 
enzymes have been described recently.  
Since their discovery by Gross and Lapierre (GROSS and LAPIERE 1962) matrix 
metalloproteases have been an object of intensive studies due to their crucial contribution to a 
variety of physiological and pathological processes. MMP family consists of Zn2+-dependent 
endopeptidases, composed by at least by 23 members in humans and 24 in mice (Page-McCaw et 
al. 2007), which share a conserved domain structure and function, and collectively are capable to 
degrade almost any kind of extracellular matrix (ECM) components. 
Nowadays, it is recognized that MMPs functions are extended beyond breaking down the 
surrounding extracellular matrix. As a result of pericellular proteolysis matrix-bound protein 
fragments or growth factors can be released from matrix by ectodomain shedding or secreted 
proteins (e.g. cytokines, other enzymes) can be activated, deactivated or modified their biological 
activity. Thus MMPs can not only regulate tissue architecture but also can directly alter the 
availability of bioactive molecules and trigger signaling cascades (Page-McCaw et al. 2007; 
Sternlicht and Werb 2001). In addition, some of MMP members can impact cellular behavior by 
regulation of gene transcription in as yet undefined manner (Toriseva et al. 2012). This process is 
more evident in membrane-inserted MMPs in which their short cytosolic tail can regulate 
intracellular signaling by interaction with a number of partners or by undergoing posttranslational 
modifications thus affecting cell migration, invasiveness, intracellular trafficking, gene 
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transcription and protein expression (Gingras and Béliveau 2010). These aspects will be detailed in 
further paragraphs.  
 
MMPs as multifunctional enzymes  
The ability of cells to migrate into tridimensional complex matrices and invade 
surrounding tissues is achieved thanks to proteases and protease-like proteins. Among 553 human 
proteases, the most numerous is the family of metalloproteases and in particular MMPs play a 
fundamental role in this process (Puente et al. 2003).  
Tissue remodeling occurring during embryonic growth and development are events that 
require MMPs’ activity to break basement membrane and ECM to allow cell to proliferate, migrate 
and growth. Analysis of genetic knockouts of MMPs provided additional information about 
functions and substrates of each MMP. Surprisingly, no gestation lethality was observed in any of 
MMPs’ knockout mice, suggesting a high grade of compensation and redundancy among the whole 
family. In contrast, individual MMP adult mutants show serious defects related to failed tissue 
remodeling. Several MMP knock out mice (MMP-2, -9, -13, -14, -20) present bone and skeletal 
remodeling defects demonstrated in reduced endochondral ossification, delayed healing of bone 
fractures, failed transition from cartilage to bone, abnormal bone resorption, secondary ossification 
centers and defective tooth enamel (Caterina et al. 2002; Colnot et al. 2003; Holmbeck et al. 1999; 
Holmbeck et al. 2003; Holmbeck et al. 2005; Inada et al. 2004; Stickens et al. 2004; Vu et al. 1998; 
Zhou et al. 2000). So far the most severe phenotype was decribed for MMP-14 knockout mice that 
die postnatal (Holmbeck et al. 1999; Zhou et al. 2000). In addition, MMP-2-MMP-14 double 
knockout mice die at birth indicating that MMP-2 and MMP-14 have overlapping functions (Oh et 
al. 2001). 
In addition to their classical degradative activity, various MMPs are involved in 
development during embryonic and postnatal life. MMP-2 and -3 are implicated in postnatal 
mammary development by regulating mammary gland branching morphogenesis during puberty 
(Wiseman et al. 2003).  
 
Role of MMPs in inflammation and angiogenesis  
MMPs are also important in tissue homeostasis, regulating processes like wound healing, 
inflammation or angiogenesis. MMP-7 knockout mice display defective innate intestinal immunity 
manifesting susceptibility to bacterial infection due to impaired proteolysis of endogenous 
antibiotic peptide pro-cryptdin (Wilson et al. 1999). In addition, MMP-7 mutant mice exhibit 
abnormal chemokine release from lung epithelium (neutrophil attractant CXC-motif ligand-1) 
resulting in defective recruitment of inflammatory cells after lung injury (Li et al. 2002). Pro- and 
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anti-inflammatory properties were showed for MMP-2 and MMP-9; which can guide inflammatory 
cell recruitment and clearance of inflammatory cells by cleaving of inflammatory mediators like 
MCP3, CXCL1, CXCL4, CXCL6, CXCL8, CXCL12 (D'Haese et al. 2000; Kumagai et al. 1999; 
McQuibban et al. 2002; Overall 2002; Van den Steen et al. 2000). Finally, several MMP mutant 
mice exhibit defects in blood vessel remodeling observed only at the postnatal stage both in normal 
and pathological conditions. Nevertheless, role of MMPs in angiogenesis is complex, and similarly 
to their impact on inflammation, they may act in both ways: either promoting or inhibiting new 
vessel formation. It has been widely described the relevance of these enzymes in tumor 
angiogenesis. Increased MMPs’ activity can enhance carcinogenesis by processing and activation 
of proangiogenic factors like VEGF, bFGF and TGF-β (Belotti et al. 2003; Bergers et al. 2000; 
Deryugina et al. 2002a; Sounni et al. 2002; Yu and Stamenkovic 2000). In particular, MMP-9 
mutant mice have defects in neovascularization at the growth plates of long bones and in response 
to injury model of retinal degeneration (Lambert et al. 2003; Vu et al. 1998). This latter, was also 
observed in MMP-2 knockouts and even strongly in MMP-2 MMP-9 double mutant indicating the 
redundant effect of those two MMPs. The unique exception of this general rule is observed in 
MMP-8 knockout mice, which in absence of protease strongly increase the evidence of skin tumors 
(Balbín et al. 2003). Likely mechanism through which MMPs contribute to angiogenesis includes 
overexpression of protease in vascular cells (macrophages and endothelial cells) under tumorigenic 
conditions and thus increased processing of basement membrane, in particular collagen I, 
promoting cell migration, processing and modulation of activity of signaling molecules (e.g. 
VEGF, PDGF) and regulating perivascular cells coverage (Bergers et al. 2000; Chantrain et al. 
2004; Galvez et al. 2001; Hiratsuka et al. 2002; P. H. Huang et al. 2009; Johnson et al. 2004). 
However, the contrary effect to these proangiogenic MMPs functions was recently described for 
several proteases. Using again an example of MMP-9, proteolysis of type IV collagen lead to 
release tumstatin protein with suppressive consequence on pathological angiogenesis (Hamano et 
al. 2003). Moreover several MMPs are able to cleave precursors of angiostatin, endostatin or 
thrombospondins known endogenous inhibitors of angiogenesis (J. C. Adams 2004; Cornelius et al. 
1998; Rodriguez-Manzaneque et al. 2001).  
Lack of any of this angiogenic drawback at the embryonic stage of knock out mice which 
born with normal vasculature suggest that role of MMPs are mostly attributed to postnatal 
angiogenesis and remodeling.  
 
MMPs in human disease models 
Apart of an evident implication in cancer, diverse human diseases were associated with 
various MMP-loss-of-function mutations: a rare osteolytic syndrome, Missouri variant of 
spondyloepimetaphyseal dysplasia (SEMD), and the tooth enamel defect amelogenesis imperfecta, 
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are caused by point MMP-13, MMP-20 and MMP-2 mutations (Kennedy et al. 2005; Kim et al. 
2005; Martignetti et al. 2001). Similarly, homozygous mutations in MMP-14 are responsible for 
human Winchester syndrome, one of examples of “vanishing bone” disorders (Evans et al. 2012). 
Other data based on mouse models indicates implication of MMPs to inflammatory-related 
pathologies such as asthma and lung inflammation, stroke, heart attack, Alzheimer’s disease and 
aortic aneurysm. Also skin, kidney and brain inflammation have been shown the great implications 
of MMPs (Egeblad and Werb 2002; Page-McCaw et al. 2007; Siefert and Sarkar 2012).  
 
Domain structure and classification 
The first classification and nomenclature of MMP family was based on the principal 
substrate that a particular MMP processed, thus we could distinguish collagenases (MMP-1, MMP-
8, MMP-13, MMP-18), gelatinases (MMP-2, MMP-9), stromelysins (MMP-3, MMP-10, MMP-11) 
and matrilysins (MMP-7, MMP-26). Results of more recent works unified the MMP nomenclature, 
as it is well known that each MMP degrades a range of substrates, in fact there is considerable 
substrate overlapping between individual MMPs (Cauwe et al. 2007; GROSS and LAPIERE 1962; 
Overall et al. 2002; Rawlings et al. 2006).  
With minimal variations, all MMPs share the same domain structure that contains from the 
N-terminus: directing their secretion a SIGNAL PEPTIDE, a PRODOMAIN necessary to maintain enzyme 
latency, and the conserved CATALYTIC DOMAIN. Depending of each subfamily MMPs optionally 
possess HEMOPEXIN-LIKE DOMAIN that define substrate specificity, and in case of membrane-tethered 
members TRANSMEMBRANE DOMAIN or GLYCOSYLPHOPHATIDYLINOSITOL (GPI) LINK and a CYTOSOLIC TAIL 
at the C-terminus (Folgueras et al. 2004; Overall et al. 2002).  
MMPs, like most proteolytic enzymes are synthesized and released as inactive proenzymes 
or zymogens. MMPs activation occurs through several mechanisms; in vitro a variety of agents like 
mercurial and thiol modifying compounds, reactive oxygen radicals, denaturant agents as well as 
low pH and high temperature can drive the proenzyme activation (Nagase 1997). This mechanism, 
known as the cysteine-switch model, where interaction between the thiol group of a pro-domain 
cysteine residue and the zinc ion of the catalytic site is being disrupted (Van Wart and Birkedal-
Hansen 1990). In vivo, MMPs form part of proteolytic cascade, where cleavage of N-terminal pro-
peptide is done by other protease (Sato et al. 1994; Strongin et al. 1995). In addition, some MMPs 
possesses a furin-like recognition sequence (RXKR or RRKR) between the pro- and catalytic 
domains which is cleaved intracellular by furin-like convertases (Yana and Weiss 2000; Zucker et 
al. 2003).  
MMPs are expressed by most of the normal and tumor cells and its expression and activity 
is regulated at several levels from upon mentioned proteolytic activation, gene transcription 
(controlled by cytokines and growth factors), by posttranslational modifications (e.g. 
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phosphorylation, palmitoylation) or directly by interaction with ECM components or other cells 
(Anilkumar et al. 2005; Biswas et al. 1995; Nagase and Woessner 1999; Nyalendo et al. 2007).  
Under physiological conditions exists an equilibrium between proteolytic degradation and 
inhibition of proteolysis, precisely controlled by a group of specific broad-spectrum inhibitors 
TIMPs (tissue inhibitors of metalloproteases); those are expressed as soluble proteins (TIMP-1, -2, 
-4) or associated with ECM (TIMP-3) and block MMPs’ activity by forming complexes with their 
catalytic site (Borden and Heller 1997; Nagase et al. 2006; Visse and Nagase 2003; Westermarck 
and Kähäri 1999). Apart of TIMPs, MMPs activity can be blocked by binding to plasma proteins 
such as alpha-2 macroglobulin or membrane-bound glycoprotein RECK (reversion including 
cysteine-rich protein with kazal motifs (Baker et al. 2002; Oh et al. 2001).  
In pathological situations like cancer progression and metastasis this MMP/TIMP axis is 
disrupted since many of MMPs are upregulated. Moreover studies have shown that MMPs activity 
is linked to advanced, invasive or metastatic stage of several cancers and thus their expression is 
often associated with a poor prognosis (Curran et al. 2004; Duffy et al. 2000; Folgueras et al. 2004; 
Forget et al. 1999; López-Otín and Overall 2002; Stamenkovic 2000). This offered a possibility to 
use MMPs as targets for anticancer therapy, however different studies demonstrates that relation 
between MMPs’ levels and cancer progression seems not be so linear and thus their use as 
therapeutics did no fulfilled expectation (Coussens et al. 2002). 
 
This work focused on one particular member of membrane-type (MT-) subfamily of MMPs 
(Figure 3), subdivided in two categories, based on the manner they attach to the cell surface:  
 
1. TRANSMEMBRANE MT-MMPs, with short transmembrane domain inserted in the cellular 
membrane as a standard type I single pass molecule. Short cytosolic tail is involved in 
regulation of intracellular trafficking, protein turnover and activity (Lehti et al. 2000; 
Uekita et al. 2001). Followed members are included here: MT1-MMP (MMP-14), MT2-
MMP (MMP-15), MT3-MMP (MMP-16), MT5-MMP (MMP-24) and the unique type II 
transmembrane protein member MMP-23.  
2. GPI-ANCHORED MT-MMPs, which bind to the cell membrane trough GPI-linker and thus lacked 
transmembrane and cytosolic domain, which is cleaved off in endoplasmic reticulum 
lumen. Two members compose this group: MT4-MMP (MMP-17) and MT6-MMP (MMP-
25) (Itoh et al. 1999; Kojima et al. 2000). 
 
This unique and restricted positioning of MT-MMPs confers them specific properties to 
regulate extracellular microenvironment and, in the particular case of MT1-MMP, affecting some 
cellular function by interaction with its intracellular C-terminal.  
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MT1-MMP as a paradigm of membrane-tethered MMP 
MT1-MMP (MMP-14) was discovered as 582 amino acids, 63kDa product expressed by 
invasive lung carcinoma cells and with potent ability to activate pro-MMP-2 secreted by stromal 
cells of the same tumor (Sato et al. 1994). cDNA screening identified a protein closely aligned to 
MMPs’ family with a potential 24-amino acid transmembrane domain at the C-terminus (Sato et al. 
1994).  
 
Figure 3.   Schematic domain structure 
of MT-MMPs. MT1-, MT2-, MT3-, MT5-
MMP contain short transmembrane domain 
(TD) followed by an intracellular cytosolic 
tail. MT4-MMP and MT6-MMP are 
anchored to the membrane via a 
glycosylphosphatidylinositol (GPI motif). 
 
 
 
 
 
 
MT1-MMP shares a common domain structure with other MMP family members (Figure 
3), including propetide (M1-R111), catalytic domain (Y112-G285), a hinge region (E286-I318), a 
hemopexin domain (C319-C508), a stalk region (P509-S538), a transmembrane domain (A539-F562), and 
a cytoplasmic tail (R563-V582) (Itoh and Nagase 2002; Sato et al. 1994; Zucker et al. 2003). A point 
mutation in catalytic domain active site of Glu240 to Ala (MT1-MMP-E240A) has been shown to be 
proteolytic inactive and incapable to self-proteolysis (Rozanov et al. 2001).  
Like other MMPs, MT1-MMP is produced as an inactive zymogen, with an additional 
insertion of basic residues (RRKR111) between the propeptide and the catalytic domain, which is 
proteolytically removed by at least four members furin-like serine proteases (Zucker et al. 2003). 
These protein convertases are transmembrane calcium-dependent protein associated with trans 
Golgi network; in this manner MT1-MMP activation takes place intracellularly, in the Golgi, and 
the already mature enzyme is expressed on the cell surface (Itoh and Seiki 2006; Nagase 1997; 
Yana and Weiss 2000; Zucker et al. 2003).  
 
Regulatory mechanisms controlling MT1-MMP expression 
MT1-MMP is ubiquitously expressed in a number of cells and tissues and its regulation is 
driven by the same mechanisms that in other MMPs i. e. transcriptional and non-transcriptional 
(e.g. posttranslational modifications, trafficking, dimerization, interaction with cells or ECM 
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components). Importantly, MT1-MMP in endothelial cells is expressed at low levels in steady-state 
conditions and may be upregulated upon stimulation. A number of cytokines and growth factors 
were shown to stimulate MT1-MMP expression; these include IL-1α, IL-1β, TNFα, bFGF, GM-
CSF, TGFβ, CCL2, IL-8 and others (Tomita et al. 2000) (Rajavashisth et al. 1999) (Galvez et al. 
2005; Han et al. 2001). Tyrosine phosphorylation of c-met activates signaling pathways of 
MAPK/Erk or PI-2 kinase and STAT components; these factors work as mitogens or migration 
factors in response to cell-environment stimuli (Han et al. 2001; Zucker et al. 2003). Consensus 
binding sites for transcription factors such as Sp1, Erg-1, NF-kB were described for endothelial cell 
MT1-MMP gene promoter (Haas et al. 1999). Traffic to the cell surface and to particular domains 
is an important stimulating factor. Expression of some members of the claudin family, endothelial 
tight junction proteins, can directly recruit MT1-MMP to cell surface (Miyamori et al. 2001). In 
addition, other reports point than many of the extracellular matrix proteins like collagen, 
fibronectin, laminin, tenascin etc. can regulate MT1-MMP synthesis indirectly by cytoskeletal 
changes that arise after interaction of these ECM proteins with cell (Galvez et al. 2002; Zucker et 
al. 2003). Also cell-cell contact also has been reported to modulate MT1-MMP expression; MT1-
MMP mRNA levels were showed to decrease in epithelial cells once they reach confluence 
(Tanaka et al. 1997). 
 
MT1-MMP subcellular location 
MT1-MMP is anchored to the plasma membrane but its precise location and 
compartmentalization at membrane microdomains might vary thus impacting on its accessibility to 
process certain substrates. Our previous studies and others showed that MT1-MMP is found in 
endothelial and other cells in different cell compartments in association to distinct molecular 
partners (Figure 4, and (Gonzalo et al. 2010):  
 
1. LAMELLIPODIA and FILOPODIA PROTRUSIONS in association with caveolin-1 and integrin αvβ3 where 
MT1-MMP is catalytically active (Galvez et al. 2002). Our group has also demonstrated that 
caveolae-mediated MT1-MMP internalization is required for its proper localization, activity and 
function in endothelial cell migration (Galvez et al. 2004); 
 
2. CELL-CELL JUNCTIONS IN TSP4 (TETRASPANIN)-ORGANIZED MICRODOMAINS associated with integrin α3β1 
where MT1-MMP seems to be proteolytically inactive (Yanez-Mo et al. 2008); 
  
3. FOCAL ADHESIONS likely associated to other integrin β1 members and/or adapter proteins such as 
p130Cas and FAK where MT1-MMP might be playing additional functions related to signalling, 
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focal adhesion turnover, and matrix invasion (D'Alessio et al. 2008; Gonzalo and Arroyo 2010; 
Wang and McNiven 2012); 
 
4. PODOSOMES / INVADOPODIA where MT1-MMP is also a well-characterized component of the 
invasive machinery and the contribution of MT1-MMP to the formation and function of these 
protrusive structures is well established (Destaing et al. 2011; Frittoli et al. 2011; Nakahara et al. 
1997; Poincloux et al. 2009);  
 
5. INTRACELLULARLY in association with NUCLEUS or GOLGI COMPARTMENTS. Several studies suggest 
that this intracellular location MT1-MMP can impact gene transcription as shown for VEGF, 
PI3Kδ, FIH1 and others (Table 1), but MT1-MMP may also process nuclear protein pericentrin 
(Golubkov et al. 2005; Shimizu-Hirota et al. 2012). These findings indicate that under certain 
circumstances MT1-MMP might unexpectedly be proteolytically active inside cells, through as-yet 
unclear mechanisms.  
 
 
Figure 4.   MT1-MMP subcellular localization. MT1-MMP preferentially localizes at the membrane 
protrusions like filopodia, lamellipodia or invadopodia where it is most active but also in caveolae where 
associates with integrins or cell-to-cell contact at tetraspanin domains where mostly participate in protein 
interaction and matrix degradation. Less common is MT1-MMP intracellular localization to Golgi or 
nucleus. Moreover cytosolic tail interaction with intracellular protein can lead to activation of gene 
transcription. 
 
 
Taraboletti and coll. reported that MT1-MMP was found in endothelial microvesicles shed 
from localized area of the plasma membrane. This shedding was stimulated by some growth factors 
and addition of this vesicle-enriched medium to the endothelial cells activates cell migration and 
invasion through basement membrane layers (Taraboletti et al. 2002).  
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  Important role for MT1-MMP cellular localization, invasive activity, trafficking and 
signalling is assigned to its short cytosolic tail. In fact collection of proteins have been identified as 
associated to the MT1-MMP cytosolic tail and several signalling pathways are triggered or 
regulated by MT1-MMP pointing to its contribution in a variety of biological processes. Different 
groups showed that MT1-MMP required its cytoplasmic tail to localize to the invadopodia of tumor 
cells; moreover it promotes invasion of several types of tumor cells (Lehti et al. 2000; Nakahara et 
al. 1997; Rozanov et al. 2001; Shimizu-Hirota et al. 2012).  
MT1-MMP subcellular location drives and orchestrates its accessibility to distinct cellular 
and extracellular substrates contributing to fine-tuned regulation of specific substrate processing 
and therefore MT1-MMP functionality. As an example, forced location into lipid rafts resulted in 
limited MT1-MMP-dependent processing of E-cadherin in tumors cells (Rozanov et al. 2004). This 
information suggests that the compartmentalization of MT1-MMP is linked to proteolytic-
dependent and proteolytic-independent functions, through which it can coordinate extracellular 
cues with cellular responses. 
 
Cleavage preferences and targets of MT1-MMP 
In terms of proteolytic activity, MT1-MMP displays a wide substrate repertoire including 
triple helical collagens and other major ECM components, but also transmembrane receptors, 
cytokines, growth factors and other proteases such as pro-MMP2, thus being considered one of the 
most critical modulators of pericellular environment. On top of that it is becoming evident that 
MT1-MMP can behave as a transmembrane receptor with novel functions in which catalytic 
activity is dispensable like altering gene expression (Koziol et al. 2012a).  
Main MT1-MMP substrates and biological consequences of their processing were briefly 
summarized in Table 1 (Baciu et al. 2003; Basile et al. 2006; Belkin et al. 2001; Covington et al. 
2006; d'Ortho et al. 1997; Deryugina et al. 2002b; Egawa et al. 2006; Endo et al. 2003; Golubkov 
et al. 2005; Guo et al. 2012; Hikita et al. 2006; Hiller et al. 2000; Holopainen et al. 2003; Hotary et 
al. 2002; Karsdal et al. 2002; Koshikawa et al. 2000; Koziol et al. 2012b; Lehti et al. 2002; Lehti et 
al. 2005; McQuibban et al. 2001; McQuibban et al. 2002; Nishida et al. 2012; Ohuchi et al. 1997; 
Shimizu-Hirota et al. 2012; Sounni et al. 2004; Strongin et al. 1995). 
 
Table 1.   Biological consequences of MT1-MMP catalytic and non-catalytic activity  
Changes in matrix proteins and in the tissue architecture 
Cleavage of triple helical collagen (I, II and III), laminin, vitronectin, tenascin, fibrin, fibrinogen, 
aggrecan, PDGFRbeta,  
 
Converting structural matrix proteins to signaling molecules 
Fibronectin, nidogen, thrombospondin, semaphorin 4D, CD44, E-cadherin 
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Changes in protein bioactivity 
pro-MMP-2, pro-MMP-8, pro-MMP-13, MT1-MMP, factor XII, pro-TGF-β, αvβ3 integrin, LRP, 
EMMPRIN, KIM-1 
 
Chemoattraction 
SDF1, MCP-3, RANKL,  
 
Proliferation and Motility 
Pericentrin, CD44, syndecan-1, laminin-5, E- and N-cadherin, transglutaminase, αvβ3 integrin 
 
Gene expression 
VEGF-A, PI3Kδ, FIH1 
 
Kridel and coll. provided studies identifying specific short amino acid motifs recognized 
by MT1-MMP that defined the degree of substrate specificity for protease cleavage. In this way 
highly selective MT1-MMP’s substrates compromised of the Arg – nonPro – Xpolar – XHy motif 
where Arg at the P4 position is essential for efficient hydrolysis and lack of Pro which is principally 
assigned to motif recognized by MMPs in general and poorly selective for MT1-MMP. This 
combination was shown to bind specifically to the catalytic pocket of MT1-MMP. Therefore 
selective substrates may become non-selective by insertion of Pro at P3 position. (Kridel et al. 
2002). 
  
MT1-MMP in physiology and pathology  
MT1-MMP is expressed in both embryonic and adult tissues, suggesting that MT1-MMP-
mediated proteolysis of ECM is important during development and in postnatal tissue remodeling. 
Increased MT1-MMP mRNA level are found in mesenchymal and mesenchyma-derived cells 
(fibroblasts, chondrocytes, muscle and neural cells, pulmonary and renal epithelium and 
endothelial cells) and decreased with postnatal maturation and thus implicates protease in 
embryogenesis and developmental processes of kidney tubules formation, bone and lung 
development (Apte et al. 1997; Kadono et al. 1998; Kheradmand et al. 2002; Tanney et al. 1998).  
However the role of MT1-MMP is not limited to the developmental homeostasis, but its 
requirement has been reported in processes like inflammation, injury and wounding. MT1-MMP 
produced by keratinocytes and stromal cells in granulation tissue is required for cell migration and 
ECM remodeling during wound healing (Okada et al. 1997). In healthy adult tissues MT1-MMP is 
expressed in hematopoietic cells – macrophages, neutrophils and lymphocytes, as well as 
endothelial cells where become upregulated by inflammatory stimuli such as TNFα, chemokines 
MCP-1/CCL2, IL-8 and SDF-1/CXCL12, nitric oxide and prostaglandin E2, that induces 
endothelial cells migration and tube formation (Alfranca et al. 2008; Gálvez et al. 2005; Genis et al. 
2007; Han et al. 2001). Increased protease expression on the inflamed endothelium leads to 
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shedding and activation of a number of cytokines, growth factors and adhesion molecules crucial 
for correct course and resolution of inflammation (Table 1). MT1-MMP has temporal expression 
in endometrial epithelium where it is critical for glandular regeneration (Zhang et al. 2000).  
The destructive capability of MMPs initially focused most research onto disease and that 
includes MT1-MMP, which expression similarly to the rest of MMP family was found in many 
carcinomas and was directly linked to cancer invasion. Therefore to define better the importance of 
MT1-MMP as a collagenase, independent groups have generated MT1-MMP-deficient mice 
(Holmbeck et al. 1999; Zhou et al. 2000), which resulted to be the only lethal MMP null mice. 
Even though they are apparently normal till birth, postnatal display a severe phenotype with gross 
developmental problems in skeleton, lung and adipose tissue some of them related to impaired 
remodelling of connective tissues and die around 3-12 weeks of age (Holmbeck et al. 1999; Zhou 
et al. 2000). At birth the neonatal null mice are indistinguishable from their wildtype counterparts, 
but shortly they develop apparent growth and skeletal impartments due to severe fibrosis in soft 
tissue and delayed in secondary ossification centres caused by failed collagen degradation by 
osteocytes (Holmbeck et al. 1999; Holmbeck et al. 2005) (Figure 5). It was confirmed by in vitro 
experiments that MT1-MMP knockout fibroblasts were not able to degrade type I collagen matrices 
(Holmbeck et al. 1999). Accordingly, craniofacial and axial skull bones are smaller and deformed. 
Long bones are severely affected due to impaired chondrocyte proliferation in the growth plates 
causing dwarfism (Zhou et al. 2000). Concurrently to skeletal development MT1-MMP knockout 
mice exhibit gross defects in angiogenesis. Defective vascular invasion leads to joints overgrowth 
and arthritis. MT1-MMP-deficient mice failed to form neovessels in collagen type I matrix (Chun 
et al. 2004), similarly showed impaired response to FGF-2 in an in vivo corneal implantation assay 
(Zhou et al. 2000).  
No other MMP gene KO mice have shown such drastic phenotypes, suggesting that MT1-
MMP is an essential cellular collagenase important for organizing the ECM microenvironment, 
impacting physiologic response as well as disease conditions, and which cannot be substituted for 
by any other MMP during development. 
 
 
Figure 5.   Retarded growth of MT1-MMP-deficient mice. Example of 7-day old littermates. MT1-MMP-
deficient mice demonstrates dramatic retardation in the growth, showing a difference in the size and body 
weight.  
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Role of MT1-MMP in angiogenesis 
MT1-MMP is considered to play important role in the vascular system and, as shown for 
MT1-MMP-deficient mice, developmental and postnatal angiogenic response in markedly reduced 
in these animals. However, its function in the cells present in the vasculature still remains poorly 
defined. MT1-MMP is expressed in smooth muscle cells in the vessel wall during embryonic 
development in aorta and other vascular territories being required for normal pericyte/VSMC 
recruitment through regulation of PDGFR signaling pathway (Apte et al. 1997; Lehti et al. 2005). 
In the adult however, MT1-MMP expression is low in the vasculature and is upregulated by 
inflammatory stimuli in ECs, VSMCs and macrophages upon injury contributing to angiogenesis 
and to vascular pathologies e.g. proinflammatory stimuli (IL-1α, TNF-α, and oxidized LDL) 
upregulate MT1-MMP expression in vascular smooth muscle cells and macrophages in 
atherosclerotic arteries affecting matrix remodeling and misregulating capillary morphogenesis 
(Rajavashisth et al. 1999).  
MT1-MMP contributes to postnatal vascular development through several independent 
mechanisms, which include both catalytic and non-catalytic activity: 
1. DEGRADATION OF BASAL LAMINA AND ECM PROTEINS is critical initiating step leading to break of 
the physical barrier, to clear the path and facilitates cell migration. MT1-MMP was shown 
to be the main and most potent fibrinolysin in endothelial cells during angiogenesis and 
cells with deleted form of transmembrane MT1-MMP resulted noninvasive (Hiraoka et al. 
1998). But also the secondary effect of MT1-MMP on ECM and non-ECM protein 
processing can promote or inhibit angiogenesis by generation of degradation products of 
vascular basement membrane components, such as semaphoring-4D, endoglin, 
thrombospondin, soluble chemokines and growth factors, integrins and cadherins 
(Covington et al. 2006; Deryugina et al. 2002b; McQuibban et al. 2001; McQuibban et al. 
2002; Ratnikov et al. 2002). 
2. INVASION AND MIGRATION BY ACTIVATED ENDOTHELIAL CELLS are also essential requirements for 
the first steps in efficient angiogenesis. Quiescent endothelial cells express low levels of 
MT1-MMP that become upregulated by their migration and/or invasion within 2D and 3D 
matrices (Galvez et al. 2001). Highly migratory and invasive endothelial cells localized at 
the capillary front, so-called tip cells, express high levels of MT1-MMP (Fisher et al. 2009; 
Yana et al. 2007). In addition MT1-MMP is required for the formation of vascular 
guidance tunnels, which ECs use to migrate through ECM (Stratman et al. 2009). 
3. ACTIVATION OF PROANGIOGENIC GENES; as above-mentioned MT1-MMP enhances the 
transcriptional activation of VEGF-A via src tyrosine kinase, a master regulator of 
angiogenesis, which in turn partially increases the proteolytic capacity of MT1-MMP 
(Deryugina et al. 2002a; Sounni et al. 2004). 
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4. DIRECTING NEOINTIMA FORMATION BY PERIVASCULAR CELLS (VSMCs). MT1-MMP derived from 
VSMCs mobilizes pericellular proteolysis, but protease deletion results to exhibit 
beneficial effect protecting from neointimal hyperplasia and lumen narrowing (Filippov et 
al. 2005). Other works described MT1-MMP-PDGFβ axis responsible for controlling 
VSCMs proliferation and chemotaxis leading to decreased mural cell density and abnormal 
vessel wall morphology (Lehti et al. 2005).  
5. REGULATION OF VASCULAR TUBE REGRESSION.  Aplin and coll. showed that blocking MT1-
MMP expression interferes tube regression, due to impaired collagen degradation along the 
abluminal surface of neovessels (Aplin et al. 2009). 
Taken together, these data suggest that MT1-MMP can actively regulate neovessel formation via 
different mechanisms starting from initial sprouting to the stabilization and maturation of vessels 
(Figure 6). 
 
 
 
Figure 6.   MT1-MMP is important at several steps of neovascularization. MT1-MMP is upregulated 
during first steps of angiogenesis and its expression on activated endothelial tip cells facilitates basement 
membrane degradation and EC migration. At following steps crosstalk between EC and pericytes (SMCs) is 
a key factor in initiating vessel stabilization (adapted from Ghajar et al., 2008). 
 
 
 
- PROTEOMIC APPROACHES TO ANALYZE THE PROTEASE SYSTEM - 
 
Traditional in vitro and in vivo techniques as well as MMP-mutant mouse models have 
been used for years to investigate the effect of a protease or the type of substrates it can process. 
However techniques such as these provide only partial information and can mask heterogeneity and 
dynamical processes of the individual protease, since in many occasions they are focused on single 
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substrate. In that way by the homology to the first discover MMP later were called interstitial 
collagenases able to degrade extracellular matrix molecules and thus classified to the same family. 
Nowadays it is much more elucidate that although many of MMP family members share similar 
ability to cleave some of the ECM components, the structure and function of each individual MMP 
can be unique and process substrates beyond matrix proteins. Several powerful approaches that can 
comprehensively clarify a protease role in a single cell, tissue or even the whole organism are 
based on genomic and proteomic techniques.  
Over the last few years proteomic techniques have advanced significantly, resulting in a 
variety of powerful tools to complex analysis of biological samples. The group of C. Overall has 
been pioneered in mass spectrometry (MS)-based proteomic use and other ‘omics’ techniques for 
proteases, their inhibitors and substrates. A new term was coined to define these emerging 
concepts: DEGRADOMICS defines “all genomic and proteomic investigations and techniques 
regarding the genetic, structural and functional identification and characterization of proteases, and 
their substrates and inhibitors, that are present in an organism” and DEGRADOME that encompasses 
two concepts “first, is the complete set of proteases that are expressed at a specific moment or 
circumstance by a cell, tissue or organism. Second, the degradome of a protease is the complete 
natural substrate repertoire of that enzyme in a cell, tissue or organism” (López-Otín and Overall 
2002). 
One of the most important functions of matrix metalloproteases is the regulation of 
bioactivity and availability of a number of proteins. That occurs mostly in a process of proteolytic 
shedding, which is a form of post-translational modification independent of the mRNA expression 
level (Müllberg et al. 2000; Schlöndorff and Blobel 1999). Thus screening the protease-dependent 
events require quantitative proteomic techniques, which not only provide the information about 
identified proteins but also can quantitatively compare two conditions, e.g. effect of an inhibitor, 
wildtype versus protease-deficient culture, normal and disease-affected tissue, etc.  
The identification of MMPs’ substrates increased significantly when using proteomic-
based techniques. C. Overall’s group used ICAT (Isotope-Coded Affinity Tags) applied to breast 
carcinoma cell line stably transfected with MT1-MMP and discovered several promising 
candidates, the most important are: secretory leukocyte protease inhibitor, EGF-containing fibulin-
like extracellular matrix protein-1, death receptor-6, neuropilin-1 and connective tissue growth 
factor (Tam et al. 2004). Moreover proteomic analysis of human plasma showed other candidates 
such as gelsolin and apopoproteins (Hwang et al. 2004). These and other works bring in 
unparalleled information about how MT1-MMP influences on protein function in pathology and 
showed how the MT1-MMP substrate degradome changes depending on cell type/condition.  
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Fundamentals of SILAC approach 
SILAC (stable-isotope labeling by amino acids in cell culture) method was developed last 
decade as an alternative metabolic to standard isotope labeling techniques like ICAT or iTRAQ to 
label mammalian cells and whole organisms using a non-invasive and efficient method (Ong et al. 
2002). By using non-radioactive amino acids, which are indispensable for normal cell growth, all 
proteins synthesized by the cell are labeled and because isotope analogues are chemically identical, 
there is no impact on cell behaviour or function (Mann 2006). The incorporation of amino acid 
isotopes lead to known mass shift compared with the control peptide (Figure 7). 
A fundamental limitation of this method is the requirement for living cells to proliferate for 
a several cell cycle doublings. An important advantage of SILAC is that metabolic labeling allows 
mixing labeled and unlabeled cultured before lysis, which are further processed as one sample thus 
eliminating possible errors during fractionation or purification steps. The quantification is 
straightforward; each correctly labeled peptide appears as a pair of fragmentation peaks (for two-
condition labeling or more if more than two conditions are considered). The ratio of intensity of 
each labeled peaks will provide information about abundance of protein, for instance if ratio is 
close or equal to one then no difference in protein is observed and thus processing of this proteins 
is not affected between different culture conditions. In contrast, higher intensity of one of peptide 
suggest higher abundance of protein this that particular condition (for more details see MATERIALS 
AND METHODS section). When analyzing supernatants of a cell culture from protease deficient versus 
wildtype cells, SILAC allows for identifying a set of putative substrates. 
 
 
Figure 7.   Principles of SILAC labeling. Two population of 
cells are cultures for at least six doubling times in medium 
containing either “light” or “heavy” amino acids. Cells or 
conditioned medium are then combined at 1:1 ratio and after 
sample purification are dissolved in SDS-PAGE. Protein bands 
are excised from the gel and digested with trypsin followed by the 
analysis of LC-MS/MS. Relative quantification is achieved by cal 
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- MORFOGÉNESIS DEL SISTEMA VASCULAR - 
 
Los vasos sanguíneos se forman bien mediante el proceso de diferenciación a partir de 
progenitores (vasculogénesis) o a través de la formación coordinada de nuevos capilares a partir de 
la vasculatura preexistente (angiogénesis). La vasculogénesis, formación de novo de los vasos a 
partir de los precursores de las células endoteliales derivadas del mesodermo (angioblastos), es 
responsable de la formación del primer sistema vascular en el embrión (Risau 1995; Carmeliet 
2003). Sin embargo, crecimiento fisiológico o patológico del la red vascular en el organismo adulto 
se produce principalmente mediante angiogénesis (Risau 1995, 1997). La angiogénesis es crítica 
durante el desarrollo y en el adulto aparece a menudo asociada a la respuesta inflamatoria (De Smet 
et al. 2009). 
El crecimiento de una red vascular es un proceso dinámico con multitud de etapas 
individuales tales como la migración e invasión direccional de las células endoteliales, su 
proliferación, la anastomosis, la remodelación y regresión vascular, la especificación en arterias, 
venas y capilares, y el reclutamiento de células murales (pericitos y células del músculo liso). La 
iniciación del proceso de ramificación capilar requiere la especificación de células endoteliales en 
tres tipos: las células líder o ‘tip’ especializadas en la invasión del tejido circundante, las células 
tallo o ‘stalk’ encargadas de la elongación del vaso y la formación de la luz capilar, y las células 
falange o ‘phalanx’ encargadas de la homeostasis y quiescencia vascular para promover la 
formación de vasos estables. Además participan las células mieloides, las cuales pueden estimular 
la ramificación capilar y el establecimiento apropiado de conexiones (anastomosis). Las células 
endoteliales ‘tip’ se localizan en el frente del capilar emergente, no forman lumen y son poco 
proliferativas, además presentan un elevado número de filopodios que se extienden hacia los 
factores pro-angiogénicos, los cuales inducen la migración direccional de estas células tip 
(Gerhardt et al. 2003).  
La molécula clave en el inicio de la ramificación capilar y su posterior dirección tanto en 
situaciones fisiológicas como patológicas es el factor de crecimiento endotelial vascular (VEGF, 
del inglés Vascular Endotelial Growth Factor). El VEGF se expresa en múltiples tipos celulares 
incluidos las células endoteliales, los macrófagos y las células tumorales (Ferrara 1999; Salgado et 
al. 2001). El efecto de VEGF depende de la presencia de receptores del mismo localizados en las 
células tip (VEGFR2 y VEGFR3) y ‘stalk’ (VEGFR1) (Phng and Gerhardt 2009). La activación de 
estos receptores causa primero un incremento de la permeabilidad vascular así como la activación y 
migración de las células endoteliales hacia el gradiente de VEGF (de Smet et al. 2009). Además, el 
VEGF induce la expresión de Delta-ligand 4 (Dll4), uno de los ligandos de Notch en las células 
‘tip’. Dll4 a continuación induce la activación de Notch en las células ‘stalk’ adyacentes lo que 
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inhibe la expresión de los receptores VEGFR2 y -3 en éstas células (Benedito et al. 2009; 
Hellstrom et al. 2007; Suchting et al. 2007). Por otro lado las células ‘stalk’ expresan altos niveles 
de otro ligando de la familia Notch – Jagged1 (Jag1), que activa más débilmente la vía de Notch en 
las células ‘tip’ favoreciendo la ramificación capilar (Benedito et al. 2009). Este equilibrio entre las 
vías de señalización de la familia Notch y sus dianas (los receptores VEGFR entre otras) mantiene 
el número correcto de células ‘tip’ y ‘stalk’ y define el carácter dinámico de las células endoteliales 
durante la expansión de la red vascular.  
La angiogénesis es crítica durante el desarrollo y en el adulto aparece a menudo asociada a 
la respuesta inflamatoria (De Smet et al. 2009). Recientemente se ha descrito que factores 
inflamatorios como el Factor de Necrosis Tumoral alfa (TNFα) puede inducir un fenotipo similar al 
de las células endoteliales ‘tip’ (Sainson et al. 2008). La respuesta inflamatoria puede activar el 
proceso de angiogénesis a través de varios mecanismos: i) el aumento de la permeabilidad vascular 
y de leucocitos en el tejido inflamado conducen a un aumento local de factores angiogénicos que 
estimulan la producción de VEGF (Ferrara 1999); ii) el aumento del flujo sanguíneo puede 
estimular la angiogénesis mediante señales inducidas por el ‘estrés de flujo’ en el endotelio 
(Schaper and Scholz 2003); y iii) finalmente, en el tejido inflamado existen condiciones de hipoxia 
que estimulan también la expresión de factores pro-angiogenicos como VEGF (Taylor and 
Sivakumar 2005). Habitualmente la angiogénesis asociada al proceso inflamatorio es beneficiosa y 
necesaria para su resolución, pero en el caso de que la nueva vasculatura persista puede contribuir a 
la progresión de enfermedades inflamatorias crónicas. Por lo tanto la angiogénesis inflamatoria se 
considera como un importante patogénico de enfermedades como la psoriasis, la artritis 
reumatoide, la enfermedad inflamatoria intestinal, la diabetes o el cáncer (Folkman 1995a, 1995b). 
 
 
- LA FAMILIA DE LAS PROTEASAS MMP - 
 
Para el inicio del proceso de ramificación capilar es fundamental la capacidad de las 
células endoteliales de invadir el tejido circundante compuesto principalmente por la membrana 
basal y la matriz extracelular (ECM). La degradación de la ECM es crítica para las primeras etapas 
de la angiogénesis y las proteasas, en particular, la familia de las metaloproteasas de matriz 
(MMPs) desempeña un papel importante en este proceso. Las MMPs son capaces de degradar casi 
cualquier componente de la matriz extracelular así como factores de crecimiento, proteínas de 
unión a factores de crecimiento e inhibidores de proteasas, lo que les permite modular la migración 
e invasión celular y por tanto la angiogénesis y la inflamación, entre otros procesos (Zucker et al. 
2003). Además, las MMPs pueden aumentar la disponibilidad de moléculas bioactivas y 
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desencadenar vías de señalización (Page-McCaw et al. 2007), así como alterar el comportamiento 
de las células afectando la transcripción de genes (Toriseva et al. 2012).  
Por su capacidad de remodelar la matriz extracelular, las MMPs participan en el 
mantenimiento de la homeostasis del organismo, regulando procesos como la cicatrización, la 
inflamación o la angiogénesis. El análisis de animales deficientes en MMPs concretas ha 
proporcionado información adicional sobre sus funciones y sustratos.  
Varios de los modelos de animales deficientes en MMPs han demostrado defectos 
asociados a inflamación y angiogénesis. En particular, los ratones deficientes en la proteasa MMP-
9 muestran defectos en la angiogénesis del cartílago de huesos largos y en la respuesta angiogénica 
en el modelo de lesión degenerativa de la retina (Lambert et al. 2003; Vu et al. 1998). Este último 
se observó también en ratones dobles mutantes para MMP-2 y MMP-9 indicando la redundancia 
funcional de estas dos proteasas. Aunque en su mayor parte las MMPs favorecen el desarrollo de 
tumores, los ratones deficientes en MMP-8 constituyen una excepción y muestran la importancia 
de las MMPs en regular la respuesta inflamatoria e inmune, ya que en ausencia de esta proteasa se 
observó un aumento de los tumores de la piel (Balbin et al. 2003). Sorprendentemente no hay 
evidencias de muerte gestacional en ningún mutante de las MMPs, lo que sugiere que las funciones 
desempeñadas por la MMPs son especialmente importantes durante la angiogénesis postnatal. El 
posible mecanismo a través de cual las proteasas de matriz contribuyen al proceso de angiogénesis 
incluye el aumento de su expresión en las células vasculares como células endoteliales y, 
observado en condiciones tumorales, así como el aumento del procesamiento de la matriz 
extracelular, en particular colágeno tipo I, que promueve la migración celular. Otros mecanismos 
incluyen el procesamiento de los factores de señalización como VEGF o PDGF o la regulación de 
la cobertura perivascular (Bergers et al. 2003; Chantrain et al. 2004; Galvez et al. 2001; Hiratsuka 
et al. 2002; Huang et al. 2009; Johnson et al. 2004).  
 
Todos los miembros de la familia de las MMPs comparten la misma estructura en varios 
dominios principales que están compuestos por un péptido señal en el extremo N-terminal, un pro-
dominio que las mantiene en forma de zimógeno, seguido de un sitio de corte por furina por el que 
serán procesadas y activadas. Luego presentan el dominio catalítico, crucial para su actividad 
proteolítica y el dominio hemopexina que participa en la dimerización y regulación de la 
migración. Por último, en el extremo C-terminal, puede haber un motivo transmembrana que ancla 
la proteína a la membrana plasmática y un dominio citosólico que participa en varias funciones 
como la localización o la transducción de señales (Zucker et al. 2003; Folgueras et al. 2004; 
Overall et al. 2002). Según esto, se diferencian dos tipos principales de MMPs, las secretadas y las 
unidas a la membrana (MT-MMPs). Las MT-MMPs se organizan en dos grupos dependiendo de su 
forma de anclaje a la membrana:  
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1. las MT-MMPs transmembrana, que contienen un dominio transmembrana y 
una pequeña cola citosólica (MT1-, MT2-, MT3- y MT5-MMP);  
2. y las MT-MMPs ancladas a dominios GPI (MT4- y MT6-MMP), que se unen a 
la membrana mediante un puente glicosilfosfatidilinositol.  
La MMP-23 también se incluye dentro del grupo de las proteasa transmembrana, aunque a 
diferencia de las demás es una proteína tipo II.  
MT1-MMP (MMP-14), fue la primera metaloproteinasa de matriz identificada anclada a la 
membrana  (Sato et al. 2004). Pertenece al grupo de las MT-MMPs transmembrana y se expresa en 
la gran mayoría de las células. Debido a su alto potencial proteolítico, MT1-MMP está regulada a 
varios niveles, incluyendo su transcripción, activación de las formas zimógenas y su inhibición por 
inhibidores tisulares (TIMPs, del inglés Tissue Inhibitors of Metalloproteinases). Como otras 
MMPs, MT1-MMP se produce en forma de zimógeno inactivo con una inserción de cuatro 
residuos entre el pro-péptido y el dominio catalítico. La activación de la proteasa se lleva a cabo 
por convertasas de la familia de las furinas y se produce a nivel de retículo endoplasmático antes de 
que proteasa llegue a la membrana celular (Zucker et al. 2003; Itoh and Seiki 2006; Yana and 
Weiss 2000).  
La MT1-MMP se localiza en diferentes microdominios de la membrana celular, donde se 
asocia a otras proteínas y esta localización específica define su accesibilidad a los sustratos, así 
como sus principales funciones. MT1-MMP se encuentra en los siguientes compartimientos en las 
células endoteliales:  
1. Lamelipodios y filopodios, así como otras protrusiones de la membrana, donde 
se es proteolíticamente activa y asociada a caveolina-1 e integrina αvβ3 (Galvez 
et al. 2010); 
2. Las uniones célula – célula en los dominios de tetraspaninas, donde la MT1-
MMP parece ser proteolíticamente inactiva (Yanez-Mo et al. 2008); 
3. Adhesiones focales, asociada a otros miembros de las integrinas β1 y proteínas 
adaptoras como p130Cas o FAK donde MT1-MMP puede regular vías de 
señalización como la de Rac1 (D’Alessio et al. 2008; Gonzalo and Arroyo 2010; 
Wang and McNiven 2012); 
4. Podosomas e invadopadios donde MT1-MMP forma parte de la maquinaria de 
formación de estas estructuras que son también clave para la invasión celular 
(Destaing et al. 2011; Frittoli et al. 2011; Nakahara et al. 1997; Poincloux et al. 
2009); 
5. Intracelular, en el retículo endoplasmático/Golgi o en el núcleo, donde se ha 
demostrado que la MT1-MMP puede regular la función de proteínas tales como 
FIH1 o impactar en la transcripción de genes como PI3Kσ, respectivamente. 
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También se ha sugerido que MT1-MMP podría tener actividad proteolítica 
intracelular y procesar proteínas centrosomales como pericentrin (Golubkov et 
al. 2005; Shimizu-Hirota et al. 2012). 
 
MT1-MMP es la principal fibrinolisina y colagenasa en células endoteliales, siendo 
esencial para el desarrollo (Hiraoka et al. 1998). Esto se manifiesta en los defectos vasculares 
presentes en los ratones deficientes en MT1-MMP, que presentan una vascularización defectuosa 
en respuesta a FGF en el modelo de córnea así como problemas en la osificación secundaria y en la 
expansión pulmonar postnatal relacionado con problemas en la vascularización en estos tejidos 
(Zhou et al. 2000; Holmbeck et al. 1999; Gálvez et al. 2005). 
La proteasa MT1-MMP es esencial para la formación de capilares como han demostrado 
trabajos con animales y células deficientes en MT1-MMP. Además, la expresión de MT1-MMP se 
ha observado en células ‘tip’ in vitro y ex vivo (Yana et al. 2007; Aplin et al. 2009), y modelos 
matemáticos sugieren que MT1-MMP podría participar en la capacidad invasiva de estas células 
‘tip’ (Kargiannis et al. 2006). MT1-MMP puede contribuir al desarrollo vascular a través de varios 
mecanismos dependientes o independientes de su actividad catalítica: 
1. Degradación de la lámina basal y las proteínas de la ECM, es un proceso 
crítico en la iniciación de la ramificación capilar ya que facilita la migración 
celular. MT1-MMP también puede generar y/o activar proteínas activadoras o 
inhibitorias de procesos angiogénicos como trombospondinas, citoquinas 
solubles o factores de crecimiento (Covington et al. 2006; McQuibban et al. 
2002, Ratnikov et al. 2002). 
2. Invasión y migración de las células endoteliales. En condiciones basales las 
células endoteliales expresan bajos niveles de MT1-MMP, pero estos niveles se 
encuentran aumentados durante la migración e invasión en matrices 2D y 3D 
(Galvez et al. 2001). Además, se ha demostrado que las células ‘tip’ que se 
localizan en el frente vascular expresan MT1-MMP (Fisher et al. 2009; Yana et 
al. 2007). 
3.  Activación de genes pro-angiogénicos, como se ha mencionado anteriormente 
MT1-MMP puede activar la expresión de algunos genes de forma independiente 
de su actividad catalítica; unos de ellos es VEGF, el regulador clave del proceso 
de formación de nuevos vasos (Deryugina et al. 2002ª; Sounni et al. 2004).  
4. Reclutamiento y activación de células perivasculares tanto durante el 
desarrollo de la pared vascular como en respuesta a daño vascular (Filippov et 
al. 2005). 
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5. Regulación de la regresión vascular. Aplin y coll. han demostrado que la 
inhibición de la expresión de MT1-MMP interfiere en la regresión de la 
vasculatura (Aplin at al. 2009).  
 
 
- ABORDAJE PROTEOMICO PARA EL ANALISIS DE LAS PROTEASAS - 
 
Uno de los abordajes más potentes para caracterizar la función de una proteasa es la 
identificación de sus sustratos. Actualmente las técnicas de la proteómica cuantitativa permiten 
caracterizar exhaustivamente la función de una proteasa en una célula, tejido u organismo. Durante 
los últimos años se ha introducido el concepto del degradoma que engloba dos significados: i) el 
conjunto completo de proteasas e inhibidores secretados en un momento específico por una célula, 
tejido u organismo y ii) el conjunto de los sustratos de una determinada proteasa en una célula, 
tejido u organismo (López-Otín and Overall 2002). La identificación de sustratos de MT1-MMP se 
ha mejorado considerablemente como resultado del uso de técnicas de proteómica como ICAT 
(Isotope-Coded Affinity Tags) aplicadas a células tumorales (Tam et al. 2004).   
Uno de los métodos de proteómica cuantitativa desarrollado recientemente es el marcaje 
metabólico llamado SILAC (del inglés, stable-isotope labeling by amino acids in cell culture), 
basado en el uso de isótopos no radioactivos de amino ácidos esenciales que se incorporan a todas 
las proteínas de la célula durante su cultivo. La incorporación de dos isótopos diferentes crea una 
variación de masa en los amino ácidos, que permite calcular de forma precisa la diferencia en 
abundancia de una determinada proteína entre dos o más condiciones. En el caso de las proteasas 
de membrana, la aplicación de esta técnica para el análisis del medio condicional del cultivo 
derivado de células deficientes en dicha proteasa versus cultivo control permite identificar las 
proteínas de membrana o secretadas procesadas por la proteasa de interés. En otras palabras, esta 
técnica permite la identificación del conjunto completo de sustratos procesados por esa proteasa.  
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- OBJECTIVES - 
 
The analysis of knockout mice performed by our group and others confirmed that MT1-
MMP might play an essential role in angiogenesis and inflammation. In order to expand our 
understanding about MT1-MMP functions in proteolytic events during inflammation-induced 
angiogenesis we proposed the following aims: 
 
• Set up an in vitro model of inflammation-induced endothelial tip cells expressing MT1-
MMP; 
 
• Identify and characterize the degradome (collection of substrates) of MT1-MMP in these 
cells by application of quantitative proteomics to gain insights into its function in 
inflammatory angiogenesis; 
 
• Validate in vitro and in vivo processing of putative MT1-MMP substrates in MT1-MMP-
deficient endothelial cells; 
 
• Evaluate the possible application of MT1-MMP proteolytic substrates as biomarkers in 
pathological models of inflammation-driven angiogenesis such as observed in 
inflammatory bowel diseases. 
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- MATERIALS AND REAGENTS - 
 
All reagents were of the highest grade commercially available. Tissue-culture plasticware plates 
were from Falcon (BD Biosciences) or Costar (Corning Incorporated). µ-Slide Angiogenesis were 
from IBIDI®. Microscope slides and coverslips were purchased from Thermo Fisher Scientific.  
 
Table 2.   Cell culture media 
DMEM Ham’s F-12 (Dulbecco’s modified Eagle’s medium) 
IMDM (Iscove’s modified Dulbecco’s medium) 
Opti-MEM®I Reduced Serum Medium 
M199 
DMEM (Dulbecco’s modified Eagle’s medium) 
SILAC Advance D-MEM F-12 Flex Medium 
 
Lonza, BioWhittaker 
Lonza, BioWhittaker 
Lonza, BioWhittaker 
Gibco, Invitrogen 
Sigma-Aldrich 
Invitrogen 
 
 
Table 3.   Cell culture supplements 
Penicillin (50UI/ml), streptomycin (50 µg/ml) (P/S) 
Fungizone (2,5 µg/ml) 
2 mM L-glutamine 
10 mM HEPES 
Fetal bovine serum (FBS) 
Endothelial cell growth factors (ECGFs, 50 µg/ml) 
10 UI/ml heparine 
Fibronectin (10 µg/ml) 
Gelatin (0.1% w/v) 
Polybrene  (8 µg/ml) 
Type I collagen PureCol™ 10 µg/ml 
Matrigel® basement membrane matrix  
Collagenase type I (3,33 mg/ml) 
 
Lonza, BioWhittaker 
Lonza, BioWhittaker 
Lonza, BioWhittaker 
Lonza, BioWhittaker 
Gibco, Invitrogen 
Extracted from bovine cerebrum 
Mayne 
Sigma 
Sigma 
Sigma 
INAMED Biomaterials 
BD Biosciences  
Worthington 
 
 
Table 4.   Reagents and buffers 
Red blood cells lysis buffer - ACK buffer (150mM NH4Cl; 0.1mM Na2EDTA; 
10mM KHCO3, pH=7.4) 
Dynabeads M-450 sheep anti-rat IgG  
WGA-agarose beads  
Dextran sodium sulphate (DSS) 
ColoScreen hemoccult 
Cell Dissociation Buffer 
 
 
 
Dynal Biotech ASA 
Vector Laboratories 
Biomedicals 
Helena Laboratories 
Gibco 
 
 
Table 5.   Cytokines and ELISA 
Interleukin 3 (IL-3) 
Stem cell factor (SCF) 
Granulocyte macrophage colony-stimulating factor (GM-CSF) 
Macrophage colony-stimulating factor (M-CSF) 
Monocyte chemotactic protein-1 (MCP-1/CCL2) 
Tumor necrosis factor-alpha (TNFα) 
Mouse VEGF DuoSet® ELISA 
Mouse TNFα ELISA 
Mouse Nidogen-1 (NID1) ELISA kit 
Mouse Thrombospondin-1 ELISA kit 
PeproTech (Rocky Hill, NJ) 
PeproTech (Rocky Hill, NJ) 
PeproTech (Rocky Hill, NJ) 
PeproTech (Rocky Hill, NJ) 
PeproTech (Rocky Hill, NJ) 
PeproTech (Rocky Hill, NJ) 
RnD Systems 
BD Biosciences 
Cusabio 
Cusabio 
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Human VEGF DuoSet® ELISA 
Human Thrombospondin-1 DuoSet® ELISA 
Human Nidogen-1 DuoSet® ELISA 
VEGF-A 
 
 
RnD Systems 
RnD Systems 
RnD Systems 
PeproTech (Rocky Hill, NJ) 
 
 
 
Table 6.   Antibodies 
MT1-MMP (mouse anti m, h) 
MT1-MMP (rabbit anti m, r, h) 
β actin (mouse anti m, r, h) 
CD31 (PECAM-1) (hamster anti m, h) 
ICAM-1 (biotin hamster a m) 
VCAM-1 (rat anti m) 
Jagged1 (rabbit anti m) 
VEGFR2 (rabbit anti m) 
Delta-ligand 4 (rabbit anti m) 
Integrin β3 (hamster anti m) 
CXCR4 (rat anti m) 
Phalloidin-Texas Red 
TSP1 (rabbit anti m) clone 7280 
TSP1 (mouse anti h) 
NID1 (goat anti m, h) 
CYR61 (goat anti m, h) 
SEM3C (goat anti m, h) 
Isolectin IB4 
Mac1 (rabbit anti m, h) 
Collagen IV (rabbit anti m) 
CD16/32 (rat anti m) 
ICAM-2 
CD31 (rabbit anti m, h) 
NID1 (rat anti m) 
 
LEM 2/63, LEM 2/15 (Gálvez, Matías-Román et al. 2001) 
Abcam 
Sigma-Aldrich 
Millipore 
BD Biosciences 
BD Biosciences 
Cell Signaling 
Abcam 
Santa Cruz Biotechnology 
BD Biosciences 
BD Biosciences 
BD Biosciences 
ML Iruela-Arispe  
Thermo Fisher Scientific 
Santa Cruz Biotechnology 
Santa Cruz Biotechnology 
Santa Cruz Biotechnology 
Sigma 
Abcam 
AbD Serotec 
BD Biosciences 
BD Biosciences 
Abcam 
Abcam 
 
 
 
- ANIMAL MODELS - 
 
Mmp14 knockout mice (MT1-/-) 
Generation of mice deficient in MT1-MMP was described elsewhere (Zhou, Apte et al. 2000). 
Briefly, MT1-MMP-null mice (MT1+/-) were generated by gene targeting in embryonic stem cells 
and bred by heterozygote mating, and heterozygotes were crossed back to the C57BL/6 strain 
(wildtype, WT). Mice were bred and maintained under specific pathogen-free conditions at the 
animal unit of the National Centre for Cardiovascular Research (CNIC). Mice were kept at a room 
temperature and a 12h:12h light/dark cycle and housed at max 5 animals per cage. Mice were fed 
on a commercial pellet diet and water was available ad libitum. All procedures involving animals 
were conducted in accordance with an institutional Committee’s approved protocol for the use of 
animals in research.  
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Genotyping was performed by PCR of genomic DNA extracted from tail snips. To confirm the 
presence of wildtype or null allele the following primers were used respectively, 5’-GCTC ATG 
AGG CGC CCT CGC-3’ and 5’-GGG CAC TTC TGG GAA GCG-3’; 5’-CAC GAG ACT AGT 
GAG ACG T-3’ and 5’-TCA GAA TTA CAC CCC TAA GG-3’ (Isogen Life Science). 7-10 day-
old mouse pups were used for all experiment involved MT1-MMP-deficient mice. 
 
Induction of colitis in mice 
Colitis was induced in 10-14 weeks of age C57BL/6 mice by administration of 1% or 4% (wt/vol) 
dextran sodium sulphate (DSS) for 7 days applied to mice ad libitum as drinking water in a feeding 
glass bottle. Animals were monitored daily during next 7 days by measuring body weight and 
colitis score. The baseline colitis score determined at day 0 was scored as 0; weight loss of 1-5% 
was scored as 1, 5-10% as 2, 10-20% as 3 and more than 20% as 4. For stool consistency normal, 
well-formed pellet were scored as 0, semi-formed pellet, which not adhere to the anus were 
qualified as 2 and liquid stool adhering to the anus was scored as 4. Similarly 0 score was assigned 
for no bleeding, 2 for positive hemoccult (ColoScreen) and 4 for gross rectal bleeding.  
After 7 days, mice were sacrificed and serum was collected by cardiac puncture and was used for 
ELISA measurement of soluble TNFα, VEGF, TSP1 and NID1. The whole colon was removed, 
cleaned with PBS and sectioned in OCT/paraffin for histological analysis or the whole mount 
staining. The remaining part of colon was homogenized in 0.05% Tween 20/PBS supplemented 
with PMSF (1mM) and protease inhibitor cocktail and centrifuges 10 min at 18,000 rpm.  
 
 
- PATIENT POPULATION - 
 
Patient with active and inactive CD and UC as well as healthy individuals were selected at the 
Servicio de Aparato Digestivo, Hospital Universitario La Princesa, Madrid, Spain and the study 
was approved by the institutional committee. The diagnosis of IBD was based on the generally 
accepted clinical, endoscopic and histopathological criteria. Moreover patients with CD and UC 
were divided into two groups, with low and high activity based on Mayo index. 
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- CELL CULTURE - 
 
Primary mouse lung endothelial cells (pMLEC)  
Mouse neonates were sacrificed by decapitation and spray down with 70% ethanol. Lungs were 
excised in the culture hood and placed in a sterile tube containing DMEM-F12 and kept on ice until 
beginning the cell isolation procedure. After any fat, blood clots and connective tissues were 
removed, using sterile scissors or scalpel lungs were minced for 5 minutes until the tissues was 
homogenous. Prepared this way lungs were transferred to a 50 ml tube containing 5 ml of 
collagenase and incubated in a water bath for 1 hr at 37oC with occasionally swirling. After 1 hr 
medium was added to stop the digestion and solution was poured 4 times with 21-gauge needle and 
next passed through a 70 µm cell strainer into a tube containing medium. Cells were pellet by 
centrifugation and plated into tissue culture flask coated with 10µg/ml fibronectin, 10µg/ml 
collagen I (Pure Col) and 0.1% gelatin and kept for at least 24 hrs. To produce pure population of 
endothelial cells obtained cell culture was sorted first to remove macrophages. For that cells were 
incubated with rat anti-mouse FcγR (CD16/CD32) followed by incubation with sheet anti-rat 
magnetic Dynabeads and separation on a magnetic holder. Cells were left to grow from 1-3 days 
and the positive sort was performed. Cells were incubated with antibody solution (rat anti-mouse 
ICAM-2) and next anti-rat Dynabeads. If needed positive sort was repeated once the cells reached 
50% confluence (Oblander, Zhou et al. 2005). Cells were grown in DMEM Ham’s F-12 medium 
supplemented with 20% FBS, L-glutamine, heparin, antibiotics and growth factors.  
 
 
Immortalized mouse lung endothelial cells (iMLEC)  
After selections primary MLEC cells were immortalized using middle T-antigen of polyoma virus 
by overnight infection with conditioned medium from Gpmt cell line supplemented with 10mM 
Hepes, 8µg/ml of polybrene and growth factors (25mg/ml). Gpmt cell line producing virus was a 
kind gift from Dr Reinhard Fässler (Max Planck Institute of Biochemistry, Munich, Germany). 
MT1-MMP expression and endothelial cell markers for immortalized MLEC were monitored by 
western blot and flow cytometry. iMLEC were grown in DMEM Ham’s F-12 medium 
supplemented with 10% FBS, L-glutamine, P/S and Hepes and the culture plates were coated with 
0.5% gelatin.  
 
 
Human umbilical vein endothelial cells (HUVECs) 
HUVECs from different donors (cultured up to passage 6) were purchased from Lonza or isolated 
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from freshly harvested umbilical cords as previously described (Gálvez, Matías-Román et al. 
2002). Cells were cultured in M199 medium supplemented with 20% fetal bovine serum, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 2.5 µg/ml fungizone, 10 UI/ml heparin and 50 µg/ml of EC 
growth supplement extracted from bovine brain. 
 
 
- EXPERIMENTAL PROCEDURES - 
 
SILAC labelling procedure 
MLEC were grown in complete SILAC Advance D-MEM F-12 Flex Medium supplemented with 
‘light’ and ‘heavy’ amino acids and dialyzed serum to exclude the possibility of incorporating non-
labeled amino acids. We used non-labeled lysine and the 13C6 form of arginine (‘light’ conditions) 
for MT1-MMP null MLEC, and isotopes of lysine (13C6) and arginine (13C6 15N4) for WT MLEC 
(‘heavy’ conditions). Cells were cultured for 7 days, corresponding to about 6 doublings, and 
appropriate amounts of isotopic lysine and arginine were used to optimize isotopic incorporation 
while minimizing the risk of arginine to proline conversion. For the last 48 h of culture, medium 
was replaced by serum-free medium, to reduce the serum protein background, and for the last 24 h 
cells were stimulated with 20 ng/ml TNFα. At the end of the 7 day period, conditioned medium 
from null and WT cultures was collected and the cells harvested with cold PBS + 10 mM EDTA. 
Supernatants from null (‘light’ condition) and WT (‘heavy’ condition) were pooled 1:1 after 
bicinchoninic acid protein determination (BCA Protein Assay, Pierce). The pooled media were 
incubated for 3 h at 4oC with WGA-agarose beads to extract glycoproteins, and the glycoproteins 
were eluted by incubation with 0.5 M N-acetyl-D-glucosamine. The glycoprotein mixture was 
concentrated on a 3kDa cut-off centrifugal filter (Amicon Ultra-4, Millipore) to a final volume of 
200 µl. Urea was added to a final concentration of 8M, pH 8.5. Proteins were reduced by addition 
of 50 mM DTT, followed by carbamidomethylation with 125 mM iodoacetamide. Finally, the 
protein mixture was purified by acetone-trichloroacetic acid precipitation (2D-CleanUp kit, GE 
Healthcare). The pellet was resuspended in loading buffer, and proteins were separated by 10% 
SDS-PAGE. 
 
Protein identification and data analysis 
After separation of proteins on 10% SDS-PAGE gel, the Coomassie–stained protein bands were 
excised as 20 slices (Figure 8) and each one was subjected to in-gel tryptic digestion using 
modified porcine trypsin (Promega).  
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Figure 8.   Supernatant protein separation in SDS-PAGE gel after WGA lectin-affinity purification 
and N-deglycosylation. Supernatant proteins from WT and MT1-/- iMLEC cultures were mixed 1:1. The 
whole gel lane was divided in 20 horizontal pieces; each band was separately digested with trypsin. In 
addition to peptide quantitation we obtained information about peptide origin (intact versus protein 
fragment).   
 
The digests were then dried in a vacuum centrifuge, extracted with formic acid solution and 
analyzed on an Esquire HCT IT mass spectrometer (Bruker), coupled to a nano-HPLC system 
(Ultimate, LC Packings). Peptide mixtures were first concentrated on a 300 mm i.d., 1 mm PepMap 
nanotrapping column and then loaded onto a 75 mm i.d., 15 cm PepMap nanoseparation column 
(LC Packings). Peptides were then eluted by an acetonitrile (ACN) gradient (0–60% B in 150 min, 
where B is 80% ACN, 0.1% formic acid in water; flow rate ca. 300 nl/min) through a PicoTip 
emitter nanospray needle (New-Objective, Woburn) onto the nanospray ionization source of the IT 
mass spectrometer. MS/MS fragmentation (1.9 s, 100–2800 m/z) was performed on two of the 
most intense ions, as determined from a 1.2 s MS survey scan (310–1500 m/z), using a dynamic 
exclusion time of 1.2 min for precursor selection and excluding single-charged ions. Data were 
processed for protein identification and quantification with Protein Scape 2.1 and WARP-LC 1.2 
(Bruker, Bremen), a software platform that integrates processing of LC-MS run data, protein 
identification through database search of MS/MS spectra, and protein quantification based on the 
integration of the chromatographic peaks of MS extracted ion chromatograms for each precursor. 
Amino acid sequences were used to screen the protein databases with dedicated software (Protein 
Scape). Proteins were identified using Mascot (Matrix Science) search engine and for further 
protein analysis Protein Knowledgebase UniProtKB (http://www.uniprot.org) and GeneCards 
database (http://www.genecards.org) were used. MS/MS spectra were searched with a precursor 
mass tolerance of 1.5 Da, fragment tolerance of 0.5 Da, trypsin specificity with a maximum of 1 
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missed cleavage, cysteine carbamidomethylation as a fixed modification, and methionine oxidation 
and the N-terminal and corresponding Lys and Arg SILAC labels as variable modifications. A 
positive identification criterion was set as an individual Mascot score for each peptide MS/MS 
spectrum higher than the corresponding homology threshold score. The false positive rate for 
Mascot protein identification was measured by searching a randomized decoy database and 
estimated to be under 4%. For protein quantification, H/L ratios were calculated by averaging the 
measured H/L ratio for the observed peptides, after discarding outliers. For selected proteins of 
interest, quantitation data obtained from the automated Protein Scape software analysis were 
manually reviewed.   
 
Bioinformatic data analysis with Babelomics 
The Babelomics web tool (http://www.babelomics.org/) is a freely available program suited to 
analysis of large-scale experiments (microarrays, proteomics) with functional annotation (Medina I 
2010). The FatiGO module was used for enrichment analysis of selected proteins (Al-Shahrour, F 
2004 Bioinformatics). This functional profiling was performed by comparing two lists of genes, the 
first being the genes encoding the proteins with an H/L ratio > 1.5 in the SILAC analysis unless 
otherwise stated, and the second being the rest of the genome. 
 
 
Overlap analysis 
Overlap analysis and generation of Venn diagrams was performed at 
http://www.pangloss.com/seidel/Protocols/venn4.cgi. 
 
3D endothelial tip-like cell sprouting assay 
Matrigel® was thawed overnight on ice at 4°C and all materials were chilled before use. MLEC 
were plated at confluence in ibidi® angiogenic chambers and left to attach, after which the 
Matrigel layer was added on top. Medium containing TNFα was added and the chamber was kept 
at 37 °C for at least 18 h. At the end of incubation, medium was removed and the cells were fixed 
with freshly prepared 4% PFA for 20 min, followed with permeabilization in 0.3% Triton X-100. 
Samples were washed with PBS/Triton X-100 and stained for CYR61 as described in Supplemental 
Information. Samples were examined under a Zeiss LSM700 confocal microscope (Plan-
Apochromat 40x1.3 Oil DIC M27) and images were analyzed with ZEN software. 
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Whole-mount staining 
Eyes from 6 to 8 days-old mice (P6-P8) were removed and fixed with 4% PFA overnight at 4oC. 
Fixed retinas were flat mounted and blocked in 2% BSA/PBS/0.3% Triton X-100 followed by 
overnight incubation with primary antibodies (anti-CYR61) and isolectin IB4 (Sigma) to visualize 
vasculature. The next day retinas were extensively washed and incubated with fluorescent-
conjugated secondary antibodies.  
 
Part of colon closest to the anus was removed, cleaned and fixed with 4% PFA. Fixed samples 
were flat-mounted and blocked in 2% BSA/0.3% Triton X-100 in PBS, followed by overnight 
incubation with primary antibodies (anti-TSP1, -NID1, -MT1-MMP, -CD31). The next day, 
samples were extensively washed with 0.05% Triton X-100/PBS and incubated with fluorescent-
conjugated secondary antibodies. Images were acquired with Zeiss LSM700 confocal microscope 
(Plan-Apochromat 63X1.4 Oil DIC M27) and analysed with ZEN Software.  
 
 
Enzyme-Linked Immunosorbent Assay 
Soluble levels of VEGF-A, TSP1, NID1 and TNFα were measured in blood serum using enzyme-
linked immunosorbent assay (ELISA), according to the manufacturer's instructions. Blood was 
collected from control individuals and patients with IBD and serum was separated by 
centrifugation and store at -80oC. Optical density from an average of triplicate readings for each 
sample and control was measured at 450nm and to correct optical imperfections in the plate the 
reading was subtracted at 570nm. A four parameter logistic (4-PL) curve-fit was generated using 
Benchmark Plus microplate spectrophotometer (BIO-RAD) coupled computer software.  
 
 
Quantitative RT-PCR analysis  
For relative quantitation of expression, quantitative real-time PCR analysis was performed using 
the AB7900 FAST 384 Detection System (Applied Biosystems), according to the manufacturer's 
instructions. RNA was extracted from confluent and cDNA synthesis was performed with 1 µg of 
total RNA using Qiagen RNA synthesis kit (RNeasy Plus mini kit, Qiagen). Predesigned qPCR 
primers for mouse Mmp14, Thbs1, Cyr61, Nid1, Sema3c, Tbp and Hrpt1 were selected from 
TaqMan Gene Expression Assay database (Applied Biosystems). Relative quantitation of each 
target gene was performed using comparative threshold multiplex PCR in gene expression relative 
to the Tbp and Hrpt1. The data were analyzed by qBASE program obtaining the Ct of the 
amplification products. 
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Total cellular RNA was purified from cultured HUVEC cells using TRIZOL reagent (Invitrogen), 
according to the manufacturer’s protocol and quantified using a Nanodrop ND-1000 (Thermo 
Fisher Scientific). cDNA synthesis was performed with 1 µg of total RNA using Qiagen RNA 
synthesis kit (RNeasy Plus mini kit, Qiagen). cDNAs were subjected to PCR amplification using 
the following primer pairs for human MT1-MMP: 5’-CGCTACGCCATCCAGGGTCTC-3’ and 
5’- CGGTCATCATCGGGCAGCACAAAA-3’ (Isogen Bioscience). The PCR products were 
visualized using ethidium bromide in 1% agarose gel. 
 
Transfection of small interfering RNA (siRNA) 
SILENCERTM siRNA constructs were purchased from Ambion® (Applied Biosystems). Specific 
oligonucleotide sequences targeting human MT1-MMP were as follows: 5’- 
CAUCUGUGACGGGAACUUU- 3’ and 5’-GGAAUGAGGAUCUGAAUGG-3’ and a non- 
targeting siRNA control which bears no homology with relevant human genes. For siRNA 
transfection, cells were seeded in 6-well plates at 2.5 x 105 and grown to reach 60-70% confluence. 
The different amounts of siRNAs and OligofectamineTM Reagent (Invitrogen) were diluted in 
Opti-MEM® I (Gibco, Invitrogen). The diluted siRNA-liposome complex was added to cells and 
incubated for 4 h. Following the transfection fresh Opti-MEM® I containing 30% FBS was added 
and cells were grown for 24h. After that cells were rinsed with fresh M199 medium and cultured 
with TNF during 24h for analysis. 
 
Western Blotting 
For substrate validation by Western Blot analysis cells were cultured in SILAC conditions (see 
below) unless otherwise stated. Supernatants were taken, cell debris removed and total protein in 
conditioned medium was incubated with WGA-agarose beads (Vector Laboratories) to enrich 
medium for glycoproteins, then the protein solution was eluted with 0.5M N-acetyl-D-glucosamine 
(Sigma) and concentrated by ultracentrifugation (Amicon Ultra-4, 5 kDa cut-off centrifuge tubes, 
Millipore). Cells were lysed in RIPA buffer containing protease inhibitors. Protein concentration 
was measured using bicinchoninic acid (BCA) protein assay. In chosen experiments protease 
inhibitor GM6001 (Chemicon International) was used at concentration 250nM for 24h. Microsomal 
fraction was obtained by incubation cells with sucrose buffer (20mM Tris-HCl pH 7.4, 0,25M 
sucrose, 1mM PMSF) after which cells were cracked with 25-guage needle and ultracentrifuged 
55000 RPM for 1.5h. Microsome pellet was resuspended in guanidinium chloride (Sigma). Cell 
lysates, microsomal fraction and conditioned media were resuspended in Laemmli buffer 2x or 4x 
and loaded on the SDS-PAGE gel and electrophoresis was performed in reduced conditions. 
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Proteins separated by SDS-PAGE were transferred to nitrocellulose membrane. After blocking 
non-specific binding sites with 5% skimmed milk (w/v) in PBS containing 0.5% Tween (v/v), the 
blots were incubated with the primary antibodies overnight at 4oC. Bound primary antibodies were 
detected using a horseradish peroxidase-conjugated secondary antibody. Signal was detected by 
chemiluminescence (Amersham, ECL Signal Detection Reagent, GE Healthcare) and relative 
protein expression was determined by densitometry using ImageJ software. 
 
 
Fluorescence-activated cell sorting (FACS) 
Immortalized MLEC were left untreated or treated with 20 ng/ml of the angiogenic factors VEGF, 
TNFα, MCP-1, MIP-2 (all from PeproTech), or SDF-1 (R&D Systems). For surface expression 
analysis, cells were harvested using Cell Dissociation Buffer and stained with rat anti- mouse 
VCAM-1, biotinylated hamster anti-mouse ICAM-1, hamster anti-mouse PECAM-1, rabbit anti-
mouse Jagged-1, rabbit anti-mouse VEGFR2 and rabbit anti-mouse MT1-MMP (HR, Abcam), 
followed by incubation with appropriate fluorescent-labeled secondary antibodies. Cell surface 
expression was determined in a flow cytometer (FACScanto; Beckton Dickinson) and data were 
analyzed with FACSDiva software. 
 
Immunofluorescence staining 
For immunofluorescent staining, cells were plated on matrix-coated glass coverslips, then fixed in a 
solution of 4% PFA for 10 min at room temperature and permeabilized with 0.1% Triton X-100 if 
needed. Non-specific reactivity was blocked with 2% BSA in PBS fro 30 min. Cells were labelled 
with primary antibodies (45 min at room temperature) and fluorescently labelled secondary 
antibodies (45 min at room temperature). Samples were examined under a Zeiss LSM700 confocal 
microscope (Plan-Apochromat 63x1.4 or 40x1.3 Oil DIC M27) and images were analyzed with 
ZEN software. 
Paraffin-embedded colonic sections of mouse CU and human low and high activity CD and CU 
were cut into 3-µm slices, deparaffinized then hydrated in alcohol series of decreasing 
concentration and treated with proteinase K in TE buffer (50mM Tris Base, 1mM EDTA, 0.5% 
Triton X-100, pH 8.0) for antigen retrieval. Samples were incubated with signal enhancer 
(Invitrogen) and blocked species-dependent serum. Incubation with a primary antibodies; rabbit 
anti-mouse TSP1 (provided by Dr M. L. Iruela-Arispe, University of California, Los Angeles, CA, 
USA), rat anti-mouse NID1, rabbit anti-mouse/human MT1-MMP (HR, Abcam), mouse anti-
human TSP1, rabbit anti-human NID1 was performed at a 1:50 dilution at 4oC overnight followed 
by appropriate fluorescent-label secondary antibody. Intestinal vasculature was evaluated by 
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immunostaining with rabbit anti mouse/human CD31 (Abcam). Control individuals revealed any 
neither histopathological nor clinical changes during colonoscopy.  
 
Data analysis and statistics 
The protein expression in western blot or semiquantitative PCR images was quantified 
densitometrically using ImageJ software (NIH, Bethesda, USA) and normalized in respect to the 
corresponding band of loading control. Graphs were generated using GraphPad Prism 4.0 Software 
(GraphPad Software, La Jolla, USA). Nonparametric one-way analysis of variance with Tukey’s 
post test was used to compare means of two or more groups. For analysis of two groups within a 
single experiment Student’s t test was applied. All the experiments were performed at least in 
triplicate. Data are represented as mean value ± SEM. Differences were considered significant 
when p<0.05.  
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- SETTING UP A MODEL OF INFLAMMATORY ENDOTHELIAL TIP CELLS - 
 
In order to establish in vitro model of inflammatory endothelial cells expressing MT1-
MMP for shotgun proteomics analysis to understand the MT1-MMP function in the 
vasculature, we first analyzed its expression by real-time quantitative PCR and western blot 
in primary ECs in resting conditions or upon inflammatory stimulation with TNFα (Figure 
9). MT1-MMP mRNA and proteins levels were low in ECs in basal conditions; relative 
MT1-MMP mRNA and protein levels increased upon stimulation with TNFα. These 
expression patterns are in accordance with previous observations from our group showing 
that MT1-MMP was expressed at low levels in peripheral blood human monocytes and 
upregulated upon their activation by adhesion to matrix components such as fibronectin or 
to inflammatory endothelial ligands ICAM-1 and VCAM-1 (Matías-Román et al. 2005). 
 
 
 
Figure 9.   MT1-MMP expression in ECs - key players in vascular remodeling. Quantitavive 
mRNA (A) and protein levels (B) of MT1-MMP in ECs untreated or treated with overnight with 20 
ng/ml TNFα CNRQ: calibrated normalized relative quantity; β actin was used as a loading control; 
n=3). (C) pMLECs culture in 3D ibidi chamber expressed MT1-MMP after treatment with TNF  
(20ng/ml). 
 
 
Mouse lung endothelial cells (MLECs) are useful model to investigate inflammation-
induced capillary formation (Gálvez et al. 2005; Genis et al. 2007). Unfortunately only a 
limited number of endothelial cells can be obtained from neonate mice, meaning an 
important issue for proteomic analysis. Therefore to ensure sufficient number of cells, 
primary MLECs (pMLEC) from wildtype (WT) or MT1-MMP null mice were immortalized 
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by infection with polyoma middle T-antigen (PyV MT) virus, a membrane bound 
polypeptide transforming the primary cells into a stable cell line by directing the infected cell 
to enter the cell cycle. Transforming ability of PyV MT is exerted by association with a 
number of cellular proteins like src-family tyrosine kinases, protein phosphatase 2A (PP2A), 
phosphatidylinositol 3-kinase (PI-3K) and an adaptor protein Shc among others. These 
interactions in turn stimulate mitogenesis and thus activate cell growth and proliferation via 
stimulation of Akt and MAP kinases cascades (Cheng et al. 2009; Ichaso and Dilworth 
2001).  
Immortalized MLEC (iMLEC) maintained endothelial cell morphology and show a 
stable endothelial cell behavior manifested by monolayer formation and similar response to 
inflammatory and angiogenic factors. They express typical endothelial cell markers, such as 
CD31 (PECAM1), and an inflammatory response to TNFα stimulation showed by ICAM-1 
and VCAM-1 induction was similar to pMLEC (Figure 10). 
 
 
Figure 10.   iMLECs respond similarly than pMLECs to TNFα stimulation. (A) pMLECs were 
immortalized by infection with polyoma middle T virus. Phase contrast images show morphology of 
pMLECs and iMLECs; (B) levels of PECAM-1 and MT1-MMP in pMLECs and iMLECs assessed by 
flow cytometry are shown. (C) Histograms show representative flow cytometry analysis of the cell 
surface expression of ICAM-1 and VCAM-1 in pMLECs and iMLECs stimulated with 20 ng/ml 
TNFα (n=3). 
 
To establish a model of inflammatory tip cells, we evaluated the effect of some 
angiogenic and/or inflammatory agents like VEGF and TNFα on the expression of the 
endothelial tip cell markers Jag1, VEGFR2, Dll4, MT1-MMP, integrin β3, and CXCR4 at 
different time-points. The expression of these markers was measured 4, 24 and 48h after 
stimulus, the time window when endothelial cells upon angiogenic stimulus acquired the tip 
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phenotype and start to sprout (Sainson et al. 2008). Flow cytometry analysis of surface 
expression showed distinct regulation patterns for each cytokine stimulus (Figure 11). The 
increase of Jag1 surface expression was observed during first hours of stimulation with 
TNFα, while this induction did not occurred until 48h after pulse of VEGF. The expression 
of VEGFR2 was low during first hours with all of the stimuli, but with significant tendency 
to increase in case of TNFα early after stimulation. There were no significant changes in the 
expression of Dll4 during the treatment in any condition. Even though it was shown that 
Dll4 significantly changes its expression pattern during sprouting angiogenesis, the 
oscillation in the expression levels of Jag1/Dll4 might be too short to detect them easily at 
any time or more probably cells are being primed to induce the tip phenotype but the 
equilibration mechanism which control tip/stalk balance are not yet active. 
 
 
Figure 11.   Hierarchical clustering of patterns of induction endothelial tip cells by angiogenic and 
inflammatory factors. (A) iMLECs were left untreated (0 h) or treated with 20 ng/ml of VEGF or 
TNFα, and the expression of the tip cell markers VEGFR2, Jag1, Dll4, MT1-MMP, integrin β3 and 
CXCR4 was analyzed at the cells surface by flow cytometry at 4, 24 and 48 h (n=3). (B) Average 
percentages of positive population for each marker and condition (right) were analyzed by the high 
content analysis software Genesis upon normalization of data. Hierarchical schemes obtained for each 
angiogenic or inflammatory factor are shown (left).  
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These results confirmed that iMLECs respond to TNFα addition as previously 
described in primary human ECs (Sainson et al. 2008). In addition, MT1-MMP surface 
expression was consistently increasing during the whole period of treatment (Figure 11), 
according to previously suggested observation in other cell types (Han et al. 2001). In 
addition, this particular regulation of MT1-MMP by TNFα suggests its possible implication 
in specific aspects of angiogenesis, as it has previously been proposed by our group (Gálvez 
et al. 2005).  
To choose the appropriate inflammatory stimulus for inducing endothelial tip cells, 
we analyzed and compared the expression patterns of the endothelial tip cell markers after 
stimulation with TNFα and VEGF using hierarchical clustering analysis performed with 
Genesis (Sturn et al. 2002), a versatile, independent platform Java suite. As shown in Figure 
11, this global analysis identifies distinct patterns of induction of endothelial tip cells: (1) 
developmental, induced by VEGF and focused on Dll4 and VEGFR2 regulation (De Smet et 
al. 2009); (2) inflammatory, induced by TNFα and based on the regulation of Dll4/MT1-
MMP and Jag1/CXCR4. This high content analysis provided insights into the molecular 
heterogeneity of angiogenesis and pointed to TNFα as the prototypic inflammatory inducer 
of endothelial tip cells (Sainson et al. 2008).  
Not only TNFα also induces expression of tip cell markers, but also stimulated 
endothelial cells to induce tip cell phenotype characterized by formation characteristic 
membrane protrusions. TNFα-stimulated iMLEC in 2D and pMLEC in 3D were more 
elongated and exhibited filopodia-like membrane protrusions, respectively, compatible with 
the morphology of retinal endothelial tip cells (Figure 12).  
 
Figure 12.   TNFα-stimulated pMLECs and iMLECs showed tip cell phenotype. TNFα-stimulated 
pMLECs and iMLECs were cultured in 2D or 3D conditions and stained with phalloidin or anti-
PECAM-1 antibody; F-actin-based masks and original staining are shown for 2D and 3D conditions, 
respectively.  
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Previous studies have shown a positive correlation between vessel sprouting and 
MT1-MMP expression (Mori et al. 2013; Yana et al. 2007). Moreover mathematical models 
suggest that MT1-MMP contributes to endothelial tip cell guidance (Karagiannis and Popel 
2006), however MT1-MMP gene was not found enriched in the microarray assay performed 
in retinal tip cells (del Toro et al. 2010; Strasser et al. 2010); low levels of MT1-MMP might 
have been missed or MT1-MMP might be especially relevant in inflammatory angiogenesis.  
Although Dll4 and CXCR4 are the identified tip cell markers in developmental 
retinal angiogenesis, MT1-MMP is required for inflammation-driven angiogenesis (Gálvez et 
al. 2005) and Jag1 is the Notch ligand induced in inflammatory tip cells (Sainson et al. 
2008). Accordingly TNFα is an early tissue-damage signal for angiogenesis and can induce 
morphological and molecular changes compatible with induction of endothelial tip cell 
phenotype (Ligresti et al. 2011; Sainson et al. 2008). Other patterns induced by the 
chemokines MIP-2 (mouse ortholog of human interleukin-8) or SDF-1 are likely related to 
their distinct angiogenic properties (Gálvez et al. 2005; Stoll et al. 2011). 
The role of TNFα in angiogenesis is controversial due to its reported contrary effect 
on endothelial cells. It has been shown that TNFα can either block or promote EC migration 
and proliferation, as well as down- or upregulate VEGFR2 expression and therefore promote 
or inhibit angiogenesis in vitro and in vivo (Baluk et al. 2004; Sainson et al. 2008). However, 
as a major inflammatory mediator can induce expression of adhesion molecules or MMPs, 
and thus can affect angiogenesis differently at each step.   
Endothelial tip cells are crucial to initiate an efficient angiogenic response (De Smet 
et al. 2009). The molecular fingerprint of these tip cells has started to be elucidated by recent 
transcriptomics analysis in retinal tip cells; matrix and matrix-related genes as well as 
secreted proteins such as apelin seemed to be particularly represented (del Toro et al. 2010). 
We then hypothesized that identification of MT1-MMP collection of substrates in 
inflammatory tip cells will provide insights into their function. 
 
 
 
- A SILAC APPROACH TO CHARACTERIZE MT1-MMP DEGRADOME IN TNFα -INDUCED 
ENDOTHELIAL TIP CELLS - 
 
Proteolysis by transmembrane proteases mainly impacts other transmembrane or 
secreted glycoproteins. In particular, transmembrane proteins are present in relatively low 
abundance and they are often missed in global, broad-spectrum analysis of cell or tissue 
arrays. MT1-MMP activity might be important from first steps of angiogenic remodeling and 
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molecules contributing to these initial and probably time-limiting steps might be attractive 
therapeutic targets for clinical intervention in diseases with pathologic angiogenesis. 
Therefore comparative analysis of wildtype and MT1-MMP-deficient endothelial tip cells 
can be useful for identification of molecules specifically regulated by MT1-MMP and 
contributing to the early angiogenic events.  
Having established the model for inflammation-driven endothelial tip cells, we 
sought to define the MT1-MMP degradome by SILAC. This approach allows identifying 
and quantifying proteins regulated by MT1-MMP activity. For that wildtype iMLEC were 
labeled with essential amino acids containing ‘heavy’ (H) non-radioactive isotopes (13C6 
lysine and 13C615N4 arginine), whereas MT1-MMP null iMLEC were labeled with ‘light’ (L) 
isotopes (lysine and the 13C6 form of arginine) (Figure 13). Labeling was accomplished by 
metabolic incorporation of amino acids implemented in cell culture medium, which was 
previously dialyzed for removal of any additional lysine and arginine. This metabolic 
labeling does not affect cell behavior nor physiology and essential amino acids are easily 
incorporated and replaced in all cell proteins even for protein with low turnover. 
Approximately five to six cell doublings are needed to incorporate >95% of amino acids and 
combination of two different amino acids allows mixing differentially labeled cells and so 
subsequent purification and fractionation steps will not introduce errors in quantification 
(Mann 2006). To increase the specificity and sensitivity for the extracellular proteins, we 
have include enrichment for glycoproteins using WGA-lectin beads which can bind 
oligosaccharides commonly present in secreted and membrane glycoproteins (Guo et al. 
2012).  
 
 
 
Figure 13. SILAC in TNFα-stimulated immortalized mouse lung endothelial cells (iMLEC). (A) 
SILAC strategy for comparing the supernatant proteome of WT (MT1+/+) and MT1-MMP null (MT1-
/-) iMLEC stimulated with TNFα (20 ng/ml) for 24 h. (B) Peptide mass spectra for nidogen-1 (NID1) 
and thrombospondin-1 (TSP1), with relative abundance of heavy and light-labeled forms. 
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Our particular interest was focused in the proteolytic events; therefore we analyzed 
in details the culture supernatant from wildtype and MT1-MMP null iMLECs 
(GLYCOPROTEOME). Corresponding microsomal fraction (PROTEOME) was composed by all 
mostly plasma membrane and intracellular proteins. After mixing in 1:1 proportion based on 
protein amount, supernatant glycoproteins were separated by SDS-PAGE, and trypsin-
digested gel slices were analyzed by mass spectrometry. 157 proteins in conditioned medium 
and 797 proteins in microsomal fraction were identified and quantified (relative H/L ratios) 
(Table 7 and Table 8), with only 28 proteins found in both fractions, suggesting that the 
presence of putative substrates in the supernatant degradome reflects specific MT1-MMP-
dependent processing and not high abundance in inflammation-activated endothelial cells 
(Figure 15A).  
Although most of the identified proteins were glycoproteins, a small number of 
intracellular (nuclear and cytosolic) proteins were also detected likely related to non-specific 
release of cell proteins by apoptotic cells or to alternative functions of these processed 
intracellular proteins in the extracellular milieu (Butler et al. 2009). A list of all proteins and 
their UniProt ID accession is presented in Table 7 and 8. 
Despite our great efforts to increase protein abundance and to exclude nonspecific 
intracellular proteins from analysis, the number of identified proteins is not significantly high 
when compared to other proteomic studies. We can speculate that although our model 
endothelial cells are immortalized their activity is still far from stable cell lines or cancer cells 
used in other comparative studies.  
Interpretation of H/L ratios in the supernatant glycoproteome is complex and 
depends mostly on the protein type; a transmembrane protein or a matrix-bound secreted 
protein shed by MT1-MMP will be more frequent in conditioned medium of WT cells and 
thus yielding an H/L ratio >1. On the other hand, a secreted protein degraded by MT1-
MMP might be more frequent in medium of null cells, giving an H/L ratio <1 (Doucet et al. 
2008) (Figure 14).  
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Figure 14. Interpretation of the H/L ratio in SILAC data analysis. Interpretation of the H/L ratio is 
complex; a transmembrane protein or a matrix-bound secreted protein shed by MT1-MMP will yield 
an H/L ratio >1 and secreted proteins degraded by MT1-MMP might give H/L ratios < or >1. 
 
 
 
816 supernatant and 2765 microsomal peptides with well-defined mass spectra were 
used to quantify protein ratios between WT (heavy, H) and null (light, L) proteins (Figure 
15C and D). Peptide H/L ratio frequencies show a Gaussian distribution with a peak at log 
H/L=0, indicating equivalent labeling of WT and MT1-MMP null cells. Since H/L>1 is the 
more likely outcome for protease action on the supernatant glycoproteome, we defined the 
MT1-MMP-dependent endothelial DEGRADOME as the set of glycoproteins with an H/L ratio 
>1.5, taking as a reference well known MT1-MMP substrate collagen type III with 
H/L=1.67 (Table 7). Noteworthy, there were more altered H/L ratios in the supernatant 
glycoproteome than in the microsomal proteome (31.85% vs 17.82% H/L>1.5) suggesting 
the proteolytic impact of MT1-MMP in the extracellular compartment (Figure 15B).  
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Figure 15.  SILAC data analysis. (A) Venn diagram showing proteins identified in both microsomal 
proteome and supernatant glycoproteome. (B) Histogram shows the percentage of quantified proteins 
with H/L ratio=1, and < or >1.5-fold change in the microsomal proteome and the supernatant 
glycoproteome.Normal distribution of H/L ratios of labeled peptides in microsomal proteome (C) and 
supernatant glycoproteome (D).  
 
 
This result showed larger variations in the supernatant glycoproteome than in the 
microsomal proteome in the absence of MT1-MMP, this highlights the power of performing 
SILAC in culture supernatants for protease analysis, since catalytic activity mostly affects 
transmembrane and secreted glycoproteins that represent a small fraction of the total 
proteome (Beck et al. 2011). 
 
 
 
- MT1-MMP ENDOTHELIAL DEGRADOME: EXCLUSIVE AND NON-EXCLUSIVE 
SUBSTRATES - 
 
Functional categorization of the identified proteins based on their generic assigned 
function (DAVID application (d. W. Huang et al. 2008) and PubMed search defined a group 
of angiogenesis-related proteins and a smaller group unrelated to angiogenesis (Table 9). A 
literature search showed that while some MT1-MMP degradome proteins are also substrates 
for other MMPs/ADAMs proteases, most are exclusive substrates of MT1-MMP. Exclusive 
MT1-MMP substrates included extracellular matrix (ECM)/matricellular proteins (CYR61, 
FBLN2, SNED1) and non-ECM proteins (PR2C2, SLIT2, EGFR, SFRP1). Among non-
exclusive substrates were several ECM proteins such as TSP1 and TSP2, collagen III and IV, 
fibronectin, fibrillin, laminin, tenascin, and nidogen (Table 9). 
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Table 9. MT1-MMP degradome glycoproteins grouped in relation to their reported function in 
angiogenesis. 
Information about reported protein function was obtained from the DAVID annotation database and PubMed 
(search keywords: protein or gene name AND angiogenesis, vasculogenesis, endothelial cell migration, endothelial 
cell adhesion OR endothelial cell proliferation). Reported processing of each protein by MT1-MMP or other 
MMP/ADAM proteases is indicated. Asterisks (*) mark proteins reported to be processed by other protease 
families (serine proteases, etc.). 
Table I. MT1-MMP degradome glycoproteins grouped in relation to their reported function in angiogenesis
Protein name Protein function Ratio H/L Processed by MMP / ADAM proteases
ITPR1 Inositol 1,4,5-trisphosphate receptor type 1 Calcium signaling pathway 18.04 *
TSP2 Thrombospondin-2 Cell adhesion, ECM-receptor interaction 8.68 ADAMTS1, MMP-2, -9, 
MMP3 Stromelysin-1 Proteolysis 6.04 -
LYOX Protein-lysine 6-oxidase Vasculature development, extracellular matrix 
organization
5.68 *
PCOC1 Procollagen C-endopeptidase enhancer 1 Proteolysis 5.53 MMP-2
TRPM2 Transient receptor potential cation channel 
subfamily M member 2
Ion transport 5.33 -
EGFR Epidermal growth factor receptor Proliferation, protein interaction 4.60 -
SODE Extracellular superoxide dismutase [Cu-Zn] Oxygen metabolism 4.37 *
PTX3 Pentraxin-related protein PTX3 Membrane organization, endocytosis 4.20 MT1-MMP
PR2C2 Prolactin-2C2 Vascular development, cell migration 4.14 -
IC1 Plasma protease C1 inhibitor Immune response 3.70 -
CNTN1 Contactin-1 Cell adhesion 3.67 -
STC1 Stanniocalcin-1 Cellular ion homeostasis 3.59 MT1-MMP
SFRP1 Secreted frizzled-related protein 1 Development, differentiation 3.34 -
TIMP1 Metalloproteinase inhibitor 1 Enzyme inhibitor activity 3.14 MMP-9
SEM3C Semaphorin-3C Vasculature development, axon guidance 2.94 ADAMTS1, ADAMTS13
CO6A1 Collagen alpha-1(VI) chain Cell adhesion 2.88 MMP-9, -13
FBN1 Fibrillin-1 Metal ion binding 2.76 MT1-MMP, MMP-2, -3, -7, -9, -12, -13
SLIT3 Slit homolog 3 protein Axon guidance 2.51 -
LIF Leukemia inhibitory factor Receptor interaction, Jak-STAT signaling pathway 2.37 MMP-9
CERU Ceruloplasmin Metal ion binding 2.29 -
NID1 Nidogen-1 Cell adhesion, binding 2.26 MT1-MMP, ADAMTS1, MMP-15, -19, 
NGAL Neutrophil gelatinase-associated lipocain Response to virus 2.11 -
MMP19 Matrix metalloproteinase-19 Vascular development, differentiation 2.10 -
CSF1 Macrophage colony-stimulating factor 1 Cytokine-cytokine receptor interaction 2.06 -
GELS Gelsolin Cytoskeleton organization 2.06 MT1-MMP
TENA Tenascin Focal adhesion, ECM-receptor interaction 2.04 MT1-MMP
FBLN2 Fibulin-2 Cell adhesion, matrix binding 2.04 -
CO3 Complement C3 Immune response, ECM-receptor interaction 1.96 MT1-MMP
CCL2 C-C motif chemokine 2 Proliferation. Immune response, chemotaxis 1.86 -
TIMP3 Metalloproteinase inhibitor 3 Enzyme inhibitory activity 1.80 -
SLIT2 Slit homolog 2 protein Axon guidance, cell motion 1.73 -
TSP1 Thrombospondin-1 Migration, cell adhesion, immune response 1.68 MT1-MMP, ADAMTS1, ADAMTS13
CYR61 Protein CYR61 Vasculature development, adhesion, proliferation 1.68 MT1-MMP, *
CO3A1 Collagen alpha-1(III) chain Vasculature development 1.67 MT1-MMP
TIMP2 Metalloproteinase inhibitor 2 Enzyme inhibitory activity 1.67 -
KLRA4 Killer cell lectin-like receptor 4 Cell adhesion, NK mediated cytotoxicity 14.90 -
KPBB Phosphorylase b kinase regulatory subunit 
beta
Calcium signaling pathway 11.58 -
SNED1 Sushi, nidogen and EGF-like domain-
containing protein 1
Cell adhesion 7.05 -
CPXM1 Probable carboxypeptidase X1 Adhesion, proteolysis 6.12 -
IGS10 Immunoglobulin superfamily member 10 Receptor signaling 5.85 -
GDN Glia-derived nexin Enzyme inhibitory activity, developmental protein 1.95 -
AEBP1 Adipocyte enhancer-binding protein 1 Regulation of transcription, cell adhesion 1.77 -
LOXL3 Lysyl oxidase homolog 3 Oxidoreductase activity 1.73 -
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Thus SILAC analysis also provides insights into the question of redundancy versus 
specificity of substrate cleavage by MMP/ADAM family members in angiogenesis. MT1-
MMP shares substrates mainly with ADAMTS1, suggesting molecular and/or functional 
cooperation or overlap between these proteolytic pathways. Further support for functional 
overlap between these proteases is that ADAMTS1 is upregulated in the transcriptome of 
retinal endothelial tip cells (del Toro et al. 2010). Most of the identified MT1-MMP 
substrates are related directly or indirectly to angiogenesis, supporting the key role of this 
protease in the process of vessel formation. A few SILAC MT1-MMP substrates were 
previously identified by iTRAQ/ICAT in tumor cells (Tam et al. 2004) by DIGE in human 
plasma incubated with the MT1-MMP catalytic domain (Hwang et al. 2004) supporting the 
robustness of these techniques and pointing to MT1-MMP cleavage of a given substrate in 
different contexts.  
 
 
- MT1-MMP ACTIVITY MODULATES KEY BIOLOGICAL PROCESSES IN TNFα-
ACTIVATED ENDOTHELIAL CELLS - 
 
Since many of exclusive and non-exclusive putative substrates were known to be 
involved in angiogenesis and might reflect the essential role of MT1-MMP in this process, 
we next profiled identified degradome proteins (H/L>1.5) for Gene Ontology (GO) terms 
(Harris et al. 2004). The degradome protein set was analyzed with the FatiGO (Al-Shahrour 
et al. 2004) module in the open-source bioinformatics web tool Babelomics (Medina et al. 
2010), which compares genes/proteins of interest with the rest of the mouse genome. We 
analyzed first the Cellular Components terms to assess subcellular location and likely 
exposure of identified proteins to the protease. The FatiGO analysis indicated that potential 
MT1-MMP substrates are preferentially located in extracellular and matrix-related 
compartments (Figure 16A).  
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Figure 16.  Gene Ontology analysis of MT1-MMP substrates. MT1-MMP putative substrates with 
an H/L ratio >1.5. were analyzed for GO terms. (A) and (B) Percentages of total identified GO 
Cellular Components and Molecular Functions terms.  
 
 
 
This finding is supported by Kegg (Kanehisa et al. 2004) pathway analysis, which 
indicated an association of MT1-MMP degradome components with ECM–receptor 
interactions (Figure 17). Accordingly, FatiGO analysis of Molecular Functions GO terms 
revealed enrichment of matrix and matrix-binding related functions in the MT1-MMP 
endothelial degradome (Figure 16B). Finally, GO analysis of Biological Processes (BPs) 
showed an enrichment of the MT1-MMP degradome in processes related to cellular 
adhesion, motility and chemotaxis - key steps in endothelial tip cell function - and to 
vascular remodeling (Figure 18).  
 
 
Figure 17.   Kegg analysis of the MT1-MMP endothelial degradome. Many proteins in MT1-MMP 
endothelial degradome can interact with other matrix proteins or cellular receptors, mostly integrins 
and proteoglycans. The scheme shows information extracted from Kegg analysis that identified the 
focal adhesion pathway within MT1-MMP degradome. Proteins identified by SILAC as potential 
substrates for MT1-MMP are highlighted in bold. 
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Figure 18.  Logarithmic p-values for enrichment in GO Biological Processes. Overlap analysis of 
identified MT1-MMP substrates included in the four general GO Biological Processes relevant to 
angiogenesis: cell motility, chemotaxis, cell adhesion, and vasculature development (Table 10).  
 
 
Although we used SILAC to identify transmembrane proteins, most of the identified 
MT1-MMP substrates in inflammatory endothelial tip cells are ECM proteins in accordance 
with reported retinal endothelial tip cells transcriptome (del Toro et al. 2010) and reinforcing 
the idea that matrix and its remodeling are essential during firsts steps of angiogenic growth.  
 
 
- THE MT1-MMP DEGRADOME REVEALS A COMBINATORIAL PROTEOLYTIC PROGRAM 
DURING ANGIOGENESIS - 
 
 
Since several MT1-MMP substrates were common in more that one BP, we 
performed an overlap analysis with a 4-way Venn diagram for proteins annotated in these 
particular BPs (Table 10). The functional clustering of selected MT1-MMP substrates 
included in Table 10 points to a combinatorial model of processing during inflammatory 
activation of endothelial cells. In this model MT1-MMP substrates are grouped into specific 
functional modules linked to GO Biological Processes related to angiogenesis (Figure 19). 
This analysis revealed a proteolytic program of 14 substrates; in which combined rather than 
single substrate processing by MT1-MMP would control key steps of the angiogenic response 
(Figure 19).  
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Table 10.   Babelomics and FatiGO analysis of GO Biological Processes terms in SILAC-identified 
supernatant glycoproteins (proteins with H/L ratio >1.5, rest of proteins, blue bars) versus the rest 
of genome. 
 
 
 
 
 
TSP1 seems to be critical for the MT1-MMP response since it is present in most of the 
functional modules. TSP1 can also be processed by other proteases such as ADAMTS1 (Lee 
et al. 2006), which also is present in the MT1-MMP degradome and is upregulated in the 
transcriptome of WT pMLEC activated with the inflammatory chemokine MCP-1 
suggesting that these two proteases and TSP1 cooperate during angiogenesis. Other 
identified substrates such as MMP19, CO3A1 and LYOX are also upregulated in the 
transcriptome of MCP-1–activated WT MLEC, suggesting that their relative abundance in 
the supernatant of WT MLEC might be related to regulation of their transcription or 
processing by MT1-MMP.  
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Figure 19.  MT1-MMP combinatorial program in TNFα-activated endothelial cells. Venn diagram 
showing substrates shared between BPs, indicating combinatorial rather than single processing of 
substrates. Colored lines demark the four GO Biological Processes. 
 
 
In this combinatorial model TSP1 is a master regulator of all four BPs and its 
processing in combination with MT1-MMP-mediated cleavage of other substrates would 
lead preferentially to specific downstream outcomes; for example, co-processing with NID1 
would affect endothelial cell adhesion, while processing with PR2C2 or SLIT2 would affect 
motility. CYR61 processing together with TSP1, CCL2 and SLIT2 determines chemotaxis. 
Additional processing of TSP1 with other substrates in the modules, such as SNED1, 
FBLN2, EGFR, CSF1, CCL2 or SEM3C, would further modulate these biological 
processes, leading finally to angiogenesis and vessel morphogenesis (Figure 19). 
Interestingly, some of these proteins, such as SNED1, were not previously identified as 
related to angiogenesis (Table 9). In the proposed model, modules can cross-combine: while 
the processing of some MT1-MMP substrates is linked to defined functions (such as CCL2 or 
SLIT2 to cell motility and chemotaxis), the processing of substrates with broader roles will 
affect multiple functions; for example, CYR61, which could contribute to cell adhesion, 
chemotaxis or vascular development depending on the accompanying substrates. This 
systems biology analysis indicates the existence of finely-tuned and orchestrated rather than 
random proteolysis during the angiogenic response. Overlap analysis also showed that 
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endothelial cell adhesion and vasculature development are molecularly closer and that cell 
motility is the most unique in the combination of processed substrates. 
 
One of the most novel aspects of our study involves the identification of a 
combinatorial proteolytic program of MT1-MMP in endothelial tip cells, which suggest a 
modular organization where substrates are grouped into functional modules linked to 
Biological Processes related to angiogenesis. There is also a hierarchical organization of 
these substrates since some of them are present in several functional modules. The common 
component of key GO modules related to angiogenesis is TSP1, identifying this multi-
domain matrix glycoprotein as a master regulator of biological processes including adhesion, 
motility, chemotaxis and morphogenesis, and potentially explaining the tight regulation and 
coordinated processing by MT1-MMP and ADAMTS1 (Lee et al. 2006). The outcome of 
angiogenesis will then depend on combined rather than individual processing of substrates, 
whose fragments might act in a competitive, synergic or sequential manner to angiogenic 
response. In this regard, several of the identified substrates share structural domains and are 
therefore able to interact with similar matrix proteins or cell receptors. For instance, key 
substrates such as TSP1 and CYR61, can directly or indirectly bind integrin αvβ3, an 
adhesion receptor expressed on ECs (del Toro et al. 2010; Galvez et al. 2002).  
 
 
 
- VALIDATION OF MT1-MMP SUBSTRATE PROCESSING IN VITRO:  
TSP1, CYR61, NID1 AND SEM3C - 
 
 
Several candidate proteins that were identified by SILAC and are being enriched in 
four main BPs were selected and validated in silico to confirm that these proteins contain 
putative MT1-MMP cleavage sequence (Arg – nonPro – Xpolar – XHy) at positions that predict 
the peptides identified by SILAC. For further validation TSP1, CYR61, NID1 and SEM3C 
were chosen within each of the 4 main BPs of Venn organization. In silico analysis confirmed 
that all four selected substrates contain putative MT1-MMP cleavage sequence at distinct 
positions (Kridel et al. 2002) that coincide with distribution of peptides identified by SILAC 
(Figure 20). 
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Figure 20.   Proteolytic maps and domain structures of TSP1, CYR61, NID1 and SEM3C. Arrows 
mark potential MT1-MMP cleavage sites beginning with R and gray-shaded areas indicate SILAC-
identified tryptic peptides. Examples of H/L ratios >1.5 are also indicated; (source 
http://www.uniprot.org/).  
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Based on SILAC analysis performed in culture supernatant (CSUP) and the ability of 
the identified proteins (TSP1, CYR61, NID1 and SEM3C) to bind to ECM and/or the 
basement membrane, we next hypothesized that the absence of MT1-MMP might affect 
cleavage of these proteins from the ECM and therefore their release to the supernatant. No 
major differences were observed in mRNA and protein levels of TSP1, CYR61, NID1 
(undetectable in total lysate) and SEM3C in total lysates of WT and MT1-MMP-null 
pMLECs treated with TNFα (24h), pointing to similar expression level and abundance of 
these substrates (Figure 21A and B). Lower soluble TSP1, NID1 and SEM3C levels were 
detected in culture supernatants of MT1-MMP-null pMLECs, indicating that MT1-MMP 
proteolytic action releases these proteins or its fragments from the ECM; consistent with 
cleavage of NID1 at the N or C terminus, the molecular weight of NID1 in supernatants 
from WT pMLECs was slightly smaller (Figure 21B). Higher levels of CYR61 were, 
however, found in medium from MT1-MMP-deficient cells, correlating with a more 
complex SILAC peptide profile and pointing to an active processing of the intact secreted 
form of CYR61 by MT1-MMP. Since decreased cleavage of these proteins from ECM could 
result in accumulation of intact proteins in cells and ECM, we verified distribution of these 
proteins in 2D cultures by immunofluorescence. Impaired processing in the absence of MT1-
MMP led to accumulation of TSP1, CYR61, NID1 and SEM3C in pericellular clusters in 
contact with the matrix and/or adhesion sites in MT1-MMP-null pMLECs (Figure 21C).  
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Figure 21. Impaired processing of TSP1, CYR61, NID1 and SEM3C in MT1-MMP null pMLEC. 
(A) Quantitative mRNA levels of selected MT1-MMP substrates. (B) Immunoblots show detection of 
TSP1, CYR61, NID1 and SEM3C in total lysates (TL) and culture supernatants (CSUP) of TNFα-
stimulated WT (MT1+/+) and null (MT1-/-) pMLEC; bar charts show densitometric quantification of 
proteins in supernatants (n=3) (left). (C) Confocal microscopy analysis was performed in TNFα-
stimulated WT and MT1-MMP null pMLEC immunostained for TSP1, CYR61, NID1 or SEM3C; 
representative maximal projections are shown (n=5) (right).  
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- ALTERED MT1-MMP-DEPENDENT PROCESSING OF SELECTED SUBSTRATES IN 3D 
ANGIOGENIC MODEL AND IN IN VIVO MODEL OF RETINAL DEVELOPMENT - 
 
TSP1, CYR61, NID1 and SEM3C have been related to angiogenesis and vascular 
development (Esselens et al. 2010; Ho et al. 2008; Iruela-Arispe et al. 2004; S. Kubota and 
Takigawa 2007) and we therefore analyzed the effect of MT1-MMP-mediated processing of 
these substrates in models better mimicking vascular development, such as 3D-Matrigel 
pMLEC cultures and retina postnatal vascularization. Although no major differences were 
observed in TSP1, CYR61, NID1, and SEM3C signal along endothelial cell 3D-tubes, 
enrichment and/or pericellular clusters of these substrates, especially of CYR61 and NID1, 
were observed along the endothelial tip cells formed by MT1-MMP-null pMLEC compared 
with WT (Figure 22).  
 
 
 
 
Figure 22. Impaired processing of TSP1, CYR61, NID1 and SEM3C in 3D Ibidi model. Confocal 
immunofluorescence of TSP1, CYR61, NID1 and SEM3C (red) and F-actin (white) in TNFα-
stimulated WT and null pMLEC grown in Ibidi chambers covered by 3D-Matrigel; representative 
maximal projections are shown (n=5).  
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Accordingly, we observed accumulation of CYR61 and NID1 along the filopodia of 
endothelial tip cells at the vascular front of retinas from MT1-MMP null neonates in contrast 
to the restricted distribution of CYR61 and NID1 to the posterior pole of retinal tip cells in 
wildtype (Figure 23); this points to an active role of MT1-MMP in CYR61 and NID1 
processing during vascular sprouting also in vivo. SEM3C and TSP1 were undetectable in the 
vasculature of mouse neonate retinas. 
 
 
 
 
Figure 23. Accumulation of CYR61 and NID1 in endothelial tip cells of retinas from MT1-MMP 
null mouse neonates. Whole mount confocal immunofluorescence of isolectin B4 (green) and CYR61 
and NID1 (red) in retnas of P6 WT (MT1-MMP+/+) and null (MT1-MMP-/-) mice; representative 
maximal projections are shown (n=4). 
 
 
We focused on validation of MT1-MMP processing of selected substrates involved in the 
four main BPs, cell motility, chemotaxis, cell adhesion and vasculature development (TSP1, 
CYR61, NID1 and SEM3C) whose cleavage would likely occur within the same time-frame 
cooperating in driving cellular responses leading to inflammatory capillary sprouting. 
However, it will be interesting to explore in the future whether MT1-MMP processing of 
other identified proteins such as PR2C2, CCL2 and CSF1 might also modulate their 
angiogenic properties in different scenarios. Conversely, as we demonstrated in TNF -
stimulated MT1-MMP null pMLECs, in the absence of MT1-MMP simultaneous 
accumulation of these substrates in ECs might contribute to defective angiogenesis. 
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- VALIDATION OF SELECTED MT1-MMP SUBSTRATES IN HUMAN PRIMARY 
ENDOTHELIAL CELLS - 
 
We next investigated whether the MT1-MMP proteolytic program identified in 
mouse ECs could be extendable to the human model. To this purpose, MT1-MMP 
expression was interfered by two independent siRNA oligonucleotides in human endothelial 
cells (HUVEC); the efficiency of MT1- MMP interference was higher than 70% assessed by 
RT-PCR and western blot (Figure 24). TSP1, CYR61, NID1 and SEM3C levels in total 
lysates from negative siRNA and MT1-MMP-interfered HUVEC were similar. Lower levels 
of TSP1, CYR61, and NID1 were however found in supernatants from MT1-MMP-
interfered compared with negative siRNA-interfered HUVEC pointing to decreased 
processing of these substrates in cells with reduced levels of MT1-MMP (Figure 25A). No 
differences could be detected in supernatant levels of SEM3C.  
 
 
 
Figure 24. MT1-MMP-interfered human ECs. (A) MT1-MMP expression was interfered by siRNA 
transfection of two different MT1-MMP siRNA oligonucleotides (MT1#1 and MT1#2) or a negative 
siRNA (siNT) in HUVEC; MT1-MMP mRNA and (B) protein levels were assessed by RT-PCR and 
western-blot, respectively. (C) Representative images of MT1-MMP staining in control (siNT) and 
interfered HUVECs (siMT1-MMP).  
 
 
In a complementary approach we compared substrate subcellular distribution in MT1-MMP-
interfered HUVEC. As shown in Figure 25B, the subcellular distribution of TSP1, CYR61, 
NID1 and SEM3C was changed in HUVEC with reduced expression of MT1-MMP; in 
particular, CYR61 and SEM3C appeared more intense and NID1 formed pericellular 
clusters in HUVEC with lower expression of MT1-MMP.  
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Figure 25.  Impaired processing of TSP1, CYR61, NID1 and SEM3C in MT1-MMP-interfered 
human ECs. (A) Immunoblots show detection of TSP1, CYR61, NID1 and SEM3C in culture 
supernatants (CSUP) of TNF -stimulated HUVEC transfected with negative siRNA (siNT) or two 
different MT1-MMP-siRNA (MT1#1 and MT1#2); bar charts show densitometric quantification of 
proteins in supernatants (n=4-6). (B) Confocal microscopy analysis was performed in TNFα- 
stimulated MT1-MMP-siRNA HUVEC immunostained for MT1-MMP and TSP1, CYR61, NID1 or 
SEM3C; representative maximal projections are shown (n=4); arrows point to NID1 pericellular 
deposits. 
 
 
Present data support that the combinatorial program driven by MT1-MMP identified in 
mouse cells is also acting in human ECs since decreasing MT1-MMP expression impacts on 
the processing and subcellular distribution of TSP1, CYR61, NID1 and SEM3C in HUVEC; 
milder effects were however observed likely related to the experimental approach and maybe 
to a different repertoire of proteases expressed by human ECs. 
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TSP1 and NID1, key components of the combinatorial MT1-MMP proteolytic 
program, have been described in other cellular models as substrates of MT1-MMP (Butler et 
al. 2008; d'Ortho et al. 1997). The multidomain structure of matricellular proteins 
contributes to their pleiotropic functions in angiogenesis. Thus, TSP1 effects on angiogenesis 
largely depend on whether it is soluble or matrix-bound basement membrane localized TSP1 
in mature or quiescent vascular beds might provide stabilizing signals, whereas excess 
soluble TSP1 during angiogenesis can suppress capillary sprouting (Iruela-Arispe et al. 2004). 
TSP1 can be cleaved by ADAMTS1, releasing a soluble C-terminal monomer and leaving a 
matrix-bound N-terminal trimeric fragment (Lee et al. 2006). During inflammatory 
angiogenesis, MT1-MMP could further modulate the angiogenic properties of TSP1 either 
by cooperating with ADAMTS1 or by acting at a different cleavage site, perhaps affecting 
interactions with receptors such as integrin αvβ3, CD36 or CD47 (Li et al. 2002). Recently 
described pathways include TSP1 scavenger receptor CD36 expressed in endothelial cells 
that may promote both pro- and antiangiogenic signals depending on interaction with 
different Src family kinases; thus CD36-Fyn complex will inhibit angiogenesis while CD36-
Syk interaction can promote VEGF-A-induced endothelial cell migration and 
phosphorylation of VEGFR-2 priming angiogenic switch (Kazerounian et al. 2011). 
Accumulation of TSP1 clusters in TNFα-stimulated MT1-MMP null ECs indicates that 
MT1-MMP is required for TSP1 processing events that are not compensated for ADAMTS1. 
Increased pericellular TSP1 deposits might contribute to the reduced angiogenesis reported 
in MT1-MMP null cells (Galvez et al. 2005; Oblander et al. 2005). 
 
CYR61/CCN1, a member of the CNN family of matricellular proteins, promotes 
endothelial cell adhesion, migration and proliferation (S. Kubota and Takigawa 2007). 
CYR61 seems to be an exclusive substrate of MT1-MMP within the metalloproteinase 
family (Butler et al. 2008). CYR61 knockout is embryonically lethal due to vascular defects 
(Kubota 2007), and a dual role for this protein has been recently described in physiological 
and pathological vascularization in retina (Hasan et al. 2011). In our analysis, CYR61 
accumulated at the periphery of MT1-MMP-deficient ECs and around endothelial null 
retinas, pointing to a key role for MT1-MMP in CYR61 processing in vitro and in vivo. The 
main effect of MT1-MMP cleavage of CYR61 might be to modulate its binding to integrins 
α6β1 and αvβ3 (Leu et al. 2004) or as recently reported for its cleavage by serine proteases to 
modulate its interactions with growth factors (Guillon-Munos et al. 2011). Therefore loss of 
MT1-MMP processing of CYR61 might mimic the effect of CYR61 knockout, contributing 
to vascular defects observed in MT1-MMP null retinas.  
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Likewise, pericellular deposits of NID1, a protein normally associated to laminin 
and fibulin at the basement membrane (Ho et al. 2008) might confer basement membrane-
like ‘quiescence’ signals hindering endothelial cell active sprouting. NID1 has been reported 
to be cleaved by ADAMTS1 (downstream of the N-terminal domain) and MT1-MMP, likely 
at a different site (Canals et al. 2006; d'Ortho et al. 1997). Although NID1 was undetectable 
in total lysates, levels of soluble NID1 were also significantly increased in culture 
supernatants from WT pMLECs, suggesting MT1-MMP-dependent release of NID1 from 
the basement membrane. The effect of NID1 proteolytic processing is unknown. NID1 
contributes to basement membrane stability, and therefore the increased NID1 levels 
observed in MT1-MMP null ECs might confer basement membrane-like ‘quiescence’ signals, 
thus hindering the angiogenic response by impeding ECs engagement in active sprouting.  
Finally, since SEM3C processing by ADAMTS1 can contribute to tumor cell 
migration (Esselens et al. 2010) and therefore we can imagine that MT1-MMP-processing of 
SEM3C might impact on EC migration required for capillary sprouting; in the absence of 
this processing impaired migration might lead to defective angiogenesis. In sum, TSP1, 
CYR61, NID1 and SEM3C can modulate endothelial cell adhesive and migratory behavior 
through complementary mechanisms including binding to integrins; the synergistic or 
competitive action of these accumulated substrates in the absence of MT1-MMP would 
impair migration and adhesion, yielding a more quiescent endothelial state and defective 
angiogenesis (Figure 26).  
 
 
Figure 26. MT1-MMP combined substrate processing in inflammatory angiogenesis. Combined 
processing of TSP1, CYR61, NID1, SEM3C and other substrates by MT1-MMP has a major impact 
on the regulation of endothelial cell adhesion and motility, and chemotaxis ultimately leading to 
vasculature development. This proteolytic program is activated by inflammatory stimuli such as TNF. 
The absence of MT1-MMP in stimulated endothelial cells results in impaired processing and 
accumulation of the identified substrates dampening the capillary sprouting process and favoring 
quiescence of the vasculature. 
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- MT1-MMP IS UPREGULATED IN A MODEL OF DSS-INDUCED EXPERIMENTAL MOUSE 
COLITIS – 
  
Since angiogenesis is often linked to acute and chronic inflammatory responses, the 
role of inflammatory angiogenesis has recently focused attention in many chronic 
inflammatory disorders. To analyse the potential relevance of the identified MT1-MMP 
substrates in inflammatory angiogenesis we sought for a model of chronic inflammatory 
disease that fits two conditions: (1) involvement of inflammatory angiogenesis and (2) 
expression of MT1-MMP in ECs. Inflammation followed by angiogenesis is considered as an 
integral part of the pathology in inflammatory bowel disease (IBD) with its two major types: 
Crohn’s disease and ulcerative colitis. Upregulation of proangiogenic factors and increased 
vessel density have become a well-recognized markers of disease progression (Di Sabatino et 
al. 2004; Kanazawa et al. 2001). We analyzed the functional role of some of the identified 
proteins as biomarkers of inflammation-driven angiogenesis by employing the human and 
experimental mouse model of ulcerative colitis.  
 
DSS treatment induced colitis in mice that mimics IBD observed in human patients. 
C57BL76 mice were treated with different doses of DSS during 7 days to induce progressive 
intestinal disease. As shown in Figure 27A, treatment with 1% and 4% of DSS induced 
moderate and severe IBD, respectively. Significant body weight loss was observed after 6 
(moderate) and 3 (severe) days of consecutive administration with DSS, persisting and 
worsens until day 7 when animals were sacrificed. Daily assessment of colitis score 
represented by weight loss, stool consistency and bleeding resulted in a significant body 
weight loss and maximal colitis activity (total clinical score, Figure 27B) at the end of the 
treatment. Macroscopic analysis of the colons at day 7 showed considered colon retraction in 
case of severe colitis (Figure 27C) and remarkable epithelial tissue mucosa and crypt 
destruction (Figure 27D).  
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Figure 27.   DSS treatment induces colitis in mice that mimics IBD observed in human patients. 
(A) 1% and 4%DSS induced moderate and severe IBD, respectively. (B) Daily assessment of colitis 
score represented by weight loss, stool consistency and bleeding resulted in a significant body weight 
loss and colitis activity at the end of the treatment. (C) Macroscopic and (D) histochemical analysis at 
day 7 showed considered colon retraction and mucosa destruction, respectively.  
 
 
 
Serum levels of the pro-inflammatory cytokine TNFα were upregulated in this model 
in a DSS-dose response manner being significant in severely affected mice (Figure 28A). 
Consistent with previous reports of increased VEGF-A levels in UC and CD (Di Sabatino et 
al. 2004; Kanazawa et al. 2001) we observed increased serum levels of the proangiogenic 
growth factor VEGF-A that were significant in the severe condition (Figure 28B). Since 
TNFα enhances the expression of cell adhesion molecules and thus might promote tissue 
infiltration with inflammatory cells, we expectedly observed that according to the 
inflammatory cytokine increased secretion; administration of DSS induced an increased 
infiltration of Mac1 positive inflammatory cells into the mucosa (Figure 28C). 
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Figure 28.   Effect of DSS on proinflammatory and proangiogenic cytokines. (A) Serum levels of 
the proinflammatory cytokine TNFα were upregulated in a DSS-dose dependent manner. Moreover 
there was a significant increase of the proangiogenic growth factor VEGF in severe condition (B), as a 
result increased infiltration of inflammatory cells (Mac1+) was observed in DSS-treated animals (C) 
suggesting an active inflammation and angiogenesis; * p< 0.05.  
 
 
We next checked the vasculature morphogenesis occurring in DDS-induced model of 
experimental colitis. According to the whole-mount staining of anti-CD31 (an endothelial 
marker), administration of DSS induced increased new vessel growth both in 1 and 4 % DSS 
treatment. Nonetheless, angiogenesis in IBD does not simply mean increase in vessel 
density; vessels formed during inflammation are different from those formed during normal 
neovascularization. These vessels are immature, tortuous, lacking investment in supporting 
cells (pericytes/VSMCs), leakier and more sensitive to growth factors (Cromer et al. 2011). 
As result, new vasculature formed in IBD maintains and actively promotes disease severity.  
In fact, both in moderate and severe condition vasculature was altered with apparent 
blind-ended new sprouts, increased in small capillaries and a denser vascular meshwork 
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compared with organized polygonal vascular plexus observed in control animals (Figure 
29A). Collagen IV staining endothelial basement membrane confirmed that control 
vasculature was more stable/mature than the one from 1 and 4% DSS treatment that only 
was Col IV positive at the external part of intestine and new sprouts that were raising above 
stable vasculature were CD31+/Col IV- (Figure 29B and C). This suggest that angiogenesis, 
the formation of new vessels from preexisting capillaries, was particularly active starting in 
moderate disease and later in severe condition. 
 
 
Figure 29. DSS treatment induces increased vessel density. (A) CD31 (green) staining of instestinal 
vasculature showed denser and disorganized meshwork in moderate and severe colitis. (B) and (C) 
ColIV (red) positive vessel were mostly observed in control animals, while newly formed sprouts 
raised above stable vasculature in moderate and severe colitis.  
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We next investigated whether MT1-MMP is upregulated during DSS-induced colits.  
For that we quantitated by western blot in homogenates of colonic tissues the expression of 
the protease MT1-MMP in control and DSS-treated mice; as shown in Figure 30A and B, 
total expression of MT1-MP was significantly upregulated upon treatment with 1% to 4% 
DSS. This MT1-MMP expression was localized in both epithelial and endothelial cells 
(Figure 30C) and confirmed our previous results demonstrating that TNFα activated and 
upregulated expression of MT1-MMP in endothelial cells (Koziol et al. 2012b).  
 
 
 
Figure 30.   Regulation of MT1-MMP expression along DSS-induced experimental mouse colitis. 
(A and B). Total expression of MT1-MMP was upregulated upon treatment with 1% to 4% DSS as 
analysed by western-blot. (C) MT1-MMP localizes mostly in epithelium in control condition as well 
as in vessels in 1% and 4% DSS and in infiltrating leukocytes in 4% DSS-treated mice. 
 
 
 
- MT1-MMP SUBSTRATES AS BIOMARKERS OF INFLAMMATORY ANGIOGENESIS - 
 
As shown in the Figure 30 TNFα-activated ECs MT1-MMP can process several 
substrates thus impacting on the angiogenic process. We aimed at analyzing the expression 
pattern of two of these MT1-MMP identified substrates, TSP1 and NID1, in the vasculature 
of control or mice affected by colitis. Since TSP1 and NID1 are proteins normally present at 
the ECM, their processing by MT1-MMP might generate soluble fragments able to reach the 
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bloodstream thus serving as biomarkers of the activity of the intestinal inflammatory disease. 
To test this hypothesis we quantitated the soluble levels of TSP1 and NID1 in the serum of 
control or diseased mice. As shown in Figure 31A and B soluble serum levels of both TSP1 
and NID1 tend to be higher starting in 1%-treated mice compared with controls and reaching 
maximum in 4% DSS-treated mice. These data point to release of TSP1 and NID1 to the 
bloodstream in severe disease likely by MT1-MMP at the new vessels of DSS-treated mice.  
 
 
 
Figure 31.   Regulation of the expression of MT1-MMP substrates TSP1 and NID1 along DSS-
induced experimental mouse colitis. Serum levels of TSP1 and NID1 increased in severe colitis (A 
and B). (C) TSP1 was slightly expressed in epithelial cells and in the submucosa of all mouse groups; 
in addition, TSP1 was also expressed in some vessels of 1% and 4% DSS-treated mice (white arrows) 
and in the abundant infiltrate in 4% DSS-treated mice. (D) NID1 was mainly located at the 
submucosa and in vessels in 4% DSS-treated mice.  
 
 
MT1-MMP was expressed in epithelial cells in control and 1% or 4% DSS-treated 
mice. Interestingly, MT1-MMP was found co-localizing with CD31 in vessels observed in 1 
and 4% DSS-treated mice and in the inflammatory infiltrate. We next analyzed TSP1 and 
NID1 to address whether the pattern of these substrates change along severity of colitis in 
correlation with the observed changes in MT1-MMP pattern. TSP1 was slightly expressed in 
epithelial cells and in the submucosa of all mouse groups; in addition, TSP1 was also 
expressed in some vessels of 1% and 4% DSS-treated mice (Figure 31C, white arrows) and in 
the abundant infiltrate in 4% DSS-treated mice. NID1 was mainly located at the submucosa 
and in vessels in 4% DSS-treated mice, but also found in vessels (Figure 31D).  
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- SERUM LEVELS OF MT1-MMP SUBSTRATES TSP1 AND NID1 ARE ELEVATED IN HUMAN 
PATIENTS AFFECTED BY ACTIVE ULCERATIVE COLITIS OR CROHN’S DISEASE - 
 
Patients with UC and CD were divided into two groups, with low and high disease 
activity based on clinical score. In patients with high UC and CD activity, we found VEGF-
A levels in serum higher as compared to low activity individuals (Figure 32A and D). This 
increased VEGF concentration in serum correlates positively with clinical activity of UC and 
CD. We also observed altered levels of MT1-MMP substrates, TSP1 and NID1 in serum 
from patients with active UC and CD thus can indicate the origin of these soluble forms 
from the inflamed intestine. VEGF produced excessively by intestinal epithelium may 
induce loosening of endothelial tight junction and in consequence vessel leakage and passage 
of intestinal fluid to the bloodstream. Nevertheless, in contrast to previously observed in 
mouse colitis model, we observed increased TSP1 (Figure 32B and E) and NID1 (Figure 
32C and F) levels in conditions with low disease activity compared to high activity. 
 
 
 
Figure 32.   Levels of TSP1 and NID1 in serum from patients with ulcerative colitis (UC) or 
Crohn’s disease (CD). Samples of serum from patients suffering ulcerative colitis or Crohn’s disease 
were analysed by ELISA and we observed increased levels of soluble TSP1 and NID1 in low active 
compared to high active disease. VEGF was found elevated in patients with highly active IBD. 
 
 
The feasible mechanism for these findings is that the most active TSP1 and NID1 
processing takes place during first steps of sprouting angiogenesis, but it is not so striking 
during followed vessels maturation and stability as it occurs in advanced disease progression. 
That would concur with some clinical studies, which showed that decrease in TSP1 
expression in human colorectal carcinomas (Maeda et al. 2001; Miao et al. 2001). The 
function of TSP1 is still controversial. Treatment with DSS induced a more severe colitis in 
TSP1-/- mice (Punekar et al. 2008) and treatment with its mimetic peptide ABT-510 was 
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showed to be protective against colon cancer angiogenesis (Allegrini et al. 2004; Punekar et 
al. 2008). The TSP1 ability to bind integrins may additionally impact new vessel formation. 
Danese and coll. showed that blokage of the murine endothelial αvβ3 by ATN161 effectively 
decreases both inflammation and angiogenesis in model of IL-10-/- colitis mice (Danese et 
al. 2005). In conclusion, TSP1 seems to play an important pathological function in 
inflammation and angiogenesis acting by multiple pathways. The study of signalling 
mechanisms may be useful to elucidate the impact of TSP1 and therapeutic strategies for 
pathological angiogenesis.  
Little is known about the implication of NID1 in IBD and in inflammatory-
angiogenesis disorders in general. We can speculate that since NID1 is among others 
responsible for basement membrane stability, its role in IBD confine to a microenvironment 
factor that controls endothelial barrier function.  
Dysfunctional immune response is known to be causative factor in IBD and 
experimental colitis as well as other chronic inflammatory diseases. During inflammation 
activated cell signalling leads to increased expression of cytokines, MMPs and adhesion 
molecules on the endothelium surface what facilitates blood vessel extravasation and 
leukocyte recruitment to the inflammation site. Once on the tissue they release a range of 
inflammation and angiogenic mediators initiating chronic inflammation and activating 
endothelium to sprouting angiogenesis.  
 
We proposed a cell model system that applies in vivo during inflammatory angiogenic 
disorders such as IBD, in which protease MT1-MMP activated by inflammatory stimulus 
TNF  a is actively processing several pericellular substrates and thus impacting early 
angiogenic responses related to new vessel formation (Figure 33). Profiling of these MT1-
MMP-processed substrates in plasma could be used as a surrogate marker of angiogenic 
activity in chronic inflammatory disorders and identifying patients who might benefit from 
antiangiogenic therapies.  
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Figure 33.   Schematic illustration of healthy and IBD-affected intestinal tissue. Inflammation 
triggers a change in the endothelium of the intestinal vasculature in response to the cytokines, 
chemokines and growth factors released by immune cells leading to increased angiogenesis. Protease 
MT1-MMP can promote this process by processing of ECM molecules such as TSP1 and NID1. 
 
 
 
- GENERAL DISCUSSION - 
 
Matrix metalloproteases have been collectively quoted as able to degrade all 
components of extracellular matrix and thus being main enzymes responsible for matrix and 
basement membrane remodeling, supporting cell migration, inflammation, tumor 
progression and neovascularization.  
Persistent and aberrant angiogenesis is a hallmark of chronic inflammatory disorders 
such as psoriasis, rheumatoid arthritis, atherosclerosis or inflammatory bowel disease, thus it 
has been proposed as a therapeutic target for these conditions and MT1-MMP was found 
upregulated in several animal and human disorders.  
Over 70 pharmaceutical companies were involved in large MMP inhibitor programs 
that reached phase III clinical trials. However, most of them failed to show their therapeutic 
benefits due to negative side effects, and unexpected advantage in cancer metastasis 
(Coussens et al. 2002). This was further supported by report on MMP-8 knockout mice 
which contrary to other MMP-deficient animals strongly increased the evidence of skin 
tumors (Balbín et al. 2003). This suggests more complex roles of MMPs in angiogenesis and 
need to develop more advanced tools to define better their implication in particular cell-
dependent processes.  
We have established a valid cell model system for studying the mechanistic link 
between proteolysis and biological responses in the context of inflammation-activated ECs. 
SILAC-based proteomics identified the supernatant glycoproteome as the main protein set 
targeted by the protease MT1-MMP. Combination of SILAC with bioinformatics revealed 
  
	  
RESULTS AND DISCUSSION 
	  
91 
that the main contribution of MT1-MMP to inflammatory angiogenesis is a combinatorial 
processing of defined substrates impacting early and rapid responses such as motility, 
chemotaxis and adhesion finally leading to new vessel formation. This model can be applied 
to animal and human disorders, thus profiling of MT1-MMP-processed substrates in plasma 
could be used as a surrogate marker of angiogenic activity in chronic inflammatory disease 
such as rheumatoid arthritis, inflammatory bowel disease, psoriasis and atherosclerosis, 
potentially identifying patients who might benefit of anti-angiogenic therapies. 
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Table 7.   List of all supernatant proteins identified by SILAC and LC-MS/MS analysis in WT and MT1-MMP-deficient endothelial cells. 
Accession Protein H/L #Cmpds # quant SD (H/L) % CV 
ITPR1_MOUSE Inositol 1,4,5-trisphosphate receptor type 1 OS=Mus musculus GN=Itpr1 PE=1 SV=1 18.04 8 2 9.68 53.66 
KLRA4_MOUSE Killer cell lectin-like receptor 4 OS=Mus musculus GN=Klra4 PE=2 SV=2 14.90 1 1 0.00 0.00 
KPBB_MOUSE Phosphorylase b kinase regulatory subunit beta OS=Mus musculus GN=Phkb PE=1 SV=1 11.58 1 1 0.00 0.00 
TSP2_MOUSE Thrombospondin-2 OS=Mus musculus GN=Thbs2 PE=2 SV=1 8.68 9 8 2.73 31.49 
PRGR_MOUSE Progesterone receptor OS=Mus musculus GN=Pgr PE=2 SV=1 7.42 2 1 0.00 0.00 
PRPK_MOUSE TP53-regulating kinase OS=Mus musculus GN=Tp53rk PE=2 SV=1 7.32 1 1 0.00 0.00 
SNED1_MOUSE Sushi, nidogen and EGF-like domain-containing protein 1 OS=Mus musculus GN=Sned1 PE=2 SV=2 7.05 1 1 0.00 0.00 
CPXM1_MOUSE Probable carboxypeptidase X1 OS=Mus musculus GN=Cpxm1 PE=2 SV=1 6.12 5 5 1.46 23.83 
MMP3_MOUSE Stromelysin-1 OS=Mus musculus GN=Mmp3 PE=2 SV=2 6.04 42 13 2.18 36.08 
CDYL_MOUSE Chromodomain Y-like protein OS=Mus musculus GN=Cdyl PE=1 SV=1 6.02 1 1 0.00 0.00 
IGS10_MOUSE Immunoglobulin superfamily member 10 OS=Mus musculus GN=Igsf10 PE=2 SV=2 5.85 3 3 1.09 18.55 
LYOX_MOUSE Protein-lysine 6-oxidase OS=Mus musculus GN=Lox PE=2 SV=1 5.68 1 1 0.00 0.00 
PCOC1_MOUSE Procollagen C-endopeptidase enhancer 1 OS=Mus musculus GN=Pcolce PE=1 SV=2 5.53 2 2 1.80 32.61 
TRPM2_MOUSE Transient receptor potential cation channel subfamily M member 2 OS=Mus musculus GN=Trpm2 PE=2 SV=1 5.33 1 1 0.00 0.00 
EGFR_MOUSE Epidermal growth factor receptor OS=Mus musculus GN=Egfr PE=1 SV=1 4.60 1 1 0.00 0.00 
SODE_MOUSE Extracellular superoxide dismutase [Cu-Zn] OS=Mus musculus GN=Sod3 PE=1 SV=1 4.37 1 1 0.00 0.00 
PTX3_MOUSE Pentraxin-related protein PTX3 OS=Mus musculus GN=Ptx3 PE=1 SV=2 4.20 8 6 0.56 13.33 
SPA3N_MOUSE Serine protease inhibitor A3N OS=Mus musculus GN=Serpina3n PE=1 SV=1 4.19 4 4 0.58 13.74 
PR2C2_MOUSE Prolactin-2C2 OS=Mus musculus GN=Prl2c2 PE=2 SV=1 4.14 1 1 0.00 0.00 
IC1_MOUSE Plasma protease C1 inhibitor OS=Mus musculus GN=Serping1 PE=1 SV=2 3.70 21 12 1.26 34.01 
CNTN1_MOUSE Contactin-1 OS=Mus musculus GN=Cntn1 PE=1 SV=1 3.67 1 1 0.00 0.00 
CLCN5_MOUSE Chloride channel protein 5 OS=Mus musculus GN=Clcn5 PE=2 SV=1 3.61 10 2 0.31 8.45 
STC1_MOUSE Stanniocalcin-1 OS=Mus musculus GN=Stc1 PE=2 SV=1 3.59 1 1 0.00 0.00 
SFRP1_MOUSE Secreted frizzled-related protein 1 OS=Mus musculus GN=Sfrp1 PE=1 SV=2 3.34 1 1 0.00 0.00 
TIMP1_MOUSE Metalloproteinase inhibitor 1 OS=Mus musculus GN=Timp1 PE=2 SV=2 3.14 3 3 0.17 5.29 
SEM3C_MOUSE Semaphorin-3C OS=Mus musculus GN=Sema3c PE=2 SV=1 2.94 8 5 0.57 19.23 
CO6A1_MOUSE Collagen alpha-1(VI) chain OS=Mus musculus GN=Col6a1 PE=2 SV=1 2.88 3 3 0.71 24.82 
FBN1_MOUSE Fibrillin-1 OS=Mus musculus GN=Fbn1 PE=1 SV=1 2.76 5 4 0.81 29.35 
SLIT3_MOUSE Slit homolog 3 protein OS=Mus musculus GN=Slit3 PE=2 SV=1 2.51 4 4 0.49 19.40 
LIF_MOUSE Leukemia inhibitory factor OS=Mus musculus GN=Lif PE=1 SV=1 2.37 1 1 0.00 0.00 
CERU_MOUSE Ceruloplasmin OS=Mus musculus GN=Cp PE=1 SV=2 2.29 11 9 0.45 19.58 
NID1_MOUSE Nidogen-1 OS=Mus musculus GN=Nid1 PE=1 SV=1 2.26 189 56 0.34 15.06 
NGAL_MOUSE Neutrophil gelatinase-associated lipocalin OS=Mus musculus GN=Lcn2 PE=1 SV=1 2.11 5 3 0.12 5.79 
MMP19_MOUSE Matrix metalloproteinase-19 OS=Mus musculus GN=Mmp19 PE=2 SV=1 2.10 1 1 0.00 0.00 
CSF1_MOUSE Macrophage colony-stimulating factor 1 OS=Mus musculus GN=Csf1 PE=1 SV=2 2.06 36 9 0.67 32.31 
GELS_MOUSE Gelsolin OS=Mus musculus GN=Gsn PE=1 SV=3 2.06 1 1 0.00 0.00 
TENA_MOUSE Tenascin OS=Mus musculus GN=Tnc PE=1 SV=1 2.04 35 23 0.95 46.86 
FBLN2_MOUSE Fibulin-2 OS=Mus musculus GN=Fbln2 PE=1 SV=1 2.04 15 8 0.55 27.13 
CO3_MOUSE Complement C3 OS=Mus musculus GN=C3 PE=1 SV=2 1.96 17 6 1.05 53.71 
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Accession Protein H/L #Cmpds # quant SD (H/L) % CV 
GSTP1_MOUSE Glutathione S-transferase P 1 OS=Mus musculus GN=Gstp1 PE=1 SV=2 1.95 1 1 0.00 0.00 
GDN_MOUSE Glia-derived nexin OS=Mus musculus GN=Serpine2 PE=2 SV=2 1.93 3 3 0.38 19.52 
CCL2_MOUSE C-C motif chemokine 2 OS=Mus musculus GN=Ccl2 PE=1 SV=1 1.86 99 15 0.63 33.88 
TIMP3_MOUSE Metalloproteinase inhibitor 3 OS=Mus musculus GN=Timp3 PE=2 SV=1 1.80 2 2 0.32 17.84 
AEBP1_MOUSE Adipocyte enhancer-binding protein 1 OS=Mus musculus GN=Aebp1 PE=1 SV=1 1.77 16 8 0.59 33.34 
LOXL3_MOUSE Lysyl oxidase homolog 3 OS=Mus musculus GN=Loxl3 PE=2 SV=1 1.73 1 1 0.00 0.00 
SLIT2_MOUSE Slit homolog 2 protein OS=Mus musculus GN=Slit2 PE=2 SV=1 1.73 3 3 0.38 21.94 
TSP1_MOUSE Thrombospondin-1 OS=Mus musculus GN=Thbs1 PE=1 SV=1 1.68 227 52 0.66 39.44 
CYR61_MOUSE Protein CYR61 OS=Mus musculus GN=Cyr61 PE=1 SV=1 1.68 4 2 0.27 15.93 
CO3A1_MOUSE Collagen alpha-1(III) chain OS=Mus musculus GN=Col3a1 PE=2 SV=4 1.67 1 1 0.00 0.00 
TIMP2_MOUSE Metalloproteinase inhibitor 2 OS=Mus musculus GN=Timp2 PE=1 SV=2 1.67 5 4 0.22 13.44 
CATL1_MOUSE Cathepsin L1 OS=Mus musculus GN=Ctsl1 PE=1 SV=2 1.43 1 1 0.00 0.00 
WWC2_MOUSE Protein WWC2 OS=Mus musculus GN=Wwc2 PE=2 SV=1 1.42 1 1 0.00 0.00 
QSOX1_MOUSE Sulfhydryl oxidase 1 OS=Mus musculus GN=Qsox1 PE=2 SV=1 1.31 2 2 0.51 38.64 
LG3BP_MOUSE Galectin-3-binding protein OS=Mus musculus GN=Lgals3bp PE=1 SV=1 1.31 10 8 0.46 35.26 
PNPH_MOUSE Purine nucleoside phosphorylase OS=Mus musculus GN=Np PE=1 SV=2 1.30 2 2 0.11 8.57 
FSTL1_MOUSE Follistatin-related protein 1 OS=Mus musculus GN=Fstl1 PE=1 SV=1 1.30 26 10 0.60 46.14 
B4GT1_MOUSE Beta-1,4-galactosyltransferase 1 OS=Mus musculus GN=B4galt1 PE=2 SV=1 1.28 1 1 0.00 0.00 
ASPG_MOUSE N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase OS=Mus musculus GN=Aga PE=2 SV=1 1.27 1 1 0.00 0.00 
CO4A1_MOUSE Collagen alpha-1(IV) chain OS=Mus musculus GN=Col4a1 PE=2 SV=4 1.27 1 1 0.00 0.00 
TPA_MOUSE Tissue-type plasminogen activator OS=Mus musculus GN=Plat PE=1 SV=3 1.25 1 1 0.00 0.00 
HGFA_MOUSE Hepatocyte growth factor activator OS=Mus musculus GN=Hgfac PE=1 SV=1 1.22 2 1 0.00 0.00 
FBLN3_MOUSE EGF-containing fibulin-like extracellular matrix protein 1 OS=Mus musculus GN=Efemp1 PE=2 SV=1 1.21 10 4 0.42 34.72 
BMP1_MOUSE Bone morphogenetic protein 1 OS=Mus musculus GN=Bmp1 PE=2 SV=1 1.15 4 3 0.18 16.01 
SEM3F_MOUSE Semaphorin-3F OS=Mus musculus GN=Sema3f PE=2 SV=1 1.12 1 1 0.00 0.00 
SERPH_MOUSE Serpin H1 OS=Mus musculus GN=Serpinh1 PE=1 SV=2 1.09 2 2 0.16 15.07 
LUM_MOUSE Lumican OS=Mus musculus GN=Lum PE=1 SV=2 1.04 2 2 0.22 20.86 
AGRIN_MOUSE Agrin OS=Mus musculus GN=Agrn PE=2 SV=1 1.00 2 1 0.00 0.00 
SAP_MOUSE Sulfated glycoprotein 1 OS=Mus musculus GN=Psap PE=1 SV=2 0.99 5 3 0.12 12.27 
LTBP2_MOUSE Latent-transforming growth factor beta-binding protein 2 OS=Mus musculus GN=Ltbp2 PE=1 SV=2 0.99 8 7 0.25 24.89 
CADH5_MOUSE Cadherin-5 OS=Mus musculus GN=Cdh5 PE=2 SV=2 0.95 9 6 0.21 22.43 
EF2_MOUSE Elongation factor 2 OS=Mus musculus GN=Eef2 PE=1 SV=2 0.92 1 1 0.00 0.00 
LAMC1_MOUSE Laminin subunit gamma-1 OS=Mus musculus GN=Lamc1 PE=1 SV=2 0.89 13 7 0.27 30.42 
EMIL1_MOUSE EMILIN-1 OS=Mus musculus GN=Emilin1 PE=1 SV=1 0.88 1 1 0.00 0.00 
CATB_MOUSE Cathepsin B OS=Mus musculus GN=Ctsb PE=1 SV=2 0.86 1 1 0.00 0.00 
LAMB1_MOUSE Laminin subunit beta-1 OS=Mus musculus GN=Lamb1-1 PE=1 SV=2 0.85 18 8 0.34 40.44 
PEBP1_MOUSE Phosphatidylethanolamine-binding protein 1 OS=Mus musculus GN=Pebp1 PE=1 SV=3 0.84 3 3 0.17 19.56 
ECM1_MOUSE Extracellular matrix protein 1 OS=Mus musculus GN=Ecm1 PE=1 SV=1 0.83 2 2 0.12 14.29 
PGBM_MOUSE Basement membrane-specific heparan sulfate proteoglycan core protein OS=Mus musculus GN=Hspg2PE=1SV=1 0.83 17 15 0.28 33.34 
PGS1_MOUSE Biglycan OS=Mus musculus GN=Bgn PE=2 SV=1 0.83 16 8 0.38 45.91 
LOXL2_MOUSE Lysyl oxidase homolog 2 OS=Mus musculus GN=Loxl2 PE=2 SV=2 0.83 2 2 0.01 0.90 
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Accession Protein H/L #Cmpds # quant SD (H/L) % CV 
FBLN5_MOUSE Fibulin-5 OS=Mus musculus GN=Fbln5 PE=2 SV=1 0.79 1 1 0.00 0.00 
WDR19_MOUSE WD repeat-containing protein 19 OS=Mus musculus GN=Wdr19 PE=2 SV=1 0.77 2 2 0.00 0.00 
CLUS_MOUSE Clusterin OS=Mus musculus GN=Clu PE=1 SV=1 0.77 34 16 0.17 22.11 
CFAH_MOUSE Complement factor H OS=Mus musculus GN=Cfh PE=1 SV=1 0.74 15 12 0.15 20.33 
PGS2_MOUSE Decorin OS=Mus musculus GN=Dcn PE=2 SV=1 0.74 62 22 0.21 28.73 
FINC_MOUSE Fibronectin OS=Mus musculus GN=Fn1 PE=1 SV=3 0.73 405 106 0.34 47.50 
LAMA4_MOUSE Laminin subunit alpha-4 OS=Mus musculus GN=Lama4 PE=1 SV=2 0.72 21 10 0.33 46.38 
ESTD_MOUSE S-formylglutathione hydrolase OS=Mus musculus GN=Esd PE=2 SV=1 0.72 1 1 0.00 0.00 
HS90B_MOUSE Heat shock protein HSP 90-beta OS=Mus musculus GN=Hsp90ab1 PE=1 SV=2 0.70 3 3 0.03 4.60 
PGAM1_MOUSE Phosphoglycerate mutase 1 OS=Mus musculus GN=Pgam1 PE=1 SV=3 0.68 5 4 0.36 53.10 
ATS1_MOUSE A disintegrin and metalloproteinase with thrombospondin motifs 1 OS=Mus musculus GN=Adamts1 PE=1 SV=3 0.67 1 1 0.00 0.00 
CCD80_MOUSE Coiled-coil domain-containing protein 80 OS=Mus musculus GN=Ccdc80 PE=1 SV=2 0.67 10 7 0.35 52.40 
VCAM1_MOUSE Vascular cell adhesion protein 1 OS=Mus musculus GN=Vcam1 PE=1 SV=1 0.66 2 2 0.31 46.07 
A4_MOUSE Amyloid beta A4 protein OS=Mus musculus GN=App PE=1 SV=3 0.66 2 2 0.05 7.87 
K2C4_MOUSE Keratin, type II cytoskeletal 4 OS=Mus musculus GN=Krt4 PE=1 SV=2 0.66 1 1 0.00 0.00 
ANGP2_MOUSE Angiopoietin-2 OS=Mus musculus GN=Angpt2 PE=2 SV=2 0.64 36 14 0.35 54.74 
HA11_MOUSE H-2 class I histocompatibility antigen, D-B alpha chain OS=Mus musculus GN=H2-D1 PE=1 SV=2 0.63 21 7 0.33 52.97 
ICAM1_MOUSE Intercellular adhesion molecule 1 OS=Mus musculus GN=Icam1 PE=1 SV=1 0.60 4 2 0.11 18.52 
ACTS_MOUSE Actin, alpha skeletal muscle OS=Mus musculus GN=Acta1 PE=1 SV=1 0.60 8 6 0.09 14.85 
CXL16_MOUSE C-X-C motif chemokine 16 OS=Mus musculus GN=Cxcl16 PE=1 SV=2 0.60 2 2 0.19 32.50 
FSCN1_MOUSE Fascin OS=Mus musculus GN=Fscn1 PE=1 SV=4 0.60 1 1 0.00 0.00 
MA2B1_MOUSE Lysosomal alpha-mannosidase OS=Mus musculus GN=Man2b1 PE=2 SV=3 0.60 1 1 0.00 0.00 
UBR4_MOUSE E3 ubiquitin-protein ligase UBR4 OS=Mus musculus GN=Ubr4 PE=1 SV=1 0.58 1 1 0.00 0.00 
G6PI_MOUSE Glucose-6-phosphate isomerase OS=Mus musculus GN=Gpi PE=1 SV=4 0.56 3 3 0.22 39.27 
ACMSD_MOUSE 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase OS=Mus musculus GN=Acmsd PE=1 SV=2 0.55 1 1 0.00 0.00 
ACTB_MOUSE Actin, cytoplasmic 1 OS=Mus musculus GN=Actb PE=1 SV=1 0.55 17 11 0.11 19.63 
PXDN_MOUSE Peroxidasin homolog OS=Mus musculus GN=Pxdn PE=2 SV=1 0.55 25 14 0.27 49.27 
CO4A2_MOUSE Collagen alpha-2(IV) chain OS=Mus musculus GN=Col4a2 PE=2 SV=4 0.54 18 10 0.33 60.02 
PRDX1_MOUSE Peroxiredoxin-1 OS=Mus musculus GN=Prdx1 PE=1 SV=1 0.54 14 10 0.24 43.94 
CLH_MOUSE Clathrin heavy chain 1 OS=Mus musculus GN=Cltc PE=1 SV=3 0.51 2 2 0.08 15.94 
CD018_MOUSE Uncharacterized protein C4orf18 homolog OS=Mus musculus PE=2 SV=1 0.51 2 2 0.00 0.00 
CHSS1_MOUSE Chondroitin sulfate synthase 1 OS=Mus musculus GN=Chsy1 PE=2 SV=2 0.49 1 1 0.00 0.00 
SPRC_MOUSE SPARC OS=Mus musculus GN=Sparc PE=1 SV=1 0.49 11 7 0.20 40.81 
MANBA_MOUSE Beta-mannosidase OS=Mus musculus GN=Manba PE=2 SV=1 0.48 4 4 0.19 39.43 
RHOA_MOUSE Transforming protein RhoA OS=Mus musculus GN=Rhoa PE=1 SV=1 0.48 1 1 0.00 0.00 
MUC18_MOUSE Cell surface glycoprotein MUC18 OS=Mus musculus GN=Mcam PE=2 SV=1 0.41 2 2 0.13 30.91 
FAM3C_MOUSE Protein FAM3C OS=Mus musculus GN=Fam3c PE=1 SV=1 0.39 1 1 0.00 0.00 
MMRN2_MOUSE Multimerin-2 OS=Mus musculus GN=Mmrn2 PE=2 SV=1 0.37 1 1 0.00 0.00 
HA1Q_MOUSE H-2 class I histocompatibility antigen, K-Q alpha chain (Fragment) OS=Mus musculus GN=H2-K1 PE=2 SV=1 0.37 16 4 0.05 14.11 
PGK1_MOUSE Phosphoglycerate kinase 1 OS=Mus musculus GN=Pgk1 PE=1 SV=4 0.37 4 2 0.08 22.45 
TBA1A_MOUSE Tubulin alpha-1A chain OS=Mus musculus GN=Tuba1a PE=1 SV=1 0.35 2 2 0.16 44.68 
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Accession Protein H/L #Cmpds # quant SD (H/L) % CV 
TLL1_MOUSE Tolloid-like protein 1 OS=Mus musculus GN=Tll1 PE=1 SV=1 0.34 3 3 0.12 36.03 
CTGF_MOUSE Connective tissue growth factor OS=Mus musculus GN=Ctgf PE=2 SV=2 0.34 2 2 0.05 15.56 
COIA1_MOUSE Collagen alpha-1(XVIII) chain OS=Mus musculus GN=Col18a1 PE=1 SV=4 0.34 12 8 0.17 48.47 
PAI1_MOUSE Plasminogen activator inhibitor 1 OS=Mus musculus GN=Serpine1 PE=1 SV=1 0.34 29 12 0.11 33.95 
LAMP1_MOUSE Lysosome-associated membrane glycoprotein 1 OS=Mus musculus GN=Lamp1 PE=1 SV=2 0.31 1 1 0.00 0.00 
CCL2_MOUSE_L C-C motif chemokine 2 OS=Mus musculus GN=Ccl2 PE=1 SV=1 0.31 24 5 0.03 11.13 
CAD13_MOUSE Cadherin-13 OS=Mus musculus GN=Cdh13 PE=2 SV=1 0.29 8 4 0.12 39.28 
GDIB_MOUSE Rab GDP dissociation inhibitor beta OS=Mus musculus GN=Gdi2 PE=1 SV=1 0.28 1 1 0.00 0.00 
CAPZB_MOUSE F-actin-capping protein subunit beta OS=Mus musculus GN=Capzb PE=1 SV=3 0.27 2 2 0.07 27.78 
CBPE_MOUSE Carboxypeptidase E OS=Mus musculus GN=Cpe PE=1 SV=2 0.27 4 2 0.00 0.00 
COEA1_MOUSE Collagen alpha-1(XIV) chain OS=Mus musculus GN=Col14a1 PE=2 SV=2 0.27 1 1 0.00 0.00 
K2C73_MOUSE Keratin, type II cytoskeletal 73 OS=Mus musculus GN=Krt73 PE=1 SV=1 0.27 10 1 0.00 0.00 
PLGF_MOUSE Placenta growth factor OS=Mus musculus GN=Pgf PE=1 SV=1 0.25 4 2 0.13 51.52 
C1QR1_MOUSE Complement component C1q receptor OS=Mus musculus GN=Cd93 PE=1 SV=1 0.24 1 1 0.00 0.00 
MOES_MOUSE Moesin OS=Mus musculus GN=Msn PE=1 SV=3 0.24 1 1 0.00 0.00 
ELMO1_MOUSE Engulfment and cell motility protein 1 OS=Mus musculus GN=Elmo1 PE=1 SV=2 0.23 81 3 0.08 34.70 
PDGFB_MOUSE Platelet-derived growth factor subunit B OS=Mus musculus GN=Pdgfb PE=2 SV=1 0.23 8 4 0.13 54.84 
SP3_MOUSE Transcription factor Sp3 OS=Mus musculus GN=Sp3 PE=2 SV=2 0.23 84 6 0.10 44.78 
A2MP_MOUSE Alpha-2-macroglobulin-P OS=Mus musculus GN=A2mp PE=2 SV=1 0.23 19 5 0.05 23.32 
P5I13_MOUSE Tumor protein p53-inducible protein 13 OS=Mus musculus GN=Tp53i13 PE=3 SV=1 0.21 6 3 0.04 16.44 
K2C74_MOUSE Keratin, type II cytoskeletal 74 OS=Mus musculus GN=Krt74 PE=2 SV=1 0.20 91 10 0.09 43.73 
CTHR1_MOUSE Collagen triple helix repeat-containing protein 1 OS=Mus musculus GN=Cthrc1 PE=2 SV=1 0.19 4 2 0.03 15.38 
ITIH2_MOUSE Inter-alpha-trypsin inhibitor heavy chain H2 OS=Mus musculus GN=Itih2 PE=1 SV=1 0.19 4 2 0.03 15.38 
IBP3_MOUSE Insulin-like growth factor-binding protein 3 OS=Mus musculus GN=Igfbp3 PE=2 SV=1 0.19 13 5 0.06 34.02 
VIME_MOUSE Vimentin OS=Mus musculus GN=Vim PE=1 SV=3 0.19 4 4 0.04 20.00 
TGFB2_MOUSE Transforming growth factor beta-2 OS=Mus musculus GN=Tgfb2 PE=2 SV=1 0.16 1 1 0.00 0.00 
A2M_MOUSE Alpha-2-macroglobulin OS=Mus musculus GN=A2m PE=1 SV=2 0.16 6 3 0.13 78.20 
CTL2A_MOUSE Protein CTLA-2-alpha OS=Mus musculus GN=Ctla2a PE=2 SV=2 0.15 3 3 0.06 37.42 
NRCAM_MOUSE Neuronal cell adhesion molecule OS=Mus musculus GN=Nrcam PE=1 SV=2 0.15 1 1 0.00 0.00 
LYVE1_MOUSE Lymphatic vessel endothelial hyaluronic acid receptor 1 OS=Mus musculus GN=Lyve1 PE=1 SV=1 0.14 12 5 0.04 28.41 
RAB3A_MOUSE Ras-related protein Rab-3A OS=Mus musculus GN=Rab3a PE=1 SV=1 0.13 2 2 0.01 11.11 
EPCR_MOUSE Endothelial protein C receptor OS=Mus musculus GN=Procr PE=2 SV=2 0.13 5 3 0.01 5.44 
TLR3_MOUSE Toll-like receptor 3 OS=Mus musculus GN=Tlr3 PE=1 SV=2 0.07 4 2 0.03 40.00 
SOX14_MOUSE Transcription factor SOX-14 OS=Mus musculus GN=Sox14 PE=2 SV=2 0.06 4 2 0.00 0.00 
HIF1A_MOUSE Hypoxia-inducible factor 1 alpha OS=Mus musculus GN=Hif1a PE=1 SV=3 0.06 1 1 0.00 0.00 
ATRIP_MOUSE ATR-interacting protein OS=Mus musculus GN=Atrip PE=2 SV=1 0.04 4 2 0.01 20.00 
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Table 8.   List of all microsomal proteins identified by SILAC and LC-MS/MS analysis in WT and MT1-MMP-deficient endothelial cells. 
Accession Protein H/L #Cmpds # quant SD (H/L) % CV 
ARH_MOUSE Low density lipoprotein receptor adapter protein 1 OS=Mus musculus GN=Ldlrap1 PE=1 SV=2 93.66 1 1 0.00 0.00 
DNAI1_MOUSE Dynein intermediate chain 1, axonemal OS=Mus musculus GN=Dnai1 PE=2 SV=1 29.05 4 2 8.47 29.16 
AIDA_MOUSE Axin interactor, dorsalization associated protein OS=Mus musculus GN=Aida PE=1 SV=1 24.36 1 1 0.00 0.00 
ERCC3_MOUSE TFIIH basal transcription factor complex helicase XPB subunit OS=Mus musculus GN=Ercc3 PE=2 SV=1 22.63 1 1 0.00 0.00 
ECHM_MOUSE Enoyl-CoA hydratase, mitochondrial OS=Mus musculus GN=Echs1 PE=1 SV=1 18.76 1 1 0.00 0.00 
PR15B_MOUSE Protein phosphatase 1 regulatory subunit 15B OS=Mus musculus GN=Ppp1r15b PE=1 SV=1 15.88 1 1 0.00 0.00 
UBP36_MOUSE Ubiquitin carboxyl-terminal hydrolase 36 OS=Mus musculus GN=Usp36 PE=2 SV=1 15.88 3 2 6.96 43.81 
SOS2_MOUSE Son of sevenless homolog 2 OS=Mus musculus GN=Sos2 PE=1 SV=2 13.80 2 2 8.47 61.36 
RRP44_MOUSE Exosome complex exonuclease RRP44 OS=Mus musculus GN=Dis3 PE=2 SV=4 13.16 1 1 0.00 0.00 
ZMAT1_MOUSE Zinc finger matrin-type protein 1 OS=Mus musculus GN=Zmat1 PE=2 SV=2 13.14 1 1 0.00 0.00 
K1219_MOUSE Protein KIAA1219 OS=Mus musculus GN=Kiaa1219 PE=1 SV=2 12.37 1 1 0.00 0.00 
CTDSL_MOUSE CTD small phosphatase-like protein OS=Mus musculus GN=Ctdspl PE=2 SV=2 10.16 2 1 0.00 0.00 
PPID_MOUSE 40 kDa peptidyl-prolyl cis-trans isomerase OS=Mus musculus GN=Ppid PE=1 SV=3 9.71 1 1 0.00 0.00 
RPGR1_MOUSE X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 OS=Mus musculus GN=Rpgrip1 PE=1 SV=1 9.24 1 1 0.00 0.00 
SGPP1_MOUSE Sphingosine-1-phosphate phosphatase 1 OS=Mus musculus GN=Sgpp1 PE=1 SV=1 8.79 1 1 0.00 0.00 
F164A_MOUSE UPF0418 protein FAM164A OS=Mus musculus GN=Fam164a PE=2 SV=1 8.54 2 2 7.48 87.61 
CP110_MOUSE Centriolin OS=Mus musculus GN=Cep110 PE=1 SV=2 8.05 1 1 0.00 0.00 
STXB2_MOUSE Syntaxin-binding protein 2 OS=Mus musculus GN=Stxbp2 PE=2 SV=1 7.85 1 1 0.00 0.00 
IF2B3_MOUSE Insulin-like growth factor 2 mRNA-binding protein 3 OS=Mus musculus GN=Igf2bp3 PE=1 SV=1 7.64 2 1 0.00 0.00 
SDPR_MOUSE Serum deprivation-response protein OS=Mus musculus GN=Sdpr PE=1 SV=3 7.27 1 1 0.00 0.00 
DHRS7_MOUSE Dehydrogenase/reductase SDR family member 7 OS=Mus musculus GN=Dhrs7 PE=2 SV=2 7.24 2 2 6.15 84.98 
REEP5_MOUSE Receptor expression-enhancing protein 5 OS=Mus musculus GN=Reep5 PE=1 SV=1 6.38 1 1 0.00 0.00 
BT3L4_MOUSE Transcription factor BTF3 homolog 4 OS=Mus musculus GN=Btf3l4 PE=2 SV=1 6.35 1 1 0.00 0.00 
GCP60_MOUSE Golgi resident protein GCP60 OS=Mus musculus GN=Acbd3 PE=1 SV=3 6.29 2 2 5.47 86.97 
CLD23_MOUSE Claudin-23 OS=Mus musculus GN=Cldn23 PE=2 SV=1 6.09 1 1 0.00 0.00 
H4_MOUSE Histone H4 OS=Mus musculus GN=Hist1h4a PE=1 SV=2 5.67 11 5 5.22 92.11 
P66B_MOUSE Transcriptional repressor p66-beta OS=Mus musculus GN=Gatad2b PE=1 SV=1 5.44 1 1 0.00 0.00 
SYIC_MOUSE Isoleucyl-tRNA synthetase, cytoplasmic OS=Mus musculus GN=Iars PE=2 SV=1 5.38 6 4 5.67 105.42 
GSK3B_MOUSE Glycogen synthase kinase-3 beta OS=Mus musculus GN=Gsk3b PE=1 SV=2 5.24 1 1 0.00 0.00 
CTU1_MOUSE Cytoplasmic tRNA 2-thiolation protein 1 OS=Mus musculus GN=Atpbd3 PE=2 SV=1 4.99 1 1 0.00 0.00 
FAT3_MOUSE Protocadherin Fat 3 OS=Mus musculus GN=Fat3 PE=1 SV=2 4.98 1 1 0.00 0.00 
AB48R_MOUSE Apolipoprotein B-100 receptor OS=Mus musculus GN=Apob48r PE=2 SV=1 4.96 1 1 0.00 0.00 
LCA5_MOUSE Lebercilin OS=Mus musculus GN=Lca5 PE=2 SV=1 4.89 2 2 4.28 87.50 
NARG1_MOUSE NMDA receptor-regulated protein 1 OS=Mus musculus GN=Narg1 PE=1 SV=1 4.87 2 2 2.03 41.59 
TMED9_MOUSE Transmembrane emp24 domain-containing protein 9 OS=Mus musculus GN=Tmed9 PE=2 SV=2 4.86 13 6 6.60 135.79 
SYCC_MOUSE Cysteinyl-tRNA synthetase, cytoplasmic OS=Mus musculus GN=Cars PE=1 SV=2 4.78 1 1 0.00 0.00 
UACA_MOUSE Uveal autoantigen with coiled-coil domains and ankyrin repeats OS=Mus musculus GN=Uaca PE=1 SV=2 4.71 1 1 0.00 0.00 
SPT41_MOUSE Transcription elongation factor SPT4 1 OS=Mus musculus GN=Supt4h1 PE=2 SV=1 4.65 1 1 0.00 0.00 
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Accession Protein H/L #Cmpds # quant SD (H/L) % CV 
GOGA4_MOUSE Golgin subfamily A member 4 OS=Mus musculus GN=Golga4 PE=1 SV=2 4.56 26 6 5.86 128.63 
ANGL2_MOUSE Angiopoietin-related protein 2 OS=Mus musculus GN=Angptl2 PE=2 SV=1 4.48 1 1 0.00 0.00 
LYSM3_MOUSE LysM and putative peptidoglycan-binding domain-containing protein 3 OS=Mus musculus GN=Lysmd3 PE=2 SV=1 4.29 1 1 0.00 0.00 
ATRX_MOUSE Transcriptional regulator ATRX OS=Mus musculus GN=Atrx PE=1 SV=2 4.26 1 1 0.00 0.00 
BAG1_MOUSE BAG family molecular chaperone regulator 1 OS=Mus musculus GN=Bag1 PE=1 SV=3 4.17 1 1 0.00 0.00 
SCAP_MOUSE Sterol regulatory element-binding protein cleavage-activating protein OS=Mus musculus GN=Scap PE=1 SV=1 3.81 1 1 0.00 0.00 
MSPD2_MOUSE Motile sperm domain-containing protein 2 OS=Mus musculus GN=Mospd2 PE=1 SV=2 3.78 1 1 0.00 0.00 
SHQ1_MOUSE Protein SHQ1 homolog OS=Mus musculus GN=Shq1 PE=2 SV=2 3.75 1 1 0.00 0.00 
ESYT3_MOUSE Extended synaptotagmin-3 OS=Mus musculus GN=Fam62c PE=2 SV=2 3.71 1 1 0.00 0.00 
TF2H1_MOUSE General transcription factor IIH subunit 1 OS=Mus musculus GN=Gtf2h1 PE=2 SV=2 3.71 1 1 0.00 0.00 
COGA1_MOUSE Collagen alpha-1(XVI) chain OS=Mus musculus GN=Col16a1 PE=2 SV=2 3.70 1 1 0.00 0.00 
FA59B_MOUSE Protein FAM59B OS=Mus musculus GN=Fam59b PE=2 SV=2 3.70 1 1 0.00 0.00 
ANS4B_MOUSE Ankyrin repeat and SAM domain-containing protein 4B OS=Mus musculus GN=Anks4b PE=1 SV=1 3.55 1 1 0.00 0.00 
MCCB_MOUSE Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial OS=Mus musculus GN=Mccc2 PE=2 SV=1 3.47 1 1 0.00 0.00 
CAD13_MOUSE Cadherin-13 OS=Mus musculus GN=Cdh13 PE=2 SV=1 3.46 1 1 0.00 0.00 
BCORL_MOUSE BCoR-like protein 1 OS=Mus musculus GN=Bcorl1 PE=2 SV=1 3.43 1 1 0.00 0.00 
K1C10_MOUSE Keratin, type I cytoskeletal 10 OS=Mus musculus GN=Krt10 PE=1 SV=3 3.39 19 3 2.45 72.29 
F16A2_MOUSE UPF0518 protein FAM160A2 OS=Mus musculus GN=Fam160a2 PE=2 SV=2 3.35 1 1 0.00 0.00 
EPHA1_MOUSE Ephrin type-A receptor 1 OS=Mus musculus GN=Epha1 PE=1 SV=2 3.29 1 1 0.00 0.00 
DNA2L_MOUSE DNA2-like helicase OS=Mus musculus GN=Dna2 PE=2 SV=2 3.13 1 1 0.00 0.00 
FBXL2_MOUSE F-box/LRR-repeat protein 2 OS=Mus musculus GN=Fbxl2 PE=2 SV=1 3.13 1 1 0.00 0.00 
PSB4_MOUSE Proteasome subunit beta type-4 OS=Mus musculus GN=Psmb4 PE=1 SV=1 3.11 1 1 0.00 0.00 
PYC_MOUSE Pyruvate carboxylase, mitochondrial OS=Mus musculus GN=Pc PE=1 SV=1 3.05 1 1 0.00 0.00 
RL18_MOUSE 60S ribosomal protein L18 OS=Mus musculus GN=Rpl18 PE=2 SV=3 2.99 4 4 3.88 129.58 
ENAH_MOUSE Protein enabled homolog OS=Mus musculus GN=Enah PE=1 SV=2 2.97 1 1 0.00 0.00 
TSP1_MOUSE Thrombospondin-1 OS=Mus musculus GN=Thbs1 PE=1 SV=1 2.85 1 1 0.00 0.00 
CO4A2_MOUSE Collagen alpha-2(IV) chain OS=Mus musculus GN=Col4a2 PE=2 SV=4 2.80 1 1 0.00 0.00 
SCAM2_MOUSE Secretory carrier-associated membrane protein 2 OS=Mus musculus GN=Scamp2 PE=2 SV=1 2.79 1 1 0.00 0.00 
EPN4_MOUSE Clathrin interactor 1 OS=Mus musculus GN=Clint1 PE=1 SV=2 2.55 2 2 1.74 68.42 
NUCB2_MOUSE Nucleobindin-2 OS=Mus musculus GN=Nucb2 PE=1 SV=2 2.54 2 2 1.47 57.77 
STIP1_MOUSE Stress-induced-phosphoprotein 1 OS=Mus musculus GN=Stip1 PE=1 SV=1 2.52 1 1 0.00 0.00 
FA50B_MOUSE Protein FAM50B OS=Mus musculus GN=Fam50b PE=2 SV=1 2.50 1 1 0.00 0.00 
SGIP1_MOUSE SH3-containing GRB2-like protein 3-interacting protein 1 OS=Mus musculus GN=Sgip1 PE=1 SV=1 2.50 1 1 0.00 0.00 
C1TC_MOUSE C-1-tetrahydrofolate synthase, cytoplasmic OS=Mus musculus GN=Mthfd1 PE=1 SV=3 2.49 1 1 0.00 0.00 
DHRS1_MOUSE Dehydrogenase/reductase SDR family member 1 OS=Mus musculus GN=Dhrs1 PE=2 SV=1 2.47 2 1 0.00 0.00 
KIF17_MOUSE Kinesin-like protein KIF17 OS=Mus musculus GN=Kif17 PE=1 SV=1 2.44 1 1 0.00 0.00 
NDUV1_MOUSE NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial OS=Mus musculus GN=Ndufv1 PE=1 SV=1 2.43 2 2 1.40 57.67 
TMX1_MOUSE Thioredoxin-related transmembrane protein 1 OS=Mus musculus GN=Tmx1 PE=1 SV=1 2.43 1 1 0.00 0.00 
PEX14_MOUSE Peroxisomal membrane protein PEX14 OS=Mus musculus GN=Pex14 PE=1 SV=1 2.41 2 2 0.72 29.63 
MET10_MOUSE Putative methyltransferase METT10D OS=Mus musculus GN=Mett10d PE=1 SV=1 2.41 1 1 0.00 0.00 
RRAS2_MOUSE Ras-related protein R-Ras2 OS=Mus musculus GN=Rras2 PE=1 SV=1 2.38 2 2 0.63 26.65 
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Accession Protein H/L #Cmpds # quant SD (H/L) % CV 
SHIP2_MOUSE Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 2 OS=Mus musculus GN=Inppl1 PE=1 SV=1 2.37 1 1 0.00 0.00 
SEPT8_MOUSE Septin-8 OS=Mus musculus GN=Sept8 PE=1 SV=4 2.37 2 2 0.97 40.88 
WBP2_MOUSE WW domain-binding protein 2 OS=Mus musculus GN=Wbp2 PE=1 SV=1 2.37 2 1 0.00 0.00 
PDRG1_MOUSE p53 and DNA damage-regulated protein 1 OS=Mus musculus GN=Pdrg1 PE=2 SV=1 2.34 1 1 0.00 0.00 
UBP2L_MOUSE Ubiquitin-associated protein 2-like OS=Mus musculus GN=Ubap2l PE=1 SV=1 2.31 3 2 1.22 52.90 
T176A_MOUSE Transmembrane protein 176A OS=Mus musculus GN=Tmem176a PE=2 SV=2 2.29 2 1 0.00 0.00 
FGD6_MOUSE FYVE, RhoGEF and PH domain-containing protein 6 OS=Mus musculus GN=Fgd6 PE=1 SV=2 2.21 1 1 0.00 0.00 
KIF12_MOUSE Kinesin-like protein KIF12 OS=Mus musculus GN=Kif12 PE=2 SV=1 2.18 1 1 0.00 0.00 
HES6_MOUSE Transcription cofactor HES-6 OS=Mus musculus GN=Hes6 PE=1 SV=1 2.16 1 1 0.00 0.00 
HELQ_MOUSE Helicase POLQ-like OS=Mus musculus GN=Helq PE=2 SV=2 2.15 1 1 0.00 0.00 
H15_MOUSE Histone H1.5 OS=Mus musculus GN=Hist1h1b PE=1 SV=2 2.13 1 1 0.00 0.00 
T4S1_MOUSE Transmembrane 4 L6 family member 1 OS=Mus musculus GN=Tm4sf1 PE=1 SV=1 2.06 2 1 0.00 0.00 
SURF4_MOUSE Surfeit locus protein 4 OS=Mus musculus GN=Surf4 PE=2 SV=1 2.04 2 2 0.01 0.73 
NDUS7_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial OS=Mus musculus GN=Ndufs7 PE=1 SV=1 2.03 1 1 0.00 0.00 
GAB2_MOUSE GRB2-associated-binding protein 2 OS=Mus musculus GN=Gab2 PE=1 SV=2 2.02 4 2 1.66 82.29 
NIBAN_MOUSE Protein Niban OS=Mus musculus GN=Niban PE=2 SV=2 2.01 1 1 0.00 0.00 
CL070_MOUSE Uncharacterized protein C12orf70 homolog OS=Mus musculus PE=2 SV=1 2.01 1 1 0.00 0.00 
SCOT1_MOUSE Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial OS=Mus musculus GN=Oxct1 PE=1 SV=1 1.98 2 2 1.27 63.91 
CL035_MOUSE Uncharacterized protein C12orf35 homolog OS=Mus musculus GN=Kiaa1551 PE=2 SV=2 1.98 1 1 0.00 0.00 
MA7D3_MOUSE MAP7 domain-containing protein 3 OS=Mus musculus GN=Map7d3 PE=2 SV=1 1.97 1 1 0.00 0.00 
TREX1_MOUSE Three prime repair exonuclease 1 OS=Mus musculus GN=Trex1 PE=1 SV=2 1.97 1 1 0.00 0.00 
SEC20_MOUSE Vesicle transport protein SEC20 OS=Mus musculus GN=Bnip1 PE=2 SV=1 1.97 1 1 0.00 0.00 
SFI1_MOUSE Protein SFI1 homolog OS=Mus musculus GN=Sfi1 PE=2 SV=1 1.94 1 1 0.00 0.00 
VP26A_MOUSE Vacuolar protein sorting-associated protein 26A OS=Mus musculus GN=Vps26a PE=2 SV=1 1.94 1 1 0.00 0.00 
KCNH3_MOUSE Potassium voltage-gated channel subfamily H member 3 OS=Mus musculus GN=Kcnh3 PE=2 SV=1 1.92 1 1 0.00 0.00 
AKCL2_MOUSE 1,5-anhydro-D-fructose reductase OS=Mus musculus GN=Akr1e1 PE=1 SV=1 1.91 1 1 0.00 0.00 
CREG1_MOUSE Protein CREG1 OS=Mus musculus GN=Creg1 PE=2 SV=1 1.91 1 1 0.00 0.00 
ASPH_MOUSE Aspartyl/asparaginyl beta-hydroxylase OS=Mus musculus GN=Asph PE=2 SV=1 1.86 2 2 0.91 48.80 
MLKL_MOUSE Mixed lineage kinase domain-like protein OS=Mus musculus GN=Mlkl PE=2 SV=1 1.83 2 2 0.63 34.15 
RCN2_MOUSE Reticulocalbin-2 OS=Mus musculus GN=Rcn2 PE=2 SV=1 1.83 1 1 0.00 0.00 
FITM1_MOUSE Fat storage-inducing transmembrane protein 1 OS=Mus musculus GN=Fitm1 PE=1 SV=1 1.82 1 1 0.00 0.00 
ACADM_MOUSE Medium-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Mus musculus GN=Acadm PE=1 SV=1 1.82 1 1 0.00 0.00 
DLG1_MOUSE Disks large homolog 1 OS=Mus musculus GN=Dlg1 PE=1 SV=1 1.80 1 1 0.00 0.00 
IF4B_MOUSE Eukaryotic translation initiation factor 4B OS=Mus musculus GN=Eif4b PE=1 SV=1 1.80 1 1 0.00 0.00 
ARD1_MOUSE GTP-binding protein ARD-1 OS=Mus musculus GN=Trim23 PE=2 SV=1 1.79 1 1 0.00 0.00 
FUMH_MOUSE Fumarate hydratase, mitochondrial OS=Mus musculus GN=Fh PE=1 SV=2 1.79 3 2 0.64 35.83 
DNJB4_MOUSE DnaJ homolog subfamily B member 4 OS=Mus musculus GN=Dnajb4 PE=2 SV=1 1.77 2 2 0.64 36.13 
BST2_MOUSE Bone marrow stromal antigen 2 OS=Mus musculus GN=Bst2 PE=1 SV=1 1.77 6 4 0.74 41.75 
NU188_MOUSE Nucleoporin NUP188 homolog OS=Mus musculus GN=Nup188 PE=1 SV=2 1.76 1 1 0.00 0.00 
JHD2C_MOUSE Probable JmjC domain-containing histone demethylation protein 2C OS=Mus musculus GN=Jmjd1c PE=1 SV=2 1.74 1 1 0.00 0.00 
VMA5A_MOUSE von Willebrand factor A domain-containing protein 5A OS=Mus musculus GN=Vwa5a PE=1 SV=2 1.74 2 2 0.37 21.03 
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LMNB1_MOUSE Lamin-B1 OS=Mus musculus GN=Lmnb1 PE=1 SV=3 1.73 3 2 0.69 39.66 
RAB18_MOUSE Ras-related protein Rab-18 OS=Mus musculus GN=Rab18 PE=2 SV=2 1.72 3 3 1.51 87.73 
EIF1_MOUSE Eukaryotic translation initiation factor 1 OS=Mus musculus GN=Eif1 PE=2 SV=2 1.70 1 1 0.00 0.00 
ACADL_MOUSE Long-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Mus musculus GN=Acadl PE=2 SV=2 1.70 3 2 1.36 79.82 
PAWR_MOUSE PRKC apoptosis WT1 regulator protein OS=Mus musculus GN=Pawr PE=1 SV=2 1.70 1 1 0.00 0.00 
CATA_MOUSE Catalase OS=Mus musculus GN=Cat PE=1 SV=3 1.68 2 1 0.00 0.00 
DJC10_MOUSE DnaJ homolog subfamily C member 10 OS=Mus musculus GN=Dnajc10 PE=1 SV=1 1.68 1 1 0.00 0.00 
PDLI5_MOUSE PDZ and LIM domain protein 5 OS=Mus musculus GN=Pdlim5 PE=1 SV=3 1.66 4 3 1.17 70.08 
SYFA_MOUSE Phenylalanyl-tRNA synthetase alpha chain OS=Mus musculus GN=Farsa PE=2 SV=1 1.66 2 2 0.93 56.05 
ANXA6_MOUSE Annexin A6 OS=Mus musculus GN=Anxa6 PE=1 SV=2 1.66 4 4 0.81 48.81 
FSCN1_MOUSE Fascin OS=Mus musculus GN=Fscn1 PE=1 SV=4 1.66 4 4 0.70 42.14 
YA046_MOUSE Uncharacterized protein ENSP00000361571 homolog OS=Mus musculus PE=2 SV=2 1.65 1 1 0.00 0.00 
PTBP1_MOUSE Polypyrimidine tract-binding protein 1 OS=Mus musculus GN=Ptbp1 PE=1 SV=2 1.65 2 2 0.72 43.89 
CLAP1_MOUSE CLIP-associating protein 1 OS=Mus musculus GN=Clasp1 PE=1 SV=2 1.62 1 1 0.00 0.00 
DCTN2_MOUSE Dynactin subunit 2 OS=Mus musculus GN=Dctn2 PE=1 SV=3 1.62 1 1 0.00 0.00 
PDLI7_MOUSE PDZ and LIM domain protein 7 OS=Mus musculus GN=Pdlim7 PE=2 SV=1 1.61 1 1 0.00 0.00 
KAD7_MOUSE Putative adenylate kinase 7 OS=Mus musculus GN=Ak7 PE=2 SV=1 1.61 1 1 0.00 0.00 
KINH_MOUSE Kinesin-1 heavy chain OS=Mus musculus GN=Kif5b PE=1 SV=2 1.61 7 6 0.78 48.81 
DNJC3_MOUSE DnaJ homolog subfamily C member 3 OS=Mus musculus GN=Dnajc3 PE=1 SV=1 1.56 1 1 0.00 0.00 
PB1_MOUSE Protein polybromo-1 OS=Mus musculus GN=Pbrm1 PE=1 SV=3 1.56 1 1 0.00 0.00 
2AAA_MOUSE 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform OS=Mus musculus 
GN=Ppp2r1a PE=1 SV=3 1.56 1 1 0.00 0.00 
MAK10_MOUSE Protein MAK10 homolog OS=Mus musculus GN=Mak10 PE=1 SV=1 1.52 1 1 0.00 0.00 
UBR4_MOUSE E3 ubiquitin-protein ligase UBR4 OS=Mus musculus GN=Ubr4 PE=1 SV=1 1.50 1 1 0.00 0.00 
PCKGM_MOUSE Phosphoenolpyruvate carboxykinase [GTP], mitochondrial OS=Mus musculus GN=Pck2 PE=2 SV=1 1.50 2 2 0.21 13.86 
HA11_MOUSE H-2 class I histocompatibility antigen, D-B alpha chain OS=Mus musculus GN=H2-D1 PE=1 SV=2 1.50 7 5 1.15 77.16 
ALPK2_MOUSE Alpha-protein kinase 2 OS=Mus musculus GN=Alpk2 PE=2 SV=2 1.49 1 1 0.00 0.00 
AGAP1_MOUSE Arf-GAP, GTPase, ANK repeat and PH domain-containing protein 1 OS=Mus musculus GN=Agap1 PE=2 SV=1 1.49 1 1 0.00 0.00 
DOCK6_MOUSE Dedicator of cytokinesis protein 6 OS=Mus musculus GN=Dock6 PE=1 SV=3 1.49 1 1 0.00 0.00 
DNMT1_MOUSE DNA (cytosine-5)-methyltransferase 1 OS=Mus musculus GN=Dnmt1 PE=1 SV=5 1.49 1 1 0.00 0.00 
FANCI_MOUSE Fanconi anemia group I protein homolog OS=Mus musculus GN=Fanci PE=1 SV=2 1.49 1 1 0.00 0.00 
TSC1_MOUSE Hamartin OS=Mus musculus GN=Tsc1 PE=1 SV=1 1.49 1 1 0.00 0.00 
ODPA_MOUSE 
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial OS=Mus musculus GN=Pdha1 
PE=1 SV=1 1.49 1 1 0.00 0.00 
SMKTR_MOUSE Sperm motility kinase Tcr mutant form OS=Mus musculus GN=Smoktcr PE=2 SV=1 1.49 1 1 0.00 0.00 
UD17C_MOUSE UDP-glucuronosyltransferase 1-7C OS=Mus musculus GN=Ugt1a7c PE=2 SV=1 1.47 13 5 0.80 54.66 
METK2_MOUSE S-adenosylmethionine synthetase isoform type-2 OS=Mus musculus GN=Mat2a PE=2 SV=2 1.46 1 1 0.00 0.00 
RS2_MOUSE 40S ribosomal protein S2 OS=Mus musculus GN=Rps2 PE=1 SV=3 1.46 8 7 2.14 146.96 
MYH14_MOUSE Myosin-14 OS=Mus musculus GN=Myh14 PE=1 SV=1 1.45 17 9 1.03 71.04 
FA13C_MOUSE Protein FAM13C1 OS=Mus musculus GN=Fam13c1 PE=2 SV=1 1.45 1 1 0.00 0.00 
SGOL1_MOUSE Shugoshin-like 1 OS=Mus musculus GN=Sgol1 PE=2 SV=1 1.45 1 1 0.00 0.00 
ZN608_MOUSE Zinc finger protein 608 OS=Mus musculus GN=Znf608 PE=2 SV=1 1.45 1 1 0.00 0.00 
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AP2A1_MOUSE AP-2 complex subunit alpha-1 OS=Mus musculus GN=Ap2a1 PE=1 SV=1 1.44 3 3 0.47 32.45 
AP2A2_MOUSE AP-2 complex subunit alpha-2 OS=Mus musculus GN=Ap2a2 PE=1 SV=1 1.44 2 2 0.31 21.24 
RSSA_MOUSE 40S ribosomal protein SA OS=Mus musculus GN=Rpsa PE=1 SV=4 1.43 1 1 0.00 0.00 
TFP11_MOUSE Tuftelin-interacting protein 11 OS=Mus musculus GN=Tfip11 PE=1 SV=1 1.42 2 2 0.84 59.16 
PSMD1_MOUSE 26S proteasome non-ATPase regulatory subunit 1 OS=Mus musculus GN=Psmd1 PE=1 SV=1 1.42 3 2 0.51 36.13 
NICA_MOUSE Nicastrin OS=Mus musculus GN=Ncstn PE=1 SV=2 1.42 1 1 0.00 0.00 
HYEP_MOUSE Epoxide hydrolase 1 OS=Mus musculus GN=Ephx1 PE=1 SV=1 1.40 13 12 0.41 29.41 
PSA1_MOUSE Proteasome subunit alpha type-1 OS=Mus musculus GN=Psma1 PE=1 SV=1 1.40 1 1 0.00 0.00 
SVIL_MOUSE Supervillin OS=Mus musculus GN=Svil PE=1 SV=1 1.40 1 1 0.00 0.00 
MYH11_MOUSE Myosin-11 OS=Mus musculus GN=Myh11 PE=1 SV=1 1.40 27 15 1.02 73.11 
HCD2_MOUSE 3-hydroxyacyl-CoA dehydrogenase type-2 OS=Mus musculus GN=Hsd17b10 PE=1 SV=4 1.39 2 1 0.00 0.00 
MED17_MOUSE Mediator of RNA polymerase II transcription subunit 17 OS=Mus musculus GN=Med17 PE=1 SV=1 1.39 1 1 0.00 0.00 
PGAM5_MOUSE Phosphoglycerate mutase family member 5 OS=Mus musculus GN=Pgam5 PE=2 SV=1 1.39 1 1 0.00 0.00 
TR150_MOUSE Thyroid hormone receptor-associated protein 3 OS=Mus musculus GN=Thrap3 PE=1 SV=1 1.39 1 1 0.00 0.00 
EF1D_MOUSE Elongation factor 1-delta OS=Mus musculus GN=Eef1d PE=1 SV=3 1.38 5 5 0.26 18.71 
GVIN1_MOUSE Interferon-induced very large GTPase 1 OS=Mus musculus GN=Gvin1 PE=1 SV=1 1.38 2 2 0.02 1.62 
GLU2B_MOUSE Glucosidase 2 subunit beta OS=Mus musculus GN=Prkcsh PE=1 SV=1 1.37 5 4 0.65 47.54 
H12_MOUSE Histone H1.2 OS=Mus musculus GN=Hist1h1c PE=1 SV=2 1.37 5 3 1.27 93.00 
LYRIC_MOUSE Protein LYRIC OS=Mus musculus GN=Mtdh PE=1 SV=1 1.37 2 2 0.03 2.17 
MOV10_MOUSE Putative helicase MOV-10 OS=Mus musculus GN=Mov10 PE=1 SV=2 1.37 1 1 0.00 0.00 
AT2A1_MOUSE Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 OS=Mus musculus GN=Atp2a1 PE=2 SV=1 1.36 2 2 0.27 19.78 
GIMA4_MOUSE GTPase IMAP family member 4 OS=Mus musculus GN=Gimap4 PE=2 SV=1 1.34 1 1 0.00 0.00 
MESD_MOUSE LDLR chaperone MESD OS=Mus musculus GN=Mesdc2 PE=1 SV=1 1.34 1 1 0.00 0.00 
LIMS1_MOUSE LIM and senescent cell antigen-like-containing domain protein 1 OS=Mus musculus GN=Lims1 PE=1 SV=3 1.34 2 2 0.12 8.89 
GBB1_MOUSE Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 OS=Mus musculus GN=Gnb1 PE=1 SV=3 1.34 3 3 0.38 28.42 
P3H2_MOUSE Prolyl 3-hydroxylase 2 OS=Mus musculus GN=Leprel1 PE=2 SV=1 1.33 1 1 0.00 0.00 
PTN14_MOUSE Tyrosine-protein phosphatase non-receptor type 14 OS=Mus musculus GN=Ptpn14 PE=1 SV=1 1.33 1 1 0.00 0.00 
CHCH3_MOUSE 
Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, mitochondrial OS=Mus musculus GN=Chchd3 PE=1 
SV=1 1.32 5 5 0.72 54.78 
MVP_MOUSE Major vault protein OS=Mus musculus GN=Mvp PE=2 SV=3 1.32 4 4 0.42 31.86 
PSD12_MOUSE 26S proteasome non-ATPase regulatory subunit 12 OS=Mus musculus GN=Psmd12 PE=2 SV=3 1.31 1 1 0.00 0.00 
YX017_MOUSE Uncharacterized protein ENSP00000358542 homolog OS=Mus musculus PE=2 SV=1 1.31 1 1 0.00 0.00 
HNRH2_MOUSE Heterogeneous nuclear ribonucleoprotein H2 OS=Mus musculus GN=Hnrnph2 PE=1 SV=1 1.30 3 2 0.11 8.57 
H14_MOUSE Histone H1.4 OS=Mus musculus GN=Hist1h1e PE=1 SV=2 1.30 5 3 1.33 101.93 
AFAD_MOUSE Afadin OS=Mus musculus GN=Mllt4 PE=1 SV=3 1.30 1 1 0.00 0.00 
CDIPT_MOUSE CDP-diacylglycerol--inositol 3-phosphatidyltransferase OS=Mus musculus GN=Cdipt PE=1 SV=1 1.30 1 1 0.00 0.00 
DC1L1_MOUSE Cytoplasmic dynein 1 light intermediate chain 1 OS=Mus musculus GN=Dync1li1 PE=1 SV=1 1.30 2 2 0.31 24.14 
LEMD2_MOUSE LEM domain-containing protein 2 OS=Mus musculus GN=Lemd2 PE=1 SV=1 1.30 1 1 0.00 0.00 
DYHC1_MOUSE Cytoplasmic dynein 1 heavy chain 1 OS=Mus musculus GN=Dync1h1 PE=1 SV=1 1.29 12 10 0.39 30.55 
HNRPG_MOUSE Heterogeneous nuclear ribonucleoprotein G OS=Mus musculus GN=Rbmx PE=2 SV=1 1.29 4 3 0.23 17.78 
ALDOA_MOUSE Fructose-bisphosphate aldolase A OS=Mus musculus GN=Aldoa PE=1 SV=2 1.29 11 7 0.76 58.64 
RALY_MOUSE RNA-binding protein Raly OS=Mus musculus GN=Raly PE=1 SV=2 1.29 2 2 0.20 15.61 
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DJB10_MOUSE DnaJ homolog subfamily B member 10 OS=Mus musculus GN=Dnajb10 PE=2 SV=2 1.28 1 1 0.00 0.00 
FR1L4_MOUSE Fer-1-like protein 4 OS=Mus musculus GN=Fer1l4 PE=2 SV=2 1.28 1 1 0.00 0.00 
HMOX2_MOUSE Heme oxygenase 2 OS=Mus musculus GN=Hmox2 PE=2 SV=1 1.28 1 1 0.00 0.00 
PLOD3_MOUSE Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 OS=Mus musculus GN=Plod3 PE=2 SV=1 1.28 1 1 0.00 0.00 
RAB5C_MOUSE Ras-related protein Rab-5C OS=Mus musculus GN=Rab5c PE=1 SV=2 1.28 6 3 0.21 16.07 
NCPR_MOUSE NADPH--cytochrome P450 reductase OS=Mus musculus GN=Por PE=1 SV=2 1.27 2 2 0.29 22.81 
MK01_MOUSE Mitogen-activated protein kinase 1 OS=Mus musculus GN=Mapk1 PE=1 SV=3 1.27 2 2 0.44 34.50 
SFXN1_MOUSE Sideroflexin-1 OS=Mus musculus GN=Sfxn1 PE=1 SV=3 1.27 2 2 0.23 18.13 
KAD3_MOUSE GTP:AMP phosphotransferase mitochondrial OS=Mus musculus GN=Ak3 PE=1 SV=3 1.27 3 3 0.83 65.63 
ODP2_MOUSE 
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial 
OS=Mus musculus GN=Dlat PE=1 SV=2 1.27 2 2 0.22 17.65 
SNX2_MOUSE Sorting nexin-2 OS=Mus musculus GN=Snx2 PE=1 SV=2 1.27 2 2 0.51 40.00 
FKB10_MOUSE FK506-binding protein 10 OS=Mus musculus GN=Fkbp10 PE=1 SV=1 1.26 9 8 0.35 27.73 
IRGM_MOUSE Immunity-related GTPase family M protein OS=Mus musculus GN=Irgm PE=1 SV=1 1.26 2 2 0.11 8.88 
IMMT_MOUSE Mitochondrial inner membrane protein OS=Mus musculus GN=Immt PE=1 SV=1 1.26 8 6 0.35 28.07 
PRS8_MOUSE 26S protease regulatory subunit 8 OS=Mus musculus GN=Psmc5 PE=1 SV=1 1.25 2 2 0.07 5.95 
ADDA_MOUSE Alpha-adducin OS=Mus musculus GN=Add1 PE=1 SV=2 1.25 1 1 0.00 0.00 
AOFA_MOUSE Amine oxidase [flavin-containing] A OS=Mus musculus GN=Maoa PE=1 SV=2 1.25 5 4 0.31 24.64 
NFKB2_MOUSE Nuclear factor NF-kappa-B p100 subunit OS=Mus musculus GN=Nfkb2 PE=1 SV=1 1.25 1 1 0.00 0.00 
GSTM1_MOUSE Glutathione S-transferase Mu 1 OS=Mus musculus GN=Gstm1 PE=1 SV=2 1.24 2 2 0.32 25.75 
F120A_MOUSE Constitutive coactivator of PPAR-gamma-like protein 1 OS=Mus musculus GN=FAM120A PE=1 SV=2 1.24 3 3 0.30 24.04 
ARF4_MOUSE ADP-ribosylation factor 4 OS=Mus musculus GN=Arf4 PE=2 SV=2 1.24 1 1 0.00 0.00 
ANXA3_MOUSE Annexin A3 OS=Mus musculus GN=Anxa3 PE=2 SV=3 1.24 2 2 0.10 8.43 
ATAD1_MOUSE ATPase family AAA domain-containing protein 1 OS=Mus musculus GN=Atad1 PE=1 SV=1 1.24 1 1 0.00 0.00 
SNX18_MOUSE Sorting nexin-18 OS=Mus musculus GN=Snx18 PE=2 SV=1 1.24 1 1 0.00 0.00 
DDAH1_MOUSE N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 OS=Mus musculus GN=Ddah1 PE=1 SV=3 1.23 2 2 0.45 36.97 
P3H1_MOUSE Prolyl 3-hydroxylase 1 OS=Mus musculus GN=Lepre1 PE=2 SV=2 1.23 5 4 0.43 35.47 
QCR1_MOUSE Cytochrome b-c1 complex subunit 1, mitochondrial OS=Mus musculus GN=Uqcrc1 PE=1 SV=1 1.22 1 1 0.00 0.00 
FKBP8_MOUSE FK506-binding protein 8 OS=Mus musculus GN=Fkbp8 PE=1 SV=2 1.22 2 1 0.00 0.00 
GT251_MOUSE Glycosyltransferase 25 family member 1 OS=Mus musculus GN=Glt25d1 PE=2 SV=2 1.22 1 1 0.00 0.00 
MTCH2_MOUSE Mitochondrial carrier homolog 2 OS=Mus musculus GN=Mtch2 PE=1 SV=1 1.22 2 2 0.33 26.83 
MAOM_MOUSE NAD-dependent malic enzyme, mitochondrial OS=Mus musculus GN=Me2 PE=2 SV=1 1.22 1 1 0.00 0.00 
OAT_MOUSE Ornithine aminotransferase, mitochondrial OS=Mus musculus GN=Oat PE=1 SV=1 1.22 1 1 0.00 0.00 
THOC4_MOUSE THO complex subunit 4 OS=Mus musculus GN=Thoc4 PE=1 SV=3 1.22 2 2 0.00 0.00 
LMNA_MOUSE Lamin-A/C OS=Mus musculus GN=Lmna PE=1 SV=2 1.22 16 9 0.34 28.06 
AT1A1_MOUSE Sodium/potassium-transporting ATPase subunit alpha-1 OS=Mus musculus GN=Atp1a1 PE=1 SV=1 1.22 4 4 0.47 38.39 
CTRO_MOUSE Citron Rho-interacting kinase OS=Mus musculus GN=Cit PE=1 SV=3 1.21 2 2 0.34 27.61 
FINC_MOUSE Fibronectin OS=Mus musculus GN=Fn1 PE=1 SV=3 1.21 34 20 1.00 82.40 
CS060_MOUSE Uncharacterized protein C19orf60 homolog OS=Mus musculus PE=2 SV=1 1.21 1 1 0.00 0.00 
ANXA2_MOUSE Annexin A2 OS=Mus musculus GN=Anxa2 PE=1 SV=2 1.20 4 3 0.42 35.01 
SND1_MOUSE Staphylococcal nuclease domain-containing protein 1 OS=Mus musculus GN=Snd1 PE=1 SV=1 1.20 2 2 0.10 8.07 
CS063_MOUSE UPF0510 protein C19orf63 homolog OS=Mus musculus PE=2 SV=2 1.20 2 2 0.29 24.22 
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CALR_MOUSE Calreticulin OS=Mus musculus GN=Calr PE=1 SV=1 1.20 16 9 1.68 139.79 
HNRPK_MOUSE Heterogeneous nuclear ribonucleoprotein K OS=Mus musculus GN=Hnrnpk PE=1 SV=1 1.19 11 11 0.51 42.67 
PRS10_MOUSE 26S protease regulatory subunit S10B OS=Mus musculus GN=Psmc6 PE=1 SV=1 1.19 1 1 0.00 0.00 
IL6RB_MOUSE Interleukin-6 receptor subunit beta OS=Mus musculus GN=Il6st PE=1 SV=1 1.19 2 2 0.21 17.50 
MPPA_MOUSE Mitochondrial-processing peptidase subunit alpha OS=Mus musculus GN=Pmpca PE=1 SV=1 1.19 2 2 0.57 47.50 
NIPS1_MOUSE Protein NipSnap homolog 1 OS=Mus musculus GN=Nipsnap1 PE=1 SV=1 1.19 1 1 0.00 0.00 
ERO1A_MOUSE ERO1-like protein alpha OS=Mus musculus GN=Ero1l PE=1 SV=2 1.19 3 3 0.74 61.96 
LMAN1_MOUSE Protein ERGIC-53 OS=Mus musculus GN=Lman1 PE=2 SV=1 1.19 8 6 1.25 105.24 
ENOB_MOUSE Beta-enolase OS=Mus musculus GN=Eno3 PE=1 SV=3 1.18 3 3 0.66 55.96 
STOM_MOUSE Erythrocyte band 7 integral membrane protein OS=Mus musculus GN=Stom PE=1 SV=3 1.18 1 1 0.00 0.00 
HNRPQ_MOUSE Heterogeneous nuclear ribonucleoprotein Q OS=Mus musculus GN=Syncrip PE=1 SV=2 1.18 1 1 0.00 0.00 
STX7_MOUSE Syntaxin-7 OS=Mus musculus GN=Stx7 PE=1 SV=3 1.18 1 1 0.00 0.00 
VPS35_MOUSE Vacuolar protein sorting-associated protein 35 OS=Mus musculus GN=Vps35 PE=1 SV=1 1.18 1 1 0.00 0.00 
GSTM2_MOUSE Glutathione S-transferase Mu 2 OS=Mus musculus GN=Gstm2 PE=1 SV=2 1.18 2 2 0.25 21.52 
DDX3X_MOUSE ATP-dependent RNA helicase DDX3X OS=Mus musculus GN=Ddx3x PE=1 SV=3 1.17 4 4 0.28 24.12 
GANAB_MOUSE Neutral alpha-glucosidase AB OS=Mus musculus GN=Ganab PE=1 SV=1 1.17 10 10 0.35 30.42 
MPCP_MOUSE Phosphate carrier protein, mitochondrial OS=Mus musculus GN=Slc25a3 PE=1 SV=1 1.16 47 11 0.43 37.28 
CHM1A_MOUSE Charged multivesicular body protein 1a OS=Mus musculus GN=Chmp1a PE=1 SV=1 1.16 1 1 0.00 0.00 
EIF3F_MOUSE Eukaryotic translation initiation factor 3 subunit F OS=Mus musculus GN=Eif3f PE=1 SV=1 1.16 1 1 0.00 0.00 
ROA2_MOUSE Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Mus musculus GN=Hnrnpa2b1 PE=1 SV=2 1.16 1 1 0.00 0.00 
K22E_MOUSE Keratin, type II cytoskeletal 2 epidermal OS=Mus musculus GN=Krt2 PE=1 SV=1 1.16 6 3 0.40 34.32 
DJB11_MOUSE DnaJ homolog subfamily B member 11 OS=Mus musculus GN=Dnajb11 PE=1 SV=1 1.16 3 3 0.17 14.58 
MUC18_MOUSE Cell surface glycoprotein MUC18 OS=Mus musculus GN=Mcam PE=2 SV=1 1.15 2 2 0.35 30.32 
ETFD_MOUSE Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial OS=Mus musculus GN=Etfdh PE=1 SV=1 1.15 3 3 0.14 12.33 
UBIQ_MOUSE Ubiquitin OS=Mus musculus GN=Rps27a PE=1 SV=1 1.15 4 3 0.27 23.16 
PCBP1_MOUSE Poly(rC)-binding protein 1 OS=Mus musculus GN=Pcbp1 PE=1 SV=1 1.15 8 6 0.46 40.25 
SPTA2_MOUSE Spectrin alpha chain, brain OS=Mus musculus GN=Sptan1 PE=1 SV=4 1.15 21 19 0.62 53.84 
PSMD2_MOUSE 26S proteasome non-ATPase regulatory subunit 2 OS=Mus musculus GN=Psmd2 PE=1 SV=1 1.15 1 1 0.00 0.00 
GSH0_MOUSE Glutamate--cysteine ligase regulatory subunit OS=Mus musculus GN=Gclm PE=2 SV=1 1.15 1 1 0.00 0.00 
KSR2_MOUSE Kinase suppressor of Ras 2 OS=Mus musculus GN=Ksr2 PE=2 SV=2 1.15 1 1 0.00 0.00 
MOL1B_MOUSE Mps one binder kinase activator-like 1B OS=Mus musculus GN=Mobkl1b PE=2 SV=3 1.15 1 1 0.00 0.00 
UAP56_MOUSE Spliceosome RNA helicase Bat1 OS=Mus musculus GN=Bat1 PE=1 SV=1 1.15 1 1 0.00 0.00 
SF3A1_MOUSE Splicing factor 3 subunit 1 OS=Mus musculus GN=Sf3a1 PE=1 SV=1 1.15 2 1 0.00 0.00 
SR140_MOUSE U2-associated protein SR140 OS=Mus musculus GN=Sr140 PE=2 SV=2 1.15 1 1 0.00 0.00 
NEDD4_MOUSE E3 ubiquitin-protein ligase NEDD4 OS=Mus musculus GN=Nedd4 PE=1 SV=3 1.14 2 2 0.50 43.79 
SPTB2_MOUSE Spectrin beta chain, brain 1 OS=Mus musculus GN=Sptbn1 PE=1 SV=2 1.13 15 13 0.28 24.46 
VINC_MOUSE Vinculin OS=Mus musculus GN=Vcl PE=1 SV=4 1.13 14 10 0.35 30.54 
CO4A1_MOUSE Collagen alpha-1(IV) chain OS=Mus musculus GN=Col4a1 PE=2 SV=4 1.13 1 1 0.00 0.00 
TGM2_MOUSE Protein-glutamine gamma-glutamyltransferase 2 OS=Mus musculus GN=Tgm2 PE=1 SV=4 1.13 1 1 0.00 0.00 
RAB5A_MOUSE Ras-related protein Rab-5A OS=Mus musculus GN=Rab5a PE=1 SV=1 1.13 3 2 0.43 38.16 
STAT3_MOUSE Signal transducer and activator of transcription 3 OS=Mus musculus GN=Stat3 PE=1 SV=2 1.13 2 2 0.30 26.32 
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Accession Protein H/L #Cmpds # quant SD (H/L) % CV 
FLNC_MOUSE Filamin-C OS=Mus musculus GN=Flnc PE=1 SV=3 1.13 5 5 0.41 36.39 
DYHC2_MOUSE Cytoplasmic dynein 2 heavy chain 1 OS=Mus musculus GN=Dync2h1 PE=1 SV=1 1.12 2 2 0.34 29.80 
RTN4_MOUSE Reticulon-4 OS=Mus musculus GN=Rtn4 PE=1 SV=2 1.12 42 12 0.25 22.49 
PGAM1_MOUSE Phosphoglycerate mutase 1 OS=Mus musculus GN=Pgam1 PE=1 SV=3 1.12 5 5 0.62 55.25 
CBR2_MOUSE Carbonyl reductase [NADPH] 2 OS=Mus musculus GN=Cbr2 PE=1 SV=1 1.12 2 2 0.13 12.00 
GDF5_MOUSE Growth/differentiation factor 5 OS=Mus musculus GN=Gdf5 PE=2 SV=1 1.12 1 1 0.00 0.00 
LPPRC_MOUSE Leucine-rich PPR motif-containing protein, mitochondrial OS=Mus musculus GN=Lrpprc PE=1 SV=2 1.12 1 1 0.00 0.00 
LSM12_MOUSE Protein LSM12 homolog OS=Mus musculus GN=Lsm12 PE=1 SV=1 1.12 1 1 0.00 0.00 
EWS_MOUSE RNA-binding protein EWS OS=Mus musculus GN=Ewsr1 PE=1 SV=1 1.12 2 2 0.46 41.33 
HS71L_MOUSE Heat shock 70 kDa protein 1L OS=Mus musculus GN=Hspa1l PE=2 SV=4 1.11 22 7 0.72 64.75 
MDHM_MOUSE Malate dehydrogenase, mitochondrial OS=Mus musculus GN=Mdh2 PE=1 SV=3 1.11 18 10 1.26 112.76 
G3BP1_MOUSE Ras GTPase-activating protein-binding protein 1 OS=Mus musculus GN=G3bp1 PE=1 SV=1 1.11 2 2 0.28 24.83 
COPD_MOUSE Coatomer subunit delta OS=Mus musculus GN=Arcn1 PE=2 SV=1 1.11 2 2 0.47 42.28 
NIPS2_MOUSE Protein NipSnap homolog 2 OS=Mus musculus GN=Gbas PE=2 SV=1 1.11 3 3 0.71 64.26 
SGPL1_MOUSE Sphingosine-1-phosphate lyase 1 OS=Mus musculus GN=Sgpl1 PE=2 SV=1 1.11 8 7 0.30 27.08 
TBB5_MOUSE Tubulin beta-5 chain OS=Mus musculus GN=Tubb5 PE=1 SV=1 1.11 28 13 0.52 47.29 
G6PE_MOUSE GDH/6PGL endoplasmic bifunctional protein OS=Mus musculus GN=H6pd PE=2 SV=1 1.10 8 7 0.68 61.35 
LEG9_MOUSE Galectin-9 OS=Mus musculus GN=Lgals9 PE=1 SV=1 1.10 2 2 0.21 18.92 
CDC37_MOUSE Hsp90 co-chaperone Cdc37 OS=Mus musculus GN=Cdc37 PE=2 SV=1 1.10 1 1 0.00 0.00 
CLH_MOUSE Clathrin heavy chain 1 OS=Mus musculus GN=Cltc PE=1 SV=3 1.10 12 6 0.27 24.11 
RL4_MOUSE 60S ribosomal protein L4 OS=Mus musculus GN=Rpl4 PE=1 SV=3 1.10 5 5 0.49 44.76 
VATA_MOUSE V-type proton ATPase catalytic subunit A OS=Mus musculus GN=Atp6v1a PE=1 SV=2 1.10 3 3 0.06 5.24 
IMB1_MOUSE Importin subunit beta-1 OS=Mus musculus GN=Kpnb1 PE=1 SV=1 1.10 5 3 0.27 24.32 
NDUS1_MOUSE NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial OS=Mus musculus GN=Ndufs1 PE=1 SV=1 1.10 2 2 0.07 6.12 
CAND1_MOUSE Cullin-associated NEDD8-dissociated protein 1 OS=Mus musculus GN=Cand1 PE=2 SV=2 1.10 2 2 0.04 3.40 
ACON_MOUSE Aconitate hydratase, mitochondrial OS=Mus musculus GN=Aco2 PE=1 SV=1 1.09 5 5 0.52 47.68 
TOM70_MOUSE Mitochondrial import receptor subunit TOM70 OS=Mus musculus GN=Tomm70a PE=1 SV=1 1.09 3 3 0.17 15.16 
CO3_MOUSE Complement C3 OS=Mus musculus GN=C3 PE=1 SV=2 1.09 6 5 0.54 49.53 
NDUA9_MOUSE 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial OS=Mus musculus GN=Ndufa9 
PE=1 SV=1 1.09 4 4 0.28 25.68 
RAB21_MOUSE Ras-related protein Rab-21 OS=Mus musculus GN=Rab21 PE=1 SV=4 1.09 2 2 0.16 15.07 
TTC35_MOUSE Tetratricopeptide repeat protein 35 OS=Mus musculus GN=Ttc35 PE=2 SV=1 1.08 6 4 0.37 33.76 
DHSA_MOUSE 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial OS=Mus musculus GN=Sdha PE=1 
SV=1 1.08 6 4 0.23 21.11 
HS12A_MOUSE Heat shock 70 kDa protein 12A OS=Mus musculus GN=Hspa12a PE=1 SV=1 1.08 2 2 0.42 39.31 
GNAI2_MOUSE Guanine nucleotide-binding protein G(i), alpha-2 subunit OS=Mus musculus GN=Gnai2 PE=1 SV=4 1.07 12 7 0.51 47.09 
CTND1_MOUSE Catenin delta-1 OS=Mus musculus GN=Ctnnd1 PE=1 SV=2 1.07 3 2 0.04 4.17 
PCCA_MOUSE Propionyl-CoA carboxylase alpha chain, mitochondrial OS=Mus musculus GN=Pcca PE=2 SV=2 1.07 1 1 0.00 0.00 
YIF1B_MOUSE Protein YIF1B OS=Mus musculus GN=Yif1b PE=2 SV=2 1.07 1 1 0.00 0.00 
TMM43_MOUSE Transmembrane protein 43 OS=Mus musculus GN=Tmem43 PE=1 SV=1 1.07 1 1 0.00 0.00 
CH041_MOUSE Uncharacterized protein C8orf41 homolog OS=Mus musculus PE=2 SV=1 1.07 1 1 0.00 0.00 
RSU1_MOUSE Ras suppressor protein 1 OS=Mus musculus GN=Rsu1 PE=2 SV=3 1.06 2 2 0.43 40.85 
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LMAN2_MOUSE Vesicular integral-membrane protein VIP36 OS=Mus musculus GN=Lman2 PE=2 SV=1 1.06 3 2 0.61 57.75 
VATB2_MOUSE V-type proton ATPase subunit B, brain isoform OS=Mus musculus GN=Atp6v1b2 PE=1 SV=1 1.06 7 6 0.24 22.73 
AP2B1_MOUSE AP-2 complex subunit beta-1 OS=Mus musculus GN=Ap2b1 PE=1 SV=1 1.06 1 1 0.00 0.00 
ABCD3_MOUSE ATP-binding cassette sub-family D member 3 OS=Mus musculus GN=Abcd3 PE=1 SV=1 1.06 1 1 0.00 0.00 
IF4G1_MOUSE Eukaryotic translation initiation factor 4 gamma 1 OS=Mus musculus GN=Eif4g1 PE=1 SV=1 1.06 1 1 0.00 0.00 
LYN_MOUSE Tyrosine-protein kinase Lyn OS=Mus musculus GN=Lyn PE=1 SV=4 1.06 1 1 0.00 0.00 
GBB2_MOUSE Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 OS=Mus musculus GN=Gnb2 PE=1 SV=3 1.05 3 3 0.44 41.62 
SEP11_MOUSE Septin-11 OS=Mus musculus GN=Sept11 PE=1 SV=4 1.05 3 3 0.34 32.05 
TCPH_MOUSE T-complex protein 1 subunit eta OS=Mus musculus GN=Cct7 PE=1 SV=1 1.05 4 4 0.38 36.24 
TPD54_MOUSE Tumor protein D54 OS=Mus musculus GN=Tpd52l2 PE=1 SV=1 1.05 2 2 0.23 21.99 
1433F_MOUSE 14-3-3 protein eta OS=Mus musculus GN=Ywhah PE=1 SV=2 1.05 8 6 0.35 33.53 
RAI14_MOUSE Ankycorbin OS=Mus musculus GN=Rai14 PE=1 SV=1 1.05 6 4 0.27 25.33 
TCPA2_MOUSE T-complex protein 1 subunit alpha B OS=Mus musculus GN=Cct1 PE=1 SV=3 1.05 5 4 0.33 31.39 
RU17_MOUSE U1 small nuclear ribonucleoprotein 70 kDa OS=Mus musculus GN=Snrnp70 PE=1 SV=2 1.05 4 4 0.48 45.73 
GBP5_MOUSE Guanylate-binding protein 5 OS=Mus musculus GN=Gbp5 PE=2 SV=1 1.04 5 4 0.09 8.81 
PRS4_MOUSE 26S protease regulatory subunit 4 OS=Mus musculus GN=Psmc1 PE=1 SV=1 1.04 4 4 0.43 41.03 
B2L13_MOUSE Bcl-2-like 13 protein OS=Mus musculus GN=Bcl2l13 PE=1 SV=1 1.04 1 1 0.00 0.00 
FKBP9_MOUSE FK506-binding protein 9 OS=Mus musculus GN=Fkbp9 PE=1 SV=1 1.04 1 1 0.00 0.00 
HMOX1_MOUSE Heme oxygenase 1 OS=Mus musculus GN=Hmox1 PE=2 SV=1 1.04 2 2 0.01 1.43 
DHSB_MOUSE Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial OS=Mus musculus GN=Sdhb PE=1 SV=1 1.04 1 1 0.00 0.00 
TOIP1_MOUSE Torsin-1A-interacting protein 1 OS=Mus musculus GN=Tor1aip1 PE=1 SV=1 1.04 1 1 0.00 0.00 
UBP5_MOUSE Ubiquitin carboxyl-terminal hydrolase 5 OS=Mus musculus GN=Usp5 PE=1 SV=1 1.04 1 1 0.00 0.00 
P4HA1_MOUSE Prolyl 4-hydroxylase subunit alpha-1 OS=Mus musculus GN=P4ha1 PE=2 SV=2 1.04 10 9 1.06 102.18 
TPM3_MOUSE Tropomyosin alpha-3 chain OS=Mus musculus GN=Tpm3 PE=1 SV=2 1.04 12 9 0.58 55.67 
CAP1_MOUSE Adenylyl cyclase-associated protein 1 OS=Mus musculus GN=Cap1 PE=1 SV=3 1.04 2 2 0.02 2.16 
GRP78_MOUSE 78 kDa glucose-regulated protein OS=Mus musculus GN=Hspa5 PE=1 SV=3 1.03 71 23 0.87 83.97 
PLS1_MOUSE Phospholipid scramblase 1 OS=Mus musculus GN=Plscr1 PE=2 SV=1 1.03 4 3 0.43 41.89 
SYVC_MOUSE Valyl-tRNA synthetase OS=Mus musculus GN=Vars PE=2 SV=1 1.03 3 3 0.11 10.56 
6PGL_MOUSE 6-phosphogluconolactonase OS=Mus musculus GN=Pgls PE=2 SV=1 1.03 1 1 0.00 0.00 
ASM3B_MOUSE Acid sphingomyelinase-like phosphodiesterase 3b OS=Mus musculus GN=Smpdl3b PE=2 SV=1 1.03 1 1 0.00 0.00 
NDRG1_MOUSE Protein NDRG1 OS=Mus musculus GN=Ndrg1 PE=1 SV=1 1.03 1 1 0.00 0.00 
SRPR_MOUSE Signal recognition particle receptor subunit alpha OS=Mus musculus GN=Srpr PE=1 SV=1 1.03 1 1 0.00 0.00 
NUCB1_MOUSE Nucleobindin-1 OS=Mus musculus GN=Nucb1 PE=1 SV=2 1.02 7 6 0.19 18.91 
PCYOX_MOUSE Prenylcysteine oxidase OS=Mus musculus GN=Pcyox1 PE=1 SV=1 1.02 4 3 0.23 22.10 
APOOL_MOUSE Apolipoprotein O-like OS=Mus musculus GN=Apool PE=2 SV=1 1.02 2 2 0.07 6.57 
MYPT1_MOUSE Protein phosphatase 1 regulatory subunit 12A OS=Mus musculus GN=Ppp1r12a PE=1 SV=1 1.02 2 2 0.26 25.55 
EF1A1_MOUSE Elongation factor 1-alpha 1 OS=Mus musculus GN=Eef1a1 PE=1 SV=3 1.02 18 10 0.36 35.36 
UGGG1_MOUSE UDP-glucose:glycoprotein glucosyltransferase 1 OS=Mus musculus GN=Ugcgl1 PE=1 SV=3 1.02 4 4 0.25 24.50 
SRC8_MOUSE Src substrate cortactin OS=Mus musculus GN=Cttn PE=1 SV=1 1.01 1 1 0.00 0.00 
SFPQ_MOUSE Splicing factor, proline- and glutamine-rich OS=Mus musculus GN=Sfpq PE=1 SV=1 1.01 11 5 0.39 38.30 
KTN1_MOUSE Kinectin OS=Mus musculus GN=Ktn1 PE=1 SV=1 1.01 11 9 0.19 19.13 
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PGRC2_MOUSE Membrane-associated progesterone receptor component 2 OS=Mus musculus GN=Pgrmc2 PE=1 SV=2 1.01 4 3 0.37 36.86 
VA0D1_MOUSE V-type proton ATPase subunit d 1 OS=Mus musculus GN=Atp6v0d1 PE=1 SV=2 1.01 4 3 0.74 73.80 
ACTN4_MOUSE Alpha-actinin-4 OS=Mus musculus GN=Actn4 PE=1 SV=1 1.00 25 14 0.32 31.42 
DHE3_MOUSE Glutamate dehydrogenase 1, mitochondrial OS=Mus musculus GN=Glud1 PE=1 SV=1 1.00 7 5 0.29 28.78 
MPRIP_MOUSE Myosin phosphatase Rho-interacting protein OS=Mus musculus GN=Mprip PE=1 SV=2 1.00 5 4 0.20 20.02 
PLCD1_MOUSE 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase delta-1 OS=Mus musculus GN=Plcd1 PE=2 SV=1 1.00 1 1 0.00 0.00 
LYPA1_MOUSE Acyl-protein thioesterase 1 OS=Mus musculus GN=Lypla1 PE=1 SV=1 1.00 1 1 0.00 0.00 
IMPA1_MOUSE Inositol monophosphatase OS=Mus musculus GN=Impa1 PE=2 SV=1 1.00 1 1 0.00 0.00 
ILK_MOUSE Integrin-linked protein kinase OS=Mus musculus GN=Ilk PE=1 SV=2 1.00 1 1 0.00 0.00 
K1C14_MOUSE Keratin, type I cytoskeletal 14 OS=Mus musculus GN=Krt14 PE=1 SV=2 1.00 1 1 0.00 0.00 
P4HA2_MOUSE Prolyl 4-hydroxylase subunit alpha-2 OS=Mus musculus GN=P4ha2 PE=2 SV=1 1.00 1 1 0.00 0.00 
PP2BA_MOUSE 
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform OS=Mus musculus GN=Ppp3ca PE=1 
SV=1 1.00 1 1 0.00 0.00 
GLOD4_MOUSE Glyoxalase domain-containing protein 4 OS=Mus musculus GN=Glod4 PE=2 SV=1 1.00 2 2 0.48 47.76 
LXN_MOUSE Latexin OS=Mus musculus GN=Lxn PE=1 SV=2 1.00 2 2 0.19 19.40 
PSA5_MOUSE Proteasome subunit alpha type-5 OS=Mus musculus GN=Psma5 PE=1 SV=1 1.00 2 2 0.33 32.84 
TCPG_MOUSE T-complex protein 1 subunit gamma OS=Mus musculus GN=Cct3 PE=1 SV=1 1.00 4 4 0.30 29.89 
LETM1_MOUSE LETM1 and EF-hand domain-containing protein 1, mitochondrial OS=Mus musculus GN=Letm1 PE=2 SV=1 0.99 3 3 0.26 26.45 
MLEC_MOUSE Malectin OS=Mus musculus GN=Mlec PE=2 SV=2 0.99 5 3 0.18 17.93 
TERA_MOUSE Transitional endoplasmic reticulum ATPase OS=Mus musculus GN=Vcp PE=1 SV=4 0.99 13 7 0.40 40.32 
GOLI4_MOUSE Golgi integral membrane protein 4 OS=Mus musculus GN=Golim4 PE=1 SV=1 0.99 2 2 0.39 39.85 
CERU_MOUSE Ceruloplasmin OS=Mus musculus GN=Cp PE=1 SV=2 0.99 3 3 0.15 14.89 
ACSF2_MOUSE Acyl-CoA synthetase family member 2, mitochondrial OS=Mus musculus GN=Acsf2 PE=2 SV=1 0.98 1 1 0.00 0.00 
KAD2_MOUSE Adenylate kinase 2, mitochondrial OS=Mus musculus GN=Ak2 PE=1 SV=5 0.98 3 3 0.28 28.77 
MA2A1_MOUSE Alpha-mannosidase 2 OS=Mus musculus GN=Man2a1 PE=1 SV=1 0.98 2 2 0.63 63.64 
NPM_MOUSE Nucleophosmin OS=Mus musculus GN=Npm1 PE=1 SV=1 0.98 1 1 0.00 0.00 
CTNA1_MOUSE Catenin alpha-1 OS=Mus musculus GN=Ctnna1 PE=1 SV=1 0.98 13 12 0.24 24.46 
PGAM2_MOUSE Phosphoglycerate mutase 2 OS=Mus musculus GN=Pgam2 PE=1 SV=3 0.98 5 5 0.70 71.22 
ANXA1_MOUSE Annexin A1 OS=Mus musculus GN=Anxa1 PE=1 SV=2 0.98 5 5 0.26 26.62 
NONO_MOUSE Non-POU domain-containing octamer-binding protein OS=Mus musculus GN=Nono PE=1 SV=3 0.98 5 5 0.24 24.63 
MCAT_MOUSE Mitochondrial carnitine/acylcarnitine carrier protein OS=Mus musculus GN=Slc25a20 PE=1 SV=1 0.98 2 2 0.10 9.92 
ATPB_MOUSE ATP synthase subunit beta, mitochondrial OS=Mus musculus GN=Atp5b PE=1 SV=2 0.97 34 20 0.35 36.23 
PLEC1_MOUSE Plectin-1 OS=Mus musculus GN=Plec1 PE=1 SV=2 0.97 47 40 0.31 31.65 
MUTA_MOUSE Methylmalonyl-CoA mutase, mitochondrial OS=Mus musculus GN=Mut PE=2 SV=1 0.97 1 1 0.00 0.00 
DIC_MOUSE Mitochondrial dicarboxylate carrier OS=Mus musculus GN=Slc25a10 PE=2 SV=2 0.97 1 1 0.00 0.00 
SSRD_MOUSE Translocon-associated protein subunit delta OS=Mus musculus GN=Ssr4 PE=2 SV=1 0.97 1 1 0.00 0.00 
TBA4A_MOUSE Tubulin alpha-4A chain OS=Mus musculus GN=Tuba4a PE=1 SV=1 0.97 13 6 0.44 45.72 
CN159_MOUSE UPF0317 protein C14orf159 homolog, mitochondrial OS=Mus musculus PE=2 SV=1 0.97 1 1 0.00 0.00 
CHM4B_MOUSE Charged multivesicular body protein 4b OS=Mus musculus GN=Chmp4b PE=2 SV=2 0.97 4 4 0.21 21.84 
COPA_MOUSE Coatomer subunit alpha OS=Mus musculus GN=Copa PE=1 SV=1 0.97 6 5 0.21 21.47 
FLOT1_MOUSE Flotillin-1 OS=Mus musculus GN=Flot1 PE=1 SV=1 0.97 2 2 0.10 10.77 
MYO1C_MOUSE Myosin-Ic OS=Mus musculus GN=Myo1c PE=1 SV=2 0.97 14 10 0.22 22.24 
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CTNB1_MOUSE Catenin beta-1 OS=Mus musculus GN=Ctnnb1 PE=1 SV=1 0.97 13 9 0.29 30.35 
SERPH_MOUSE Serpin H1 OS=Mus musculus GN=Serpinh1 PE=1 SV=2 0.96 25 16 0.76 79.06 
IDHP_MOUSE Isocitrate dehydrogenase [NADP], mitochondrial OS=Mus musculus GN=Idh2 PE=1 SV=3 0.96 6 6 0.32 32.92 
ACTN1_MOUSE Alpha-actinin-1 OS=Mus musculus GN=Actn1 PE=2 SV=1 0.96 14 11 0.23 23.55 
UBA1_MOUSE Ubiquitin-like modifier-activating enzyme 1 OS=Mus musculus GN=Uba1 PE=1 SV=1 0.96 6 5 0.13 14.05 
RAB14_MOUSE Ras-related protein Rab-14 OS=Mus musculus GN=Rab14 PE=1 SV=3 0.96 11 5 0.33 34.25 
FLNB_MOUSE Filamin-B OS=Mus musculus GN=Flnb PE=2 SV=2 0.96 35 30 0.36 37.52 
CAPZB_MOUSE F-actin-capping protein subunit beta OS=Mus musculus GN=Capzb PE=1 SV=3 0.96 4 4 0.36 37.33 
LAP2B_MOUSE Lamina-associated polypeptide 2, isoforms beta/delta/epsilon/gamma OS=Mus musculus GN=Tmpo PE=1 SV=3 0.96 9 5 0.20 20.46 
ANXA7_MOUSE Annexin A7 OS=Mus musculus GN=Anxa7 PE=2 SV=1 0.95 1 1 0.00 0.00 
MEST_MOUSE Mesoderm-specific transcript protein OS=Mus musculus GN=Mest PE=2 SV=1 0.95 2 2 0.16 17.19 
PTN1_MOUSE Tyrosine-protein phosphatase non-receptor type 1 OS=Mus musculus GN=Ptpn1 PE=1 SV=2 0.95 1 1 0.00 0.00 
AIFM1_MOUSE Apoptosis-inducing factor 1, mitochondrial OS=Mus musculus GN=Aifm1 PE=1 SV=1 0.95 3 3 0.08 7.97 
RS3_MOUSE 40S ribosomal protein S3 OS=Mus musculus GN=Rps3 PE=1 SV=1 0.95 10 6 0.33 34.61 
G3P_MOUSE Glyceraldehyde-3-phosphate dehydrogenase OS=Mus musculus GN=Gapdh PE=1 SV=2 0.95 13 12 0.62 65.09 
SYEP_MOUSE Bifunctional aminoacyl-tRNA synthetase OS=Mus musculus GN=Eprs PE=2 SV=3 0.95 3 3 0.22 23.10 
EF1A2_MOUSE Elongation factor 1-alpha 2 OS=Mus musculus GN=Eef1a2 PE=1 SV=1 0.95 10 6 0.38 40.20 
TBB2C_MOUSE Tubulin beta-2C chain OS=Mus musculus GN=Tubb2c PE=1 SV=1 0.94 31 14 0.44 47.03 
MTX2_MOUSE Metaxin-2 OS=Mus musculus GN=Mtx2 PE=1 SV=1 0.94 1 1 0.00 0.00 
RRAS_MOUSE Ras-related protein R-Ras OS=Mus musculus GN=Rras PE=2 SV=1 0.94 1 1 0.00 0.00 
GDPD1_MOUSE 
Glycerophosphodiester phosphodiesterase domain-containing protein 1 OS=Mus musculus GN=Gdpd1 PE=2 
SV=1 0.94 2 2 0.34 36.51 
EHD1_MOUSE EH domain-containing protein 1 OS=Mus musculus GN=Ehd1 PE=1 SV=1 0.94 5 5 0.19 19.82 
RHOA_MOUSE Transforming protein RhoA OS=Mus musculus GN=Rhoa PE=1 SV=1 0.94 6 5 0.08 8.51 
PDIA4_MOUSE Protein disulfide-isomerase A4 OS=Mus musculus GN=Pdia4 PE=1 SV=2 0.94 16 13 0.59 63.40 
SC22B_MOUSE Vesicle-trafficking protein SEC22b OS=Mus musculus GN=Sec22b PE=1 SV=3 0.93 10 7 0.40 43.31 
E41L3_MOUSE Band 4.1-like protein 3 OS=Mus musculus GN=Epb41l3 PE=1 SV=1 0.92 3 3 0.05 5.74 
CLPT1_MOUSE Cleft lip and palate transmembrane protein 1 homolog OS=Mus musculus GN=Clptm1 PE=1 SV=1 0.92 1 1 0.00 0.00 
FIGN_MOUSE Fidgetin OS=Mus musculus GN=Fign PE=2 SV=1 0.92 1 1 0.00 0.00 
ITAV_MOUSE Integrin alpha-V OS=Mus musculus GN=Itgav PE=2 SV=1 0.92 3 2 0.07 8.06 
NUCL_MOUSE Nucleolin OS=Mus musculus GN=Ncl PE=1 SV=2 0.92 1 1 0.00 0.00 
PRDX6_MOUSE Peroxiredoxin-6 OS=Mus musculus GN=Prdx6 PE=1 SV=3 0.92 3 3 0.23 24.39 
SFXN3_MOUSE Sideroflexin-3 OS=Mus musculus GN=Sfxn3 PE=1 SV=1 0.92 1 1 0.00 0.00 
CA077_MOUSE Uncharacterized protein C1orf77 homolog OS=Mus musculus GN=MNCb-1706 PE=2 SV=2 0.92 1 1 0.00 0.00 
CALU_MOUSE Calumenin OS=Mus musculus GN=Calu PE=1 SV=1 0.92 8 6 0.52 56.70 
MYH10_MOUSE Myosin-10 OS=Mus musculus GN=Myh10 PE=1 SV=2 0.92 60 36 0.40 43.39 
CH60_MOUSE 60 kDa heat shock protein, mitochondrial OS=Mus musculus GN=Hspd1 PE=1 SV=1 0.92 16 11 0.44 48.42 
RAB12_MOUSE Ras-related protein Rab-12 OS=Mus musculus GN=Rab12 PE=1 SV=3 0.92 10 4 0.26 28.46 
EFTU_MOUSE Elongation factor Tu, mitochondrial OS=Mus musculus GN=Tufm PE=1 SV=1 0.91 3 3 0.20 22.17 
PHB_MOUSE Prohibitin OS=Mus musculus GN=Phb PE=1 SV=1 0.91 9 6 0.37 40.28 
IQGA1_MOUSE Ras GTPase-activating-like protein IQGAP1 OS=Mus musculus GN=Iqgap1 PE=1 SV=1 0.91 6 6 0.27 29.70 
PABP1_MOUSE Polyadenylate-binding protein 1 OS=Mus musculus GN=Pabpc1 PE=1 SV=1 0.91 4 4 0.23 25.84 
  
	  
RESULTS AND DISCUSSION 
	  
107 
Accession Protein H/L #Cmpds # quant SD (H/L) % CV 
ACADS_MOUSE Short-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Mus musculus GN=Acads PE=2 SV=1 0.91 2 2 0.25 27.87 
ECH1_MOUSE Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial OS=Mus musculus GN=Ech1 PE=2 SV=1 0.91 1 1 0.00 0.00 
CT007_MOUSE Probable methyltransferase C20orf7 homolog, mitochondrial OS=Mus musculus PE=2 SV=1 0.91 1 1 0.00 0.00 
SEPT2_MOUSE Septin-2 OS=Mus musculus GN=Sept2 PE=1 SV=2 0.91 1 1 0.00 0.00 
TM55A_MOUSE Transmembrane protein 55A OS=Mus musculus GN=Tmem55a PE=1 SV=1 0.91 1 1 0.00 0.00 
TLN1_MOUSE Talin-1 OS=Mus musculus GN=Tln1 PE=1 SV=1 0.91 27 18 0.22 24.29 
TAGL2_MOUSE Transgelin-2 OS=Mus musculus GN=Tagln2 PE=1 SV=4 0.91 5 5 0.28 30.53 
CAPG_MOUSE Macrophage-capping protein OS=Mus musculus GN=Capg PE=1 SV=2 0.90 3 2 0.23 25.62 
FUS_MOUSE RNA-binding protein FUS OS=Mus musculus GN=Fus PE=2 SV=1 0.90 2 2 0.25 27.27 
EMD_MOUSE Emerin OS=Mus musculus GN=Emd PE=1 SV=1 0.90 2 2 0.19 20.66 
RAB6A_MOUSE Ras-related protein Rab-6A OS=Mus musculus GN=Rab6a PE=1 SV=4 0.90 15 9 0.23 25.70 
SNRPA_MOUSE U1 small nuclear ribonucleoprotein A OS=Mus musculus GN=Snrpa PE=2 SV=3 0.90 6 4 0.14 15.67 
PYRG1_MOUSE CTP synthase 1 OS=Mus musculus GN=Ctps PE=1 SV=2 0.89 1 1 0.00 0.00 
HNRPM_MOUSE Heterogeneous nuclear ribonucleoprotein M OS=Mus musculus GN=Hnrnpm PE=1 SV=3 0.89 1 1 0.00 0.00 
HYOU1_MOUSE Hypoxia up-regulated protein 1 OS=Mus musculus GN=Hyou1 PE=1 SV=1 0.89 9 7 0.40 44.28 
MYO6_MOUSE Myosin-VI OS=Mus musculus GN=Myo6 PE=1 SV=1 0.89 1 1 0.00 0.00 
PTH2_MOUSE Peptidyl-tRNA hydrolase 2, mitochondrial OS=Mus musculus GN=Ptrh2 PE=2 SV=1 0.89 1 1 0.00 0.00 
PKHO2_MOUSE Pleckstrin homology domain-containing family O member 2 OS=Mus musculus GN=Plekho2 PE=1 SV=1 0.89 1 1 0.00 0.00 
TCPQ_MOUSE T-complex protein 1 subunit theta OS=Mus musculus GN=Cct8 PE=1 SV=3 0.89 2 2 0.04 5.00 
FLNA_MOUSE Filamin-A OS=Mus musculus GN=Flna PE=1 SV=4 0.89 48 31 0.30 33.64 
RRBP1_MOUSE Ribosome-binding protein 1 OS=Mus musculus GN=Rrbp1 PE=2 SV=2 0.89 20 16 0.48 54.13 
STT3A_MOUSE 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3A OS=Mus musculus GN=Stt3a PE=1 
SV=1 0.89 2 2 0.34 37.82 
HSP7C_MOUSE Heat shock cognate 71 kDa protein OS=Mus musculus GN=Hspa8 PE=1 SV=1 0.89 40 21 0.29 33.16 
PHB2_MOUSE Prohibitin-2 OS=Mus musculus GN=Phb2 PE=1 SV=1 0.89 8 7 0.34 38.23 
SYDC_MOUSE Aspartyl-tRNA synthetase, cytoplasmic OS=Mus musculus GN=Dars PE=2 SV=1 0.88 4 4 0.09 10.15 
MYH9_MOUSE Myosin-9 OS=Mus musculus GN=Myh9 PE=1 SV=4 0.88 119 75 0.49 55.81 
ACADV_MOUSE Very long-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Mus musculus GN=Acadvl PE=1 SV=3 0.88 5 5 0.15 16.77 
GNAQ_MOUSE Guanine nucleotide-binding protein G(q) subunit alpha OS=Mus musculus GN=Gnaq PE=1 SV=4 0.88 8 7 0.31 35.33 
ETFB_MOUSE Electron transfer flavoprotein subunit beta OS=Mus musculus GN=Etfb PE=1 SV=3 0.88 6 5 0.44 49.98 
HA1B_MOUSE H-2 class I histocompatibility antigen, K-B alpha chain OS=Mus musculus GN=H2-K1 PE=1 SV=1 0.88 7 5 0.36 40.58 
RTN3_MOUSE Reticulon-3 OS=Mus musculus GN=Rtn3 PE=1 SV=2 0.88 4 2 0.37 42.37 
HS90B_MOUSE Heat shock protein HSP 90-beta OS=Mus musculus GN=Hsp90ab1 PE=1 SV=2 0.87 30 21 0.32 36.90 
GNA11_MOUSE Guanine nucleotide-binding protein subunit alpha-11 OS=Mus musculus GN=Gna11 PE=1 SV=1 0.87 8 6 0.39 44.93 
SC23A_MOUSE Protein transport protein Sec23A OS=Mus musculus GN=Sec23a PE=1 SV=2 0.87 3 3 0.40 46.56 
CO3A1_MOUSE Collagen alpha-1(III) chain OS=Mus musculus GN=Col3a1 PE=2 SV=4 0.86 1 1 0.00 0.00 
PSA2_MOUSE Proteasome subunit alpha type-2 OS=Mus musculus GN=Psma2 PE=1 SV=2 0.86 1 1 0.00 0.00 
RAB34_MOUSE Ras-related protein Rab-34 OS=Mus musculus GN=Rab34 PE=1 SV=2 0.86 1 1 0.00 0.00 
SF3A2_MOUSE Splicing factor 3A subunit 2 OS=Mus musculus GN=Sf3a2 PE=2 SV=2 0.86 1 1 0.00 0.00 
U2AF1_MOUSE Splicing factor U2AF 35 kDa subunit OS=Mus musculus GN=U2af1 PE=2 SV=4 0.86 1 1 0.00 0.00 
TXND5_MOUSE Thioredoxin domain-containing protein 5 OS=Mus musculus GN=Txndc5 PE=1 SV=2 0.86 1 1 0.00 0.00 
RPN1_MOUSE Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 OS=Mus musculus GN=Rpn1 PE=2 0.86 13 9 0.26 30.60 
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SV=1 
LDHA_MOUSE L-lactate dehydrogenase A chain OS=Mus musculus GN=Ldha PE=1 SV=3 0.86 3 3 0.03 3.56 
ITB1_MOUSE Integrin beta-1 OS=Mus musculus GN=Itgb1 PE=1 SV=1 0.85 9 6 0.12 14.51 
RS18_MOUSE 40S ribosomal protein S18 OS=Mus musculus GN=Rps18 PE=2 SV=3 0.85 2 2 0.22 26.32 
DBNL_MOUSE Drebrin-like protein OS=Mus musculus GN=Dbnl PE=1 SV=2 0.85 1 1 0.00 0.00 
PALM_MOUSE Paralemmin OS=Mus musculus GN=Palm PE=1 SV=1 0.85 1 1 0.00 0.00 
P5CR2_MOUSE Pyrroline-5-carboxylate reductase 2 OS=Mus musculus GN=Pycr2 PE=2 SV=1 0.85 2 2 0.07 8.77 
ATPA_MOUSE ATP synthase subunit alpha, mitochondrial OS=Mus musculus GN=Atp5a1 PE=1 SV=1 0.85 28 17 0.38 45.32 
VAT1_MOUSE Synaptic vesicle membrane protein VAT-1 homolog OS=Mus musculus GN=Vat1 PE=2 SV=3 0.84 5 5 0.14 16.14 
D3D2_MOUSE 3,2-trans-enoyl-CoA isomerase, mitochondrial OS=Mus musculus GN=Dci PE=2 SV=1 0.84 2 2 0.32 38.05 
JAM1_MOUSE Junctional adhesion molecule A OS=Mus musculus GN=F11r PE=1 SV=1 0.84 3 2 0.04 4.42 
TPM4_MOUSE Tropomyosin alpha-4 chain OS=Mus musculus GN=Tpm4 PE=2 SV=3 0.84 12 10 0.26 31.06 
RAB5B_MOUSE Ras-related protein Rab-5B OS=Mus musculus GN=Rab5b PE=1 SV=1 0.84 8 4 0.43 51.04 
AATM_MOUSE Aspartate aminotransferase, mitochondrial OS=Mus musculus GN=Got2 PE=1 SV=1 0.84 5 5 0.28 33.94 
VIME_MOUSE Vimentin OS=Mus musculus GN=Vim PE=1 SV=3 0.84 54 33 0.30 36.41 
RL10A_MOUSE 60S ribosomal protein L10a OS=Mus musculus GN=Rpl10a PE=1 SV=3 0.83 2 1 0.00 0.00 
DLDH_MOUSE Dihydrolipoyl dehydrogenase, mitochondrial OS=Mus musculus GN=Dld PE=1 SV=2 0.83 3 2 0.25 30.36 
DREB_MOUSE Drebrin OS=Mus musculus GN=Dbn1 PE=1 SV=4 0.83 1 1 0.00 0.00 
AL3A2_MOUSE Fatty aldehyde dehydrogenase OS=Mus musculus GN=Aldh3a2 PE=2 SV=1 0.83 2 2 0.06 7.14 
PGRC1_MOUSE Membrane-associated progesterone receptor component 1 OS=Mus musculus GN=Pgrmc1 PE=1 SV=4 0.83 3 3 0.16 19.62 
TIM50_MOUSE Mitochondrial import inner membrane translocase subunit TIM50 OS=Mus musculus GN=Timm50 PE=1 SV=1 0.83 1 1 0.00 0.00 
SCPDH_MOUSE Probable saccharopine dehydrogenase OS=Mus musculus GN=Sccpdh PE=2 SV=1 0.83 1 1 0.00 0.00 
VAPB_MOUSE Vesicle-associated membrane protein-associated protein B OS=Mus musculus GN=Vapb PE=2 SV=3 0.83 5 4 0.40 48.33 
HA1K_MOUSE H-2 class I histocompatibility antigen, K-K alpha chain OS=Mus musculus GN=H2-K1 PE=1 SV=1 0.83 7 5 0.35 41.39 
RAB10_MOUSE Ras-related protein Rab-10 OS=Mus musculus GN=Rab10 PE=1 SV=1 0.83 15 7 0.32 37.77 
LAMP1_MOUSE Lysosome-associated membrane glycoprotein 1 OS=Mus musculus GN=Lamp1 PE=1 SV=2 0.83 10 5 0.23 27.38 
VNN1_MOUSE Pantetheinase OS=Mus musculus GN=Vnn1 PE=1 SV=2 0.83 5 4 0.38 45.37 
CISY_MOUSE Citrate synthase, mitochondrial OS=Mus musculus GN=Cs PE=1 SV=1 0.83 4 4 0.26 31.31 
ACTC_MOUSE Actin, alpha cardiac muscle 1 OS=Mus musculus GN=Actc1 PE=1 SV=1 0.83 83 22 0.42 51.08 
SQRD_MOUSE Sulfide:quinone oxidoreductase, mitochondrial OS=Mus musculus GN=Sqrdl PE=2 SV=2 0.83 4 4 0.26 31.32 
PDIA6_MOUSE Protein disulfide-isomerase A6 OS=Mus musculus GN=Pdia6 PE=1 SV=3 0.83 19 10 0.32 38.91 
ENPL_MOUSE Endoplasmin OS=Mus musculus GN=Hsp90b1 PE=1 SV=2 0.82 40 24 0.30 36.79 
RAC1_MOUSE Ras-related C3 botulinum toxin substrate 1 OS=Mus musculus GN=Rac1 PE=1 SV=1 0.82 3 3 0.18 21.50 
SPCS2_MOUSE Signal peptidase complex subunit 2 OS=Mus musculus GN=Spcs2 PE=2 SV=1 0.82 4 3 0.11 13.39 
VTI1B_MOUSE Vesicle transport through interaction with t-SNAREs homolog 1B OS=Mus musculus GN=Vti1b PE=1 SV=1 0.82 3 3 0.13 15.92 
E41L2_MOUSE Band 4.1-like protein 2 OS=Mus musculus GN=Epb41l2 PE=1 SV=1 0.82 3 3 0.13 15.64 
CMC1_MOUSE Calcium-binding mitochondrial carrier protein Aralar1 OS=Mus musculus GN=Slc25a12 PE=1 SV=1 0.82 3 3 0.18 22.17 
MYL6_MOUSE Myosin light polypeptide 6 OS=Mus musculus GN=Myl6 PE=1 SV=3 0.82 2 2 0.18 21.82 
HS90A_MOUSE Heat shock protein HSP 90-alpha OS=Mus musculus GN=Hsp90aa1 PE=1 SV=4 0.82 20 14 0.31 38.30 
THIL_MOUSE Acetyl-CoA acetyltransferase, mitochondrial OS=Mus musculus GN=Acat1 PE=1 SV=1 0.81 6 6 0.39 48.47 
RBBP4_MOUSE Histone-binding protein RBBP4 OS=Mus musculus GN=Rbbp4 PE=1 SV=4 0.81 2 2 0.37 44.95 
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SNP23_MOUSE Synaptosomal-associated protein 23 OS=Mus musculus GN=Snap23 PE=1 SV=1 0.81 2 2 0.02 2.75 
RCN1_MOUSE Reticulocalbin-1 OS=Mus musculus GN=Rcn1 PE=1 SV=1 0.81 2 2 0.05 6.42 
RHOG_MOUSE Rho-related GTP-binding protein RhoG OS=Mus musculus GN=Rhog PE=2 SV=1 0.81 3 3 0.19 23.00 
CAPR1_MOUSE Caprin-1 OS=Mus musculus GN=Caprin1 PE=1 SV=2 0.81 4 4 0.33 40.71 
ADT2_MOUSE ADP/ATP translocase 2 OS=Mus musculus GN=Slc25a5 PE=1 SV=3 0.81 41 14 0.22 27.36 
VCAM1_MOUSE Vascular cell adhesion protein 1 OS=Mus musculus GN=Vcam1 PE=1 SV=1 0.81 50 22 0.22 27.71 
MCM8_MOUSE DNA replication licensing factor MCM8 OS=Mus musculus GN=Mcm8 PE=2 SV=3 0.80 1 1 0.00 0.00 
RICH2_MOUSE Rho GTPase-activating protein RICH2 OS=Mus musculus GN=Rich2 PE=2 SV=1 0.80 1 1 0.00 0.00 
RMTL1_MOUSE RNA methyltransferase-like protein 1 OS=Mus musculus GN=Rnmtl1 PE=2 SV=1 0.80 1 1 0.00 0.00 
PRDX3_MOUSE Thioredoxin-dependent peroxide reductase, mitochondrial OS=Mus musculus GN=Prdx3 PE=1 SV=1 0.80 3 3 0.43 53.95 
RL8_MOUSE 60S ribosomal protein L8 OS=Mus musculus GN=Rpl8 PE=2 SV=2 0.80 4 4 0.11 13.25 
RL10L_MOUSE 60S ribosomal protein L10-like OS=Mus musculus GN=Rpl10l PE=2 SV=1 0.80 5 5 0.18 22.19 
1433T_MOUSE 14-3-3 protein theta OS=Mus musculus GN=Ywhaq PE=1 SV=1 0.80 6 4 0.16 19.63 
SEC62_MOUSE Translocation protein SEC62 OS=Mus musculus GN=Sec62 PE=1 SV=1 0.80 2 2 0.34 42.06 
ICAM1_MOUSE Intercellular adhesion molecule 1 OS=Mus musculus GN=Icam1 PE=1 SV=1 0.80 40 15 0.16 19.87 
1433B_MOUSE 14-3-3 protein beta/alpha OS=Mus musculus GN=Ywhab PE=1 SV=3 0.80 7 5 0.31 38.57 
ACTG_MOUSE Actin, cytoplasmic 2 OS=Mus musculus GN=Actg1 PE=1 SV=1 0.79 107 25 0.39 49.27 
ECHA_MOUSE Trifunctional enzyme subunit alpha, mitochondrial OS=Mus musculus GN=Hadha PE=1 SV=1 0.79 9 8 0.24 30.71 
ALDR_MOUSE Aldose reductase OS=Mus musculus GN=Akr1b1 PE=1 SV=3 0.79 1 1 0.00 0.00 
IF2A_MOUSE Eukaryotic translation initiation factor 2 subunit 1 OS=Mus musculus GN=Eif2s1 PE=1 SV=3 0.79 1 1 0.00 0.00 
IF4E2_MOUSE Eukaryotic translation initiation factor 4E type 2 OS=Mus musculus GN=Eif4e2 PE=1 SV=1 0.79 1 1 0.00 0.00 
ROCK2_MOUSE Rho-associated protein kinase 2 OS=Mus musculus GN=Rock2 PE=2 SV=1 0.79 1 1 0.00 0.00 
TIAM1_MOUSE T-lymphoma invasion and metastasis-inducing protein 1 OS=Mus musculus GN=Tiam1 PE=1 SV=1 0.79 1 1 0.00 0.00 
RAB35_MOUSE Ras-related protein Rab-35 OS=Mus musculus GN=Rab35 PE=1 SV=1 0.78 12 5 0.25 32.01 
OST48_MOUSE 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit OS=Mus musculus GN=Ddost 
PE=1 SV=1 0.78 3 2 0.02 2.86 
K2C5_MOUSE Keratin, type II cytoskeletal 5 OS=Mus musculus GN=Krt5 PE=1 SV=1 0.78 11 2 0.38 48.57 
1433G_MOUSE 14-3-3 protein gamma OS=Mus musculus GN=Ywhag PE=1 SV=2 0.78 8 6 0.21 26.46 
TCPZ_MOUSE T-complex protein 1 subunit zeta OS=Mus musculus GN=Cct6a PE=1 SV=3 0.78 2 2 0.10 12.38 
RAB1A_MOUSE Ras-related protein Rab-1A OS=Mus musculus GN=Rab1A PE=1 SV=3 0.78 15 8 0.21 27.43 
RAB7A_MOUSE Ras-related protein Rab-7a OS=Mus musculus GN=Rab7a PE=1 SV=2 0.78 11 10 0.17 21.26 
RB11A_MOUSE Ras-related protein Rab-11A OS=Mus musculus GN=Rab11a PE=1 SV=3 0.78 7 7 0.22 27.84 
ARP2_MOUSE Actin-related protein 2 OS=Mus musculus GN=Actr2 PE=1 SV=1 0.77 1 1 0.00 0.00 
CD44_MOUSE CD44 antigen OS=Mus musculus GN=Cd44 PE=1 SV=3 0.77 2 2 0.00 0.00 
CD81_MOUSE CD81 antigen OS=Mus musculus GN=Cd81 PE=1 SV=1 0.77 1 1 0.00 0.00 
CLIC4_MOUSE Chloride intracellular channel protein 4 OS=Mus musculus GN=Clic4 PE=1 SV=3 0.77 2 2 0.01 1.92 
SSRB_MOUSE Translocon-associated protein subunit beta OS=Mus musculus GN=Ssr2 PE=1 SV=1 0.77 1 1 0.00 0.00 
COMT_MOUSE Catechol O-methyltransferase OS=Mus musculus GN=Comt PE=1 SV=1 0.77 2 2 0.16 21.15 
PCCB_MOUSE Propionyl-CoA carboxylase beta chain, mitochondrial OS=Mus musculus GN=Pccb PE=1 SV=1 0.77 3 3 0.36 46.39 
ODPB_MOUSE Pyruvate dehydrogenase E1 component subunit beta, mitochondrial OS=Mus musculus GN=Pdhb PE=1 SV=1 0.77 6 5 0.60 77.12 
NB5R3_MOUSE NADH-cytochrome b5 reductase 3 OS=Mus musculus GN=Cyb5r3 PE=1 SV=3 0.77 18 10 0.25 32.77 
ETFA_MOUSE Electron transfer flavoprotein subunit alpha, mitochondrial OS=Mus musculus GN=Etfa PE=1 SV=2 0.77 8 5 0.29 37.86 
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PLOD2_MOUSE Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 OS=Mus musculus GN=Plod2 PE=2 SV=1 0.77 5 5 0.47 60.55 
GNAS2_MOUSE Guanine nucleotide-binding protein G(s) subunit alpha isoforms short OS=Mus musculus GN=Gnas PE=1 SV=1 0.77 6 2 0.17 22.33 
PLST_MOUSE Plastin-3 OS=Mus musculus GN=Pls3 PE=1 SV=3 0.77 5 5 0.31 40.26 
CP1B1_MOUSE Cytochrome P450 1B1 OS=Mus musculus GN=Cyp1b1 PE=2 SV=2 0.76 6 4 0.32 42.51 
ADT1_MOUSE ADP/ATP translocase 1 OS=Mus musculus GN=Slc25a4 PE=1 SV=4 0.76 21 12 0.26 34.78 
RL7_MOUSE 60S ribosomal protein L7 OS=Mus musculus GN=Rpl7 PE=1 SV=2 0.76 3 3 0.12 15.27 
CTHR1_MOUSE Collagen triple helix repeat-containing protein 1 OS=Mus musculus GN=Cthrc1 PE=2 SV=1 0.76 1 1 0.00 0.00 
RPN2_MOUSE 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 OS=Mus musculus GN=Rpn2 PE=2 
SV=1 0.76 5 3 0.21 27.91 
H2AJ_MOUSE Histone H2A.J OS=Mus musculus GN=H2afj PE=2 SV=1 0.76 1 1 0.00 0.00 
ILF2_MOUSE Interleukin enhancer-binding factor 2 OS=Mus musculus GN=Ilf2 PE=1 SV=1 0.76 1 1 0.00 0.00 
MOSC2_MOUSE MOSC domain-containing protein 2, mitochondrial OS=Mus musculus GN=Mosc2 PE=1 SV=1 0.76 1 1 0.00 0.00 
YBOX1_MOUSE Nuclease-sensitive element-binding protein 1 OS=Mus musculus GN=Ybx1 PE=1 SV=3 0.76 1 1 0.00 0.00 
SFRS7_MOUSE Splicing factor, arginine/serine-rich 7 OS=Mus musculus GN=Sfrs7 PE=1 SV=1 0.76 2 1 0.00 0.00 
KPYM_MOUSE Pyruvate kinase isozymes M1/M2 OS=Mus musculus GN=Pkm2 PE=1 SV=4 0.76 10 9 0.30 39.61 
CNN2_MOUSE Calponin-2 OS=Mus musculus GN=Cnn2 PE=2 SV=1 0.76 6 6 0.23 29.91 
SC31A_MOUSE Protein transport protein Sec31A OS=Mus musculus GN=Sec31a PE=1 SV=2 0.75 3 3 0.29 37.87 
TBA1C_MOUSE Tubulin alpha-1C chain OS=Mus musculus GN=Tuba1c PE=1 SV=1 0.75 21 7 0.11 14.21 
ALDH2_MOUSE Aldehyde dehydrogenase, mitochondrial OS=Mus musculus GN=Aldh2 PE=1 SV=1 0.75 9 7 0.23 30.00 
1433E_MOUSE 14-3-3 protein epsilon OS=Mus musculus GN=Ywhae PE=1 SV=1 0.75 3 2 0.03 4.00 
CMTD1_MOUSE Catechol-O-methyltransferase domain-containing protein 1 OS=Mus musculus GN=Comtd1 PE=2 SV=1 0.75 1 1 0.00 0.00 
ODO2_MOUSE Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial OS=Mus musculus GN=Dlst PE=1 SV=1 
0.75 4 4 0.17 22.18 
ERGI3_MOUSE Endoplasmic reticulum-Golgi intermediate compartment protein 3 OS=Mus musculus GN=Ergic3 PE=2 SV=1 0.75 1 1 0.00 0.00 
HNRPL_MOUSE Heterogeneous nuclear ribonucleoprotein L OS=Mus musculus GN=Hnrnpl PE=1 SV=2 0.75 1 1 0.00 0.00 
MYO1D_MOUSE Myosin-Id OS=Mus musculus GN=Myo1d PE=1 SV=1 0.75 1 1 0.00 0.00 
CLPP_MOUSE Putative ATP-dependent Clp protease proteolytic subunit, mitochondrial OS=Mus musculus GN=Clpp PE=2 SV=1 0.75 1 1 0.00 0.00 
SMC1B_MOUSE Structural maintenance of chromosomes protein 1B OS=Mus musculus GN=Smc1b PE=1 SV=1 0.75 1 1 0.00 0.00 
TCPD_MOUSE T-complex protein 1 subunit delta OS=Mus musculus GN=Cct4 PE=1 SV=3 0.75 2 2 0.12 16.00 
T176B_MOUSE Transmembrane protein 176B OS=Mus musculus GN=Tmem176b PE=1 SV=1 0.75 1 1 0.00 0.00 
NDUS3_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial OS=Mus musculus GN=Ndufs3 PE=1 SV=2 0.74 4 3 0.23 30.59 
RAB8B_MOUSE Ras-related protein Rab-8B OS=Mus musculus GN=Rab8b PE=1 SV=1 0.74 6 3 0.07 9.05 
SCFD1_MOUSE Sec1 family domain-containing protein 1 OS=Mus musculus GN=Scfd1 PE=2 SV=1 0.74 3 3 0.16 21.71 
ATPG_MOUSE ATP synthase subunit gamma, mitochondrial OS=Mus musculus GN=Atp5c1 PE=1 SV=1 0.74 8 5 0.33 44.51 
GRPE1_MOUSE GrpE protein homolog 1, mitochondrial OS=Mus musculus GN=Grpel1 PE=2 SV=1 0.74 2 2 0.07 9.09 
SFRS3_MOUSE Splicing factor, arginine/serine-rich 3 OS=Mus musculus GN=Sfrs3 PE=2 SV=1 0.74 2 2 0.07 9.09 
RL15_MOUSE 60S ribosomal protein L15 OS=Mus musculus GN=Rpl15 PE=2 SV=4 0.74 2 2 0.01 1.01 
MPRD_MOUSE Cation-dependent mannose-6-phosphate receptor OS=Mus musculus GN=M6pr PE=2 SV=1 0.74 3 2 0.17 23.23 
ECHB_MOUSE Trifunctional enzyme subunit beta, mitochondrial OS=Mus musculus GN=Hadhb PE=1 SV=1 0.73 5 4 0.23 31.66 
EF2_MOUSE Elongation factor 2 OS=Mus musculus GN=Eef2 PE=1 SV=2 0.73 5 5 0.22 29.58 
RS3A_MOUSE 40S ribosomal protein S3a OS=Mus musculus GN=Rps3a PE=1 SV=3 0.73 5 5 0.32 43.28 
MOES_MOUSE Moesin OS=Mus musculus GN=Msn PE=1 SV=3 0.73 28 24 0.33 45.69 
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GRP75_MOUSE Stress-70 protein, mitochondrial OS=Mus musculus GN=Hspa9 PE=1 SV=2 0.73 19 15 0.24 32.94 
IF4A1_MOUSE Eukaryotic initiation factor 4A-I OS=Mus musculus GN=Eif4a1 PE=2 SV=1 0.73 3 3 0.24 33.20 
LONM_MOUSE Lon protease homolog, mitochondrial OS=Mus musculus GN=Lonp1 PE=1 SV=2 0.73 1 1 0.00 0.00 
NDUBA_MOUSE NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 OS=Mus musculus GN=Ndufb10 PE=1 SV=3 0.73 1 1 0.00 0.00 
GDIB_MOUSE Rab GDP dissociation inhibitor beta OS=Mus musculus GN=Gdi2 PE=1 SV=1 0.73 1 1 0.00 0.00 
STX12_MOUSE Syntaxin-12 OS=Mus musculus GN=Stx12 PE=2 SV=1 0.73 1 1 0.00 0.00 
CAZA1_MOUSE F-actin-capping protein subunit alpha-1 OS=Mus musculus GN=Capza1 PE=1 SV=4 0.73 3 3 0.27 36.96 
QCR2_MOUSE Cytochrome b-c1 complex subunit 2, mitochondrial OS=Mus musculus GN=Uqcrc2 PE=1 SV=1 0.72 5 5 0.17 23.95 
H2B1C_MOUSE Histone H2B type 1-C/E/G OS=Mus musculus GN=Hist1h2bc PE=1 SV=3 0.72 2 2 0.54 75.00 
ACDSB_MOUSE Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial OS=Mus musculus GN=Acadsb PE=1 SV=1 0.72 2 2 0.21 29.17 
3HIDH_MOUSE 3-hydroxyisobutyrate dehydrogenase, mitochondrial OS=Mus musculus GN=Hibadh PE=2 SV=1 0.72 1 1 0.00 0.00 
AKA12_MOUSE A-kinase anchor protein 12 OS=Mus musculus GN=Akap12 PE=1 SV=1 0.72 1 1 0.00 0.00 
API5_MOUSE Apoptosis inhibitor 5 OS=Mus musculus GN=Api5 PE=2 SV=1 0.72 1 1 0.00 0.00 
CCD18_MOUSE Coiled-coil domain-containing protein 18 OS=Mus musculus GN=Ccdc18 PE=2 SV=1 0.72 1 1 0.00 0.00 
CC90B_MOUSE Coiled-coil domain-containing protein 90B, mitochondrial OS=Mus musculus GN=Ccdc90b PE=2 SV=1 0.72 1 1 0.00 0.00 
GHITM_MOUSE Growth hormone-inducible transmembrane protein OS=Mus musculus GN=Ghitm PE=2 SV=1 0.72 1 1 0.00 0.00 
H33_MOUSE Histone H3.3 OS=Mus musculus GN=H3f3a PE=1 SV=2 0.72 1 1 0.00 0.00 
S45A4_MOUSE Solute carrier family 45 member 4 OS=Mus musculus GN=Slc45a4 PE=2 SV=1 0.72 3 1 0.00 0.00 
VAPA_MOUSE Vesicle-associated membrane protein-associated protein A OS=Mus musculus GN=Vapa PE=1 SV=2 0.72 6 5 0.18 24.72 
CX4NB_MOUSE Neighbor of COX4 OS=Mus musculus GN=Cox4nb PE=1 SV=1 0.71 5 4 0.45 63.32 
SRPRB_MOUSE Signal recognition particle receptor subunit beta OS=Mus musculus GN=Srprb PE=1 SV=1 0.71 3 3 0.07 9.81 
VDAC1_MOUSE Voltage-dependent anion-selective channel protein 1 OS=Mus musculus GN=Vdac1 PE=1 SV=3 0.71 12 9 0.33 46.51 
CARKD_MOUSE Carbohydrate kinase domain-containing protein OS=Mus musculus GN=Carkd PE=1 SV=1 0.70 1 1 0.00 0.00 
CP2B9_MOUSE Cytochrome P450 2B9 OS=Mus musculus GN=Cyp2b9 PE=2 SV=1 0.70 1 1 0.00 0.00 
AL4A1_MOUSE Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial OS=Mus musculus GN=Aldh4a1 PE=1 SV=2 0.70 2 2 0.24 34.04 
SPAT5_MOUSE Spermatogenesis-associated protein 5 OS=Mus musculus GN=Spata5 PE=2 SV=2 0.70 1 1 0.00 0.00 
CJ118_MOUSE Uncharacterized protein C10orf118 homolog OS=Mus musculus GN=Otg1 PE=2 SV=2 0.70 1 1 0.00 0.00 
PDIA3_MOUSE Protein disulfide-isomerase A3 OS=Mus musculus GN=Pdia3 PE=1 SV=2 0.70 37 30 0.27 39.15 
IDH3A_MOUSE Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial OS=Mus musculus GN=Idh3a PE=1 SV=1 0.70 3 3 0.22 31.56 
RL6_MOUSE 60S ribosomal protein L6 OS=Mus musculus GN=Rpl6 PE=1 SV=3 0.69 5 5 0.36 51.48 
FERM2_MOUSE Fermitin family homolog 2 OS=Mus musculus GN=Fermt2 PE=2 SV=1 0.69 2 2 0.07 9.68 
LAMP2_MOUSE Lysosome-associated membrane glycoprotein 2 OS=Mus musculus GN=Lamp2 PE=2 SV=1 0.69 2 2 0.16 22.58 
RL26_MOUSE 60S ribosomal protein L26 OS=Mus musculus GN=Rpl26 PE=2 SV=1 0.69 1 1 0.00 0.00 
ATLA3_MOUSE Atlastin-3 OS=Mus musculus GN=Atl3 PE=2 SV=1 0.69 2 2 0.03 4.35 
MGST1_MOUSE Microsomal glutathione S-transferase 1 OS=Mus musculus GN=Mgst1 PE=1 SV=3 0.69 1 1 0.00 0.00 
OLF8_MOUSE Olfactory receptor 8 OS=Mus musculus GN=Olfr8 PE=2 SV=2 0.69 1 1 0.00 0.00 
PGRP4_MOUSE Peptidoglycan recognition protein I-beta OS=Mus musculus GN=Pglyrp4 PE=2 SV=1 0.69 1 1 0.00 0.00 
PPWD1_MOUSE Peptidylprolyl isomerase domain and WD repeat-containing protein 1 OS=Mus musculus GN=Ppwd1 PE=2 SV=1 0.69 1 1 0.00 0.00 
PRR18_MOUSE Proline-rich protein 18 OS=Mus musculus GN=Prr18 PE=2 SV=2 0.69 1 1 0.00 0.00 
TCPE_MOUSE T-complex protein 1 subunit epsilon OS=Mus musculus GN=Cct5 PE=1 SV=1 0.69 1 1 0.00 0.00 
MARCS_MOUSE Myristoylated alanine-rich C-kinase substrate OS=Mus musculus GN=Marcks PE=1 SV=2 0.68 39 12 0.25 36.71 
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ENOA_MOUSE Alpha-enolase OS=Mus musculus GN=Eno1 PE=1 SV=3 0.68 18 14 0.24 35.52 
1433Z_MOUSE 14-3-3 protein zeta/delta OS=Mus musculus GN=Ywhaz PE=1 SV=1 0.68 8 5 0.09 13.26 
RL12_MOUSE 60S ribosomal protein L12 OS=Mus musculus GN=Rpl12 PE=1 SV=2 0.67 1 1 0.00 0.00 
ML12B_MOUSE Myosin regulatory light chain 12B OS=Mus musculus GN=Myl12b PE=1 SV=2 0.67 2 2 0.07 11.11 
TPIS_MOUSE Triosephosphate isomerase OS=Mus musculus GN=Tpi1 PE=1 SV=3 0.67 2 2 0.18 26.67 
RLA0_MOUSE 60S acidic ribosomal protein P0 OS=Mus musculus GN=Rplp0 PE=1 SV=3 0.66 8 7 0.18 26.52 
RL19_MOUSE 60S ribosomal protein L19 OS=Mus musculus GN=Rpl19 PE=1 SV=1 0.66 4 2 0.01 1.12 
EF1G_MOUSE Elongation factor 1-gamma OS=Mus musculus GN=Eef1g PE=1 SV=3 0.66 2 2 0.02 3.37 
RL18A_MOUSE 60S ribosomal protein L18a OS=Mus musculus GN=Rpl18a PE=2 SV=1 0.66 5 4 0.14 22.09 
EDC4_MOUSE Enhancer of mRNA-decapping protein 4 OS=Mus musculus GN=Edc4 PE=1 SV=2 0.66 2 2 0.22 34.09 
GLCM_MOUSE Glucosylceramidase OS=Mus musculus GN=Gba PE=1 SV=1 0.66 3 2 0.06 9.09 
CD47_MOUSE Leukocyte surface antigen CD47 OS=Mus musculus GN=Cd47 PE=1 SV=2 0.66 1 1 0.00 0.00 
NQO1_MOUSE NAD(P)H dehydrogenase [quinone] 1 OS=Mus musculus GN=Nqo1 PE=1 SV=3 0.66 2 2 0.03 4.55 
VDAC2_MOUSE Voltage-dependent anion-selective channel protein 2 OS=Mus musculus GN=Vdac2 PE=1 SV=2 0.65 10 6 0.15 23.06 
RS9_MOUSE 40S ribosomal protein S9 OS=Mus musculus GN=Rps9 PE=2 SV=3 0.65 4 4 0.11 16.35 
RL13A_MOUSE 60S ribosomal protein L13a OS=Mus musculus GN=Rpl13a PE=1 SV=4 0.65 3 2 0.13 19.54 
CALX_MOUSE Calnexin OS=Mus musculus GN=Canx PE=1 SV=1 0.65 17 15 0.22 33.91 
PAIRB_MOUSE Plasminogen activator inhibitor 1 RNA-binding protein OS=Mus musculus GN=Serbp1 PE=1 SV=2 0.64 13 7 0.18 27.88 
LRC59_MOUSE Leucine-rich repeat-containing protein 59 OS=Mus musculus GN=Lrrc59 PE=2 SV=1 0.64 4 4 0.06 9.72 
PRDX1_MOUSE Peroxiredoxin-1 OS=Mus musculus GN=Prdx1 PE=1 SV=1 0.64 21 11 0.15 23.80 
CAV1_MOUSE Caveolin-1 OS=Mus musculus GN=Cav1 PE=1 SV=1 0.64 3 2 0.22 34.88 
CD14_MOUSE Monocyte differentiation antigen CD14 OS=Mus musculus GN=Cd14 PE=1 SV=1 0.64 6 5 0.32 49.81 
PIMT_MOUSE Protein-L-isoaspartate(D-aspartate) O-methyltransferase OS=Mus musculus GN=Pcmt1 PE=1 SV=3 0.64 1 1 0.00 0.00 
TOM40_MOUSE Mitochondrial import receptor subunit TOM40 homolog OS=Mus musculus GN=Tomm40 PE=1 SV=3 0.63 2 2 0.17 27.06 
DDAH2_MOUSE N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 OS=Mus musculus GN=Ddah2 PE=1 SV=1 0.63 2 2 0.14 22.35 
STML2_MOUSE Stomatin-like protein 2 OS=Mus musculus GN=Stoml2 PE=1 SV=1 0.63 4 3 0.09 14.73 
SYNPO_MOUSE Synaptopodin OS=Mus musculus GN=Synpo PE=1 SV=2 0.63 13 5 0.16 25.85 
RS7_MOUSE 40S ribosomal protein S7 OS=Mus musculus GN=Rps7 PE=2 SV=1 0.63 1 1 0.00 0.00 
SIA8F_MOUSE Alpha-2,8-sialyltransferase 8F OS=Mus musculus GN=St8sia6 PE=1 SV=1 0.63 1 1 0.00 0.00 
CBR4_MOUSE Carbonyl reductase 4 OS=Mus musculus GN=Cbr4 PE=2 SV=2 0.63 1 1 0.00 0.00 
CPSF5_MOUSE Cleavage and polyadenylation specificity factor subunit 5 OS=Mus musculus GN=Nudt21 PE=2 SV=1 0.63 1 1 0.00 0.00 
GORS2_MOUSE Golgi reassembly-stacking protein 2 OS=Mus musculus GN=Gorasp2 PE=1 SV=3 0.63 2 2 0.04 7.14 
OX2G_MOUSE OX-2 membrane glycoprotein OS=Mus musculus GN=Cd200 PE=1 SV=1 0.63 11 5 0.16 25.24 
SCUB3_MOUSE Signal peptide, CUB and EGF-like domain-containing protein 3 OS=Mus musculus GN=Scube3 PE=1 SV=1 0.63 1 1 0.00 0.00 
CKAP4_MOUSE Cytoskeleton-associated protein 4 OS=Mus musculus GN=Ckap4 PE=2 SV=2 0.62 22 16 0.24 39.22 
ERLN2_MOUSE Erlin-2 OS=Mus musculus GN=Erlin2 PE=1 SV=1 0.62 4 4 0.35 56.08 
RL11_MOUSE 60S ribosomal protein L11 OS=Mus musculus GN=Rpl11 PE=1 SV=4 0.61 1 1 0.00 0.00 
BASI_MOUSE Basigin OS=Mus musculus GN=Bsg PE=1 SV=2 0.61 5 3 0.31 50.50 
ENTP1_MOUSE Ectonucleoside triphosphate diphosphohydrolase 1 OS=Mus musculus GN=Entpd1 PE=2 SV=1 0.61 4 4 0.13 21.61 
EIF3H_MOUSE Eukaryotic translation initiation factor 3 subunit H OS=Mus musculus GN=Eif3h PE=1 SV=1 0.61 2 2 0.15 24.39 
FAM3C_MOUSE Protein FAM3C OS=Mus musculus GN=Fam3c PE=1 SV=1 0.61 7 5 0.12 19.57 
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ATP5H_MOUSE ATP synthase subunit d, mitochondrial OS=Mus musculus GN=Atp5h PE=1 SV=3 0.61 3 3 0.32 52.41 
PPIB_MOUSE Peptidyl-prolyl cis-trans isomerase B OS=Mus musculus GN=Ppib PE=2 SV=2 0.61 4 3 0.22 35.48 
TADBP_MOUSE TAR DNA-binding protein 43 OS=Mus musculus GN=Tardbp PE=1 SV=1 0.61 3 3 0.04 7.05 
RUVB1_MOUSE RuvB-like 1 OS=Mus musculus GN=Ruvbl1 PE=1 SV=1 0.60 2 2 0.11 18.52 
H2AY_MOUSE Core histone macro-H2A.1 OS=Mus musculus GN=H2afy PE=1 SV=3 0.60 3 3 0.23 37.46 
ARC1B_MOUSE Actin-related protein 2/3 complex subunit 1B OS=Mus musculus GN=Arpc1b PE=2 SV=3 0.60 3 2 0.13 22.50 
ERP29_MOUSE Endoplasmic reticulum protein ERp29 OS=Mus musculus GN=Erp29 PE=1 SV=2 0.59 5 5 0.11 18.69 
ODO1_MOUSE 2-oxoglutarate dehydrogenase E1 component, mitochondrial OS=Mus musculus GN=Ogdh PE=1 SV=3 0.58 1 1 0.00 0.00 
ERD22_MOUSE ER lumen protein retaining receptor 2 OS=Mus musculus GN=Kdelr2 PE=2 SV=1 0.58 1 1 0.00 0.00 
MEN1_MOUSE Menin OS=Mus musculus GN=Men1 PE=2 SV=1 0.58 1 1 0.00 0.00 
RALA_MOUSE Ras-related protein Ral-A OS=Mus musculus GN=Rala PE=1 SV=1 0.58 2 2 0.00 0.00 
ATPO_MOUSE ATP synthase subunit O, mitochondrial OS=Mus musculus GN=Atp5o PE=1 SV=1 0.58 4 3 0.11 19.16 
RL3_MOUSE 60S ribosomal protein L3 OS=Mus musculus GN=Rpl3 PE=2 SV=2 0.57 6 6 0.25 43.17 
RL13_MOUSE 60S ribosomal protein L13 OS=Mus musculus GN=Rpl13 PE=2 SV=3 0.57 13 10 0.26 45.75 
MRP_MOUSE MARCKS-related protein OS=Mus musculus GN=Marcksl1 PE=1 SV=2 0.57 7 3 0.29 50.82 
M2OM_MOUSE Mitochondrial 2-oxoglutarate/malate carrier protein OS=Mus musculus GN=Slc25a11 PE=1 SV=3 0.57 4 3 0.11 18.61 
DECR_MOUSE 2,4-dienoyl-CoA reductase, mitochondrial OS=Mus musculus GN=Decr1 PE=1 SV=1 0.57 4 4 0.10 17.94 
PDLI1_MOUSE PDZ and LIM domain protein 1 OS=Mus musculus GN=Pdlim1 PE=2 SV=4 0.57 1 1 0.00 0.00 
TMEDA_MOUSE Transmembrane emp24 domain-containing protein 10 OS=Mus musculus GN=Tmed10 PE=2 SV=1 0.57 6 4 0.17 29.83 
RS8_MOUSE 40S ribosomal protein S8 OS=Mus musculus GN=Rps8 PE=1 SV=2 0.56 8 7 0.23 41.16 
PDIA1_MOUSE Protein disulfide-isomerase OS=Mus musculus GN=P4hb PE=1 SV=1 0.56 27 20 0.15 27.51 
RS4X_MOUSE 40S ribosomal protein S4, X isoform OS=Mus musculus GN=Rps4x PE=2 SV=2 0.56 5 4 0.19 34.24 
CYB5B_MOUSE Cytochrome b5 type B OS=Mus musculus GN=Cyb5b PE=1 SV=1 0.55 1 1 0.00 0.00 
DHB12_MOUSE Estradiol 17-beta-dehydrogenase 12 OS=Mus musculus GN=Hsd17b12 PE=2 SV=1 0.55 1 1 0.00 0.00 
GDIR1_MOUSE Rho GDP-dissociation inhibitor 1 OS=Mus musculus GN=Arhgdia PE=1 SV=3 0.55 1 1 0.00 0.00 
AT5F1_MOUSE ATP synthase subunit b, mitochondrial OS=Mus musculus GN=Atp5f1 PE=1 SV=1 0.55 9 7 0.13 23.46 
BAP31_MOUSE B-cell receptor-associated protein 31 OS=Mus musculus GN=Bcap31 PE=1 SV=3 0.54 9 6 0.02 4.10 
RL21_MOUSE 60S ribosomal protein L21 OS=Mus musculus GN=Rpl21 PE=2 SV=3 0.54 1 1 0.00 0.00 
VDAC3_MOUSE Voltage-dependent anion-selective channel protein 3 OS=Mus musculus GN=Vdac3 PE=1 SV=1 0.53 10 4 0.02 4.23 
LYPA2_MOUSE Acyl-protein thioesterase 2 OS=Mus musculus GN=Lypla2 PE=1 SV=1 0.52 1 1 0.00 0.00 
EF1B_MOUSE Elongation factor 1-beta OS=Mus musculus GN=Eef1b PE=1 SV=5 0.52 1 1 0.00 0.00 
LAMA2_MOUSE Laminin subunit alpha-2 OS=Mus musculus GN=Lama2 PE=1 SV=1 0.52 1 1 0.00 0.00 
SAE1_MOUSE SUMO-activating enzyme subunit 1 OS=Mus musculus GN=Sae1 PE=2 SV=1 0.52 1 1 0.00 0.00 
RL24_MOUSE 60S ribosomal protein L24 OS=Mus musculus GN=Rpl24 PE=2 SV=2 0.52 3 3 0.03 5.93 
ES1_MOUSE ES1 protein homolog, mitochondrial OS=Mus musculus GN=D10Jhu81e PE=1 SV=1 0.51 2 2 0.02 4.35 
FHL1_MOUSE Four and a half LIM domains protein 1 OS=Mus musculus GN=Fhl1 PE=2 SV=3 0.51 2 1 0.00 0.00 
MLL4_MOUSE Histone-lysine N-methyltransferase MLL4 OS=Mus musculus GN=Wbp7 PE=1 SV=2 0.51 1 1 0.00 0.00 
PPIC_MOUSE Peptidyl-prolyl cis-trans isomerase C OS=Mus musculus GN=Ppic PE=1 SV=1 0.51 3 2 0.00 0.00 
KRT82_MOUSE Keratin, type II cuticular Hb2 OS=Mus musculus GN=Krt82 PE=2 SV=1 0.50 2 2 0.01 1.49 
RAB2A_MOUSE Ras-related protein Rab-2A OS=Mus musculus GN=Rab2a PE=1 SV=1 0.50 2 2 0.04 7.46 
SODM_MOUSE Superoxide dismutase [Mn], mitochondrial OS=Mus musculus GN=Sod2 PE=1 SV=3 0.49 6 5 0.14 28.54 
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ASAH1_MOUSE Acid ceramidase OS=Mus musculus GN=Asah1 PE=2 SV=1 0.49 1 1 0.00 0.00 
CD63_MOUSE CD63 antigen OS=Mus musculus GN=Cd63 PE=2 SV=2 0.49 1 1 0.00 0.00 
FUBP2_MOUSE Far upstream element-binding protein 2 OS=Mus musculus GN=Khsrp PE=1 SV=1 0.49 1 1 0.00 0.00 
GPDM_MOUSE Glycerol-3-phosphate dehydrogenase, mitochondrial OS=Mus musculus GN=Gpd2 PE=1 SV=2 0.49 1 1 0.00 0.00 
FA81A_MOUSE Protein FAM81A OS=Mus musculus GN=Fam81a PE=2 SV=2 0.49 1 1 0.00 0.00 
RS6_MOUSE 40S ribosomal protein S6 OS=Mus musculus GN=Rps6 PE=1 SV=1 0.49 3 3 0.11 21.43 
TMED4_MOUSE Transmembrane emp24 domain-containing protein 4 OS=Mus musculus GN=Tmed4 PE=2 SV=1 0.48 6 3 0.36 76.08 
THIKA_MOUSE 3-ketoacyl-CoA thiolase A, peroxisomal OS=Mus musculus GN=Acaa1a PE=2 SV=1 0.48 1 1 0.00 0.00 
SYIM_MOUSE Isoleucyl-tRNA synthetase, mitochondrial OS=Mus musculus GN=Iars2 PE=2 SV=1 0.48 1 1 0.00 0.00 
MINT_MOUSE Msx2-interacting protein OS=Mus musculus GN=Spen PE=1 SV=2 0.48 1 1 0.00 0.00 
PRDX4_MOUSE Peroxiredoxin-4 OS=Mus musculus GN=Prdx4 PE=1 SV=1 0.48 2 2 0.06 12.50 
PTRF_MOUSE Polymerase I and transcript release factor OS=Mus musculus GN=Ptrf PE=1 SV=1 0.48 1 1 0.00 0.00 
RIF1_MOUSE Telomere-associated protein RIF1 OS=Mus musculus GN=Rif1 PE=1 SV=2 0.48 1 1 0.00 0.00 
TPPC3_MOUSE Trafficking protein particle complex subunit 3 OS=Mus musculus GN=Trappc3 PE=1 SV=1 0.48 1 1 0.00 0.00 
SSRA_MOUSE Translocon-associated protein subunit alpha OS=Mus musculus GN=Ssr1 PE=1 SV=1 0.48 4 2 0.04 9.38 
RAN_MOUSE GTP-binding nuclear protein Ran OS=Mus musculus GN=Ran PE=1 SV=3 0.47 5 3 0.08 16.78 
RL7A_MOUSE 60S ribosomal protein L7a OS=Mus musculus GN=Rpl7a PE=2 SV=2 0.47 6 3 0.01 3.01 
COF1_MOUSE Cofilin-1 OS=Mus musculus GN=Cfl1 PE=1 SV=3 0.46 1 1 0.00 0.00 
XRP2_MOUSE Protein XRP2 OS=Mus musculus GN=Rp2 PE=2 SV=3 0.46 1 1 0.00 0.00 
DYN3_MOUSE Dynamin-3 OS=Mus musculus GN=Dnm3 PE=1 SV=1 0.45 1 1 0.00 0.00 
FKB11_MOUSE FK506-binding protein 11 OS=Mus musculus GN=Fkbp11 PE=2 SV=1 0.45 3 2 0.16 36.67 
K2C8_MOUSE Keratin, type II cytoskeletal 8 OS=Mus musculus GN=Krt8 PE=1 SV=4 0.43 22 5 0.06 14.30 
CB078_MOUSE Uncharacterized protein C2orf78 homolog OS=Mus musculus PE=2 SV=1 0.43 1 1 0.00 0.00 
H10_MOUSE Histone H1.0 OS=Mus musculus GN=H1f0 PE=2 SV=4 0.42 2 1 0.00 0.00 
CEBPZ_MOUSE CCAAT/enhancer-binding protein zeta OS=Mus musculus GN=Cebpz PE=2 SV=2 0.40 1 1 0.00 0.00 
CNDG2_MOUSE Condensin-2 complex subunit G2 OS=Mus musculus GN=Ncapg2 PE=2 SV=1 0.40 1 1 0.00 0.00 
FAK1_MOUSE Focal adhesion kinase 1 OS=Mus musculus GN=Ptk2 PE=1 SV=3 0.40 1 1 0.00 0.00 
K2C79_MOUSE Keratin, type II cytoskeletal 79 OS=Mus musculus GN=Krt79 PE=2 SV=2 0.40 8 1 0.00 0.00 
RL17_MOUSE 60S ribosomal protein L17 OS=Mus musculus GN=Rpl17 PE=2 SV=3 0.39 2 2 0.04 9.43 
RS25_MOUSE 40S ribosomal protein S25 OS=Mus musculus GN=Rps25 PE=2 SV=1 0.39 1 1 0.00 0.00 
BCL7C_MOUSE B-cell CLL/lymphoma 7 protein family member C OS=Mus musculus GN=Bcl7c PE=1 SV=1 0.39 1 1 0.00 0.00 
SUCB2_MOUSE Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial OS=Mus musculus GN=Suclg2 PE=2 SV=3 0.39 2 1 0.00 0.00 
TMM19_MOUSE Transmembrane protein 19 OS=Mus musculus GN=Tmem19 PE=2 SV=1 0.39 1 1 0.00 0.00 
K0090_MOUSE Uncharacterized protein KIAA0090 OS=Mus musculus GN=Kiaa0090 PE=2 SV=1 0.39 1 1 0.00 0.00 
KAP2_MOUSE cAMP-dependent protein kinase type II-alpha regulatory subunit OS=Mus musculus GN=Prkar2a PE=1 SV=2 0.39 2 2 0.33 84.62 
RS5_MOUSE 40S ribosomal protein S5 OS=Mus musculus GN=Rps5 PE=2 SV=3 0.37 1 1 0.00 0.00 
IQEC1_MOUSE IQ motif and SEC7 domain-containing protein 1 OS=Mus musculus GN=Iqsec1 PE=1 SV=2 0.37 1 1 0.00 0.00 
RL29_MOUSE 60S ribosomal protein L29 OS=Mus musculus GN=Rpl29 PE=2 SV=2 0.36 2 2 0.00 0.00 
AA3R_MOUSE Adenosine A3 receptor OS=Mus musculus GN=Adora3 PE=2 SV=2 0.36 1 1 0.00 0.00 
LRRC7_MOUSE Leucine-rich repeat-containing protein 7 OS=Mus musculus GN=Lrrc7 PE=1 SV=2 0.36 1 1 0.00 0.00 
RABE1_MOUSE Rab GTPase-binding effector protein 1 OS=Mus musculus GN=Rabep1 PE=1 SV=1 0.36 1 1 0.00 0.00 
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CYTIP_MOUSE Cytohesin-interacting protein OS=Mus musculus GN=Cytip PE=2 SV=1 0.34 1 1 0.00 0.00 
GASP1_MOUSE G-protein coupled receptor-associated sorting protein 1 OS=Mus musculus GN=Gprasp1 PE=2 SV=1 0.34 1 1 0.00 0.00 
SCRB2_MOUSE Lysosome membrane protein 2 OS=Mus musculus GN=Scarb2 PE=1 SV=3 0.33 1 1 0.00 0.00 
MYO1B_MOUSE Myosin-Ib OS=Mus musculus GN=Myo1b PE=2 SV=2 0.33 1 1 0.00 0.00 
ZYX_MOUSE Zyxin OS=Mus musculus GN=Zyx PE=1 SV=1 0.33 1 1 0.00 0.00 
EIF3D_MOUSE Eukaryotic translation initiation factor 3 subunit D OS=Mus musculus GN=Eif3d PE=1 SV=2 0.31 1 1 0.00 0.00 
RASF6_MOUSE Ras association domain-containing protein 6 OS=Mus musculus GN=Rassf6 PE=2 SV=1 0.30 1 1 0.00 0.00 
CSRP2_MOUSE Cysteine and glycine-rich protein 2 OS=Mus musculus GN=Csrp2 PE=2 SV=3 0.28 1 1 0.00 0.00 
RPGP2_MOUSE Rap1 GTPase-activating protein 2 OS=Mus musculus GN=Garnl4 PE=1 SV=1 0.25 1 1 0.00 0.00 
TRI67_MOUSE Tripartite motif-containing protein 67 OS=Mus musculus GN=Trim67 PE=2 SV=1 0.25 1 1 0.00 0.00 
TITIN_MOUSE Titin OS=Mus musculus GN=Ttn PE=1 SV=1 0.22 1 1 0.00 0.00 
MYO5B_MOUSE Myosin-Vb OS=Mus musculus GN=Myo5b PE=2 SV=2 0.18 1 1 0.00 0.00 
K1C15_MOUSE Keratin, type I cytoskeletal 15 OS=Mus musculus GN=Krt15 PE=1 SV=2 0.16 3 1 0.00 0.00 
K1C19_MOUSE Keratin, type I cytoskeletal 19 OS=Mus musculus GN=Krt19 PE=2 SV=1 0.16 3 1 0.00 0.00 
ZN276_MOUSE Zinc finger protein 276 OS=Mus musculus GN=Znf276 PE=1 SV=3 0.16 1 1 0.00 0.00 
XRN2_MOUSE 5'-3' exoribonuclease 2 OS=Mus musculus GN=Xrn2 PE=1 SV=1 0.13 1 1 0.00 0.00 
POLK_MOUSE DNA polymerase kappa OS=Mus musculus GN=Polk PE=1 SV=1 0.13 1 1 0.00 0.00 
MAD1_MOUSE MAD protein OS=Mus musculus GN=Mxd1 PE=1 SV=2 0.12 1 1 0.00 0.00 
DACT2_MOUSE Dapper homolog 2 OS=Mus musculus GN=Dact2 PE=2 SV=2 0.10 2 1 0.00 0.00 
RPGF5_MOUSE Rap guanine nucleotide exchange factor 5 OS=Mus musculus GN=Rapgef5 PE=2 SV=2 0.10 1 1 0.00 0.00 
DAPLE_MOUSE Protein Daple OS=Mus musculus GN=Ccdc88c PE=1 SV=1 0.09 1 1 0.00 0.00 
TIF1A_MOUSE Transcription intermediary factor 1-alpha OS=Mus musculus GN=Trim24 PE=1 SV=1 0.09 2 1 0.00 0.00 
TNR6B_MOUSE Trinucleotide repeat-containing gene 6B protein OS=Mus musculus GN=Tnrc6b PE=2 SV=2 0.06 2 1 0.00 0.00 
SYT17_MOUSE Synaptotagmin-17 OS=Mus musculus GN=Syt17 PE=2 SV=1 0.04 1 1 0.00 0.00 
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- CONCLUSIONS - 
 
1st. TNFα can induce a tip cell phenotype in mouse endothelial cells, characterized by 
elongation and filopodia extension, as well as expression of the endothelial tip cell markers 
Jag1 and CXCR4 and increased MT1-MMP expression. 
 
2nd. Quantitative proteomics (SILAC) performed in TNFα-activated immortalized mouse 
endothelial cells (wildtype versus MT1-MMP-deficient) has identified the MT1-MMP 
substrates in inflammation-activated endothelial tip cells: TSP1, NID1, CYR61 and 
SEM3C. 
 
3rd. Bioinformatics analysis points to MT1-MMP combinatorial proteolytic programme, where 
processing of various MT1-MMP substrates instead of their individual processing 
determines the biological decisions in activated endothelial cells such as adhesion, motility, 
chemotaxis and vessel morphogenesis. In this combined programme matricelular protein 
TSP1 is a master regulator and contributes to all mentioned processes.   
 
4th. The absence of MT1-MMP results in impaired processing and abnormal accumulation of 
TSP1, CYR61, NID1 and SEM3C in endothelial cells in vitro and in vivo.  
 
5th. In an experimental animal model of DSS-induced colitis, levels of the angiogenic cytokine 
VEGF and inflammatory cytokine TNFα positively correlate with disease progression, 
leading to formation of new vessels and accumulation of inflammatory cells, respectively. 
 
6th. MT1-MMP expression is upregulated in colon in animals treated with DSS and it is 
localized in epithelial cells in control conditions and in vessels and infiltrating 
inflammatory cells after DSS treatment. 
 
7th. Soluble levels of MT1-MMP substrates TSP1 and NID in serum increase along DSS-
induced mouse experimental colitis suggesting their release from the extracellular matrix 
likely by MT1-MMP-dependent processing. The expression pattern of TSP1 and NID1 in 
colon changes along disease progression being upregulated in vessels and inflammatory 
cells in severe condition. 
 
8th. Soluble levels of TSP1 and NID1 are higher in serum from patients affected with 
ulcerative colitis or Crohn’s disease with low disease activity supporting the potential use 
of these MT1-MMP substrates as biomarkers in chronic inflammatory disorders. 
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- CONCLUSIONES - 
 
1º. La citoquina inflamatoria TNFα induce el fenotipo ‘tip’ (líder) en células endoteliales de 
ratón, caracterizado por la morfología alargada y por la expresión de los marcadores Jag1 y 
CXCR4 y de la proteasa MT1-MMP. 
 
2º. El ensayo de proteómica cuantitativa SILAC realizado en células endoteliales de ratón 
inmortalizadas (genotipo silvestre versus deficientes en MT1-MMP) y activadas con TNFα 
ha identificado la colección de sustratos de MT1-MMP en células endoteliales ‘tip’ 
inflamatorias. Estos sustratos incluye las proteínas TSP1, NID1, CYR61 y SEM3C.  
 
3º. El análisis bioinformático de los datos proteómicos ha desvelado un programa proteolítico 
combinatorial, en el cual el procesamiento combinado de varios sustratos por MT1-MMP 
en vez del procesamiento de sustratos individuales es el que determina las decisiones 
biológicas de las células endoteliales activadas tales como quimiotaxis, motilidad y 
adhesión celular, y desarrollo vascular. En este programa combinatorial el procesamiento 
de la proteína matricelular TSP1 es esencial y contribuye a todos los procesos biológicos 
mencionados. 
 
4º. La ausencia de MT1-MMP disminuye el procesamiento y conlleva a la  acumulación 
anómala de  TSP1, CYR61, NID1 y SEM3C en células endoteliales in vitro e in vivo.  
 
5º. En el modelo animal experimental de colitis inducida por DSS, los niveles séricos de la 
citoquina inflamatoria TNFα y del factor angiogénico VEGF-A correlacionan 
positivamente con la progresión de enfermedad y con la acumulación de células 
inflamatorias y la formación de nuevos vasos, respectivamente. 
 
6º. La expresión de MT1-MMP aumenta en el colon de ratones tratados con DSS 
localizándose en células epiteliales en condiciones basales y en vasos y en células del 
infiltrado inflamatorio tras el tratamiento con DSS. 
 
7º. Los niveles séricos de los sustratos de MT1-MMP TSP1 y NID1 aumentan con la colitis 
inducida por DSS, sugiriendo su liberación desde la matriz extracelular por la acción 
proteolítica de MT1-MMP. La distribución tisular en colon de TSP1 y NID1 también 
cambia a lo largo de la progresión de la enfermedad, aumentando en vasos y células 
inflamatorias en  condiciones severas. 
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8º. Los niveles solubles de TSP1 y NID1 están aumentados en los sueros de los pacientes 
afectados por colitis ulcerosa o enfermedad de Crohn de baja actividad apoyando el uso 
potencial de estos sustratos de MT1-MMP como biomarcadores en enfermedades 
inflamatorias crónicas 
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The  response  to  environmental  cues  such  as  inﬂammatory  stimuli  requires  coordinated  cellular  functions.
Certain proteins  have  functions  on both  sides  of the  plasma  membrane  to  allow  coordination  between  the
extracellular  and  intracellular  milieus.  The  membrane-anchored  matrix  metalloproteinase  MT1-MMP  is
well  positioned  to  sense  and  modify  the  extracellular  environment  by  processing  matrix  components,
transmembrane  proteins  and  soluble  factors.  Recent  ﬁndings  show,  however,  that  MT1-MMP  also  plays
unexpected  intracellular  roles  in macrophages  through  its location  at the  plasma  membrane,  the  Golgi  or
the  nucleus,  impacting  cell  motility,  metabolism  and  gene  transcription.  MT1-MMP  is thus  an  example  of
the evolutionary  diversiﬁcation  of  protein  function,  allowing  optimal  coordination  between  extracellularell metabolism
ypoxia
hromatin remodeling
acrophages
nﬂammation
stimuli  and  cellular  responses.  It remains  to  be determined  whether  these  new  MT1-MMP  functions
are  speciﬁc  to  macrophages,  professional  phagocytes  involved  in  inﬂammation,  or are  present  in other
inﬂammation-responsive  cells.  In this  review,  we  will  summarize  these  site-speciﬁc  MT1-MMP  functions
in macrophages  and  comment  on  the  possible  conservation  of  these  functions  in endothelial  cells.
© 2012 Elsevier GmbH. All rights reserved.
ndothelial cells
ngiogenesis
ntroduction
Cells explore their microenvironment to sense cues that activate
ppropriate adaptive responses. Different evolutionary mecha-
isms have expanded the functional repertoire of certain proteins
o allow coordination between their functions on both sides of
he plasma membrane, the extracellular and intracellular milieus.
hese mechanisms include unconventional secretion of proteins
ith dual topology, such as syntaxin 2, HGMB1 and tissue trans-
lutaminase, and interdependence of function and location for
embrane-anchored proteins, such as -catenin, which was  the
rst individual protein shown to have distinct but linked func-
ions related to its subcellular compartmentalization (Radisky et al.,
009).
Matrix metalloproteinases (MMPs) can sense and induce envi-
onmental modiﬁcations since they are secreted enzymes able
o degrade a battery of extracellular matrix (ECM) components
Page-McCaw et al., 2007). A subfamily of MMPs  is anchored to
he membrane instead of being secreted, and this fact positions
hese MT-MMPs  as prime candidates to coordinate extracellular
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ttp://dx.doi.org/10.1016/j.ejcb.2012.07.003cues with cellular responses. MT1-MMP  is especially suited for
pericellular proteolysis through its ability to process ECM compo-
nents, transmembrane proteins and soluble factors (Itoh and Seiki,
2006). Moreover, it has been proposed that MT1-MMP  might also
be involved in processing of intracellular substrates such as peri-
centrin, pro-v integrin and focal adhesion kinase (Golubkov et al.,
2005; Ratnikov et al., 2002; Shofuda et al., 2004) (Fig. 1). Accord-
ingly, as with other MMPs, recent proteomics approaches have
identiﬁed intracellular proteins as possible MT1-MMP  substrates;
for example, HGMB1 (one of the unconventional dual topology pro-
teins just mentioned), DJ-1, hsp90,  and -enolase, although it is
not clear if processing would occur in the extracellular or intracel-
lular compartments (Butler et al., 2008; Cauwe and Opdenakker,
2010) (Fig. 1). These ﬁndings indicate that under certain circum-
stances MT1-MMP  might unexpectedly be proteolytically active
inside cells, through as-yet unclear mechanisms. Regulated com-
partmentalization of MT1-MMP  is essential for this diversity of
proteolytic actions; in this regard, the presence of MT1-MMP  at
caveolae/lipid raft domains – apart from their role in its internaliza-
tion – often dictates protease location and function in different cell
contexts (Frittoli et al., 2011; Poincloux et al., 2009). As an example,
forced location of MT1-MMP  to lipid rafts by deletion of its cytoso-
lic tail limited its access and processing of E-cadherin and thereby
tumor cell locomotion and growth (Rozanov et al., 2004). Moreover,
MT1-MMP  co-localizes and co-trafﬁcs with caveolin-1 to invadopo-
dia, actin-rich invasive protrusions, resulting in matrix degradation
in several tumor cell types (Grass et al., 2012; Yamaguchi et al.,
2009).
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Fig. 1. Extracellular and intracellular substrates and partners of MT1-MMP. The domain structure of MT1-MMP is shown together with lists of selected extracellular and
intracellular substrates and binding partners associated with each domain. Intracellular binding partners that interact with MT1-MMP  at the Golgi apparatus are indicated
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But in addition to its proteolytic activities, MT1-MMP  can also
odulate intracellular responses through molecular interactions
f its cytosolic tail leading to induction of signaling pathways such
s ERK (Gingras and Beliveau, 2010). Most identiﬁed molecular
artners interact with the MT1-MMP  cytosolic tail at the plasma
embrane; however, associations at other cell compartments such
s the Golgi have been reported (Fig. 1) (Artym et al., 2006; Cauwe
t al., 2007; Gingras et al., 2008; Gonzalo et al., 2010; Labrecque
t al., 2004; Roghi et al., 2010; Sakamoto and Seiki, 2010; Smith-
earson et al., 2010; Tapia et al., 2011).
This information suggests that the compartmentalization of
T1-MMP  is linked to proteolytic-dependent and proteolytic-
ndependent functions, through which it can coordinate extracel-
ular cues with cellular responses. We  will summarize recent data
bout new functions of MT1-MMP  in macrophages linked to its
ocation at the plasma membrane, the Golgi and the nucleus and
iscuss the possible conservation of these functions in endothelial
ells, another cell type relevant to inﬂammation.
ite-speciﬁc functions of MT1-MMP  in macrophages
Macrophages, which derive from myeloid progeni-
ors/monocytes, are phagocytes with a high phenotypic plasticity
ssociated with their essential role in inﬂammation. MT1-MMP
s expressed and active at the plasma membrane of mono-
yte/macrophages (Matias-Roman et al., 2005), and also of
ematopoietic progenitors whose G-CSF-induced mobilization
nvolves enhanced MT1-MMP  location at lipid rafts (Shirvaikar
t al., 2010). Moreover, MT1-MMP  is a component of the podosome
achinery in macrophages and of the sealing zone of osteoclasts
macrophage-derived cells), and is involved in matrix degradation
t these specialized membrane protrusions (Nusblat et al., 2011).
ecent data from our group and others have, however, chal-
enged this paradigm, and shown that MT1-MMP  can also exert
on-catalytic functions at the macrophage plasma membrane,
nd more importantly has unexpected functions at other cellcompartments, including the Golgi/trans-Golgi network (TGN) and
the nucleus.
We showed that the absence of MT1-MMP  results in a defect
in the fusion of macrophages to form multinucleate osteoclasts
and giant cells, and that this defect is related to deﬁcient motil-
ity and membrane protrusive activity of MT1-MMP  null bone
marrow-derived myeloid progenitors/macrophages (Gonzalo et al.,
2010). Interestingly, normal progenitor motility and fusion was  res-
cued by re-expression of a catalytically dead mutant, pointing to
a proteolysis-independent mechanism. Further analysis showed
that MT1-MMP  associates with the adapter protein p130Cas at
the plasma membrane, promoting optimal recruitment and activ-
ity of the small GTPase Rac1 (Gonzalo et al., 2010). Association
with p130Cas involves MT1-MMP  cytosolic tail Tyr573 which had
previously been proposed to be phosphorylated by Src kinase
(Nyalendo et al., 2007). This study established that the MT1-
MMP/p130Cas/Rac1 molecular complex thus coordinates proper
macrophage cell motility, migration and fusion both in vitro and
in vivo (Fig. 2).
In an independent study, Seiki’s group reported that, unlike
macrophage invasion (which requires MT1-MMP catalytic activ-
ity), migration of mouse bone marrow-derived macrophages is also
dependent on the MT1-MMP  cytosolic tail (Sakamoto and Seiki,
2009). Macrophages are metabolically unusual in that, to enable
migration into hypoxic inﬂamed tissues, they use glycolysis rather
than oxidative phosphorylation for ATP production constitutively,
even during normoxia. Seiki’s group found that MT1-MMP  regu-
lated macrophage motility by increasing hypoxia inducible factor
(HIF)-1-mediated glycolysis and thus production of energy (ATP)
by these cells; previous transcriptomic analysis in tumor cells had
suggested regulation of energy metabolism by MT1-MMP, but the
mechanism was  undeﬁned (Rozanov et al., 2008). Dissection of
the mechanism by which the MT1-MMP  cytosolic tail regulates
macrophage metabolism revealed that this action relies on MT1-
MMP  localization to the Golgi apparatus, where its cytosolic tail
retains factor inhibiting HIF (FIH)-1. FIH-1 acts by hydroxylating a
conserved asparagine residue in HIF-1 thus impairing its inter-
action with its transcriptional co-activator p300 and abrogating
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Fig. 2. Site-speciﬁc functions of MT1-MMP  in macrophages. MT1-MMP is involved in macrophage migration and the immune response in a catalytic-independent manner
through  at least three site-speciﬁc pathways linked to distinct MT1-MMP  trafﬁc routes. At the plasma membrane, MT1-MMP  can modulate Rac1 activity through binding to
p130Cas, thereby regulating migration. The formation of this complex can be regulated by tyrosine phosphorylation of MT1-MMP cytosolic Y573 by Src kinase. At the Golgi
apparatus, MT1-MMP, through the Arg576 in its cytoplasmic tail, binds FIH-1, keeping it close to Mint-3. This inactivation of FIH-1 stabilizes HIF-1, resulting in the activation of
glycolytic ATP production needed for macrophage migration and the immune responses. Upon translocation to the nucleus through as-yet undeﬁned mechanisms, MT1-MMP
induces PI3K expression and regulates the transcription of genes critical for the inﬂammatory response.
Fig. 3. Site-speciﬁc functions of MT1-MMP  in endothelial cells. MT1-MMP can affect endothelial cell migration, metabolism and therefore angiogenesis through different
pathways involving distinct cytosolic tail interactions and subcellular locations. These actions could be especially relevant in endothelial tip cells, which are exposed to low
O2 levels. In endothelial cells, MT1-MMP  association to caveolae can regulate its trafﬁc and function at different cellular locations. In addition, interaction of the MT1-MMP
cytosolic tail with p130Cas at the plasma membrane might regulate Rac1 membrane targeting and migration, similar to the situation in macrophages. At the Golgi apparatus,
the  MT1-MMP  cytosolic tail might interact with FIH-1 as reported for macrophages, thereby promoting HIF-1-mediated cell metabolism.
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Fig. 4. p130Cas and Rac1 membrane levels are reduced in MT1-MMP null endothe-
lial  cells. (A) Mouse lung endothelial cells (MLEC) from wild type or MT1-MMP
deﬁcient mice were cultured to 70% conﬂuence and after serum deprivation for
16  h were stained for p130Cas and Rac1 (green). Images show representative confo-
cal  microscopy maximal projections. (B) MLEC cultured as in A were separated into92 A. Koziol et al. / European Journ
nduction of HIF-1-dependent genes (Fraisl et al., 2009). MT1-
MP is normally processed by the pro-convertase furin at the
olgi. In macrophages, MT1-MMP  at the Golgi interacts through its
ytosolic tail Arg576 with FIH-1, thereby favoring FIH-1 proximity to
int-3/APBA3 (another furin partner). Mint-3 in turn forms a com-
lex with FIH-1, retaining it at this site and reducing its available
ytoplasmic levels. In the presence of the MT1-MMP/FIH-1/Mint-3
omplex at the Golgi, HIF-1 will be free and stabilized, and thus
ble to induce glycolysis and ﬁnal production of ATP (Sakamoto and
eiki, 2010). In this manner MT1-MMP  might coordinate its pro-
nvasive activity with the HIF machinery and thereby the cellular
etabolism that is also required for migration (Fig. 2); in fact, it is
ossible that a feedback loop might be operative between hypoxia
nd MT1-MMP  in macrophages since at least in tumor cells both
T1-MMP  transcription and mobilization to the plasma membrane
an in turn be regulated by HIF-2 and by hypoxia, respectively
Li et al., 2012; Munoz-Najar et al., 2006; Petrella et al., 2005).
oints that remain to be deﬁned include whether MT1-MMP exerts
his function at the Golgi during its secretory path to the plasma
embrane or upon its recycling from the plasma membrane after
lathrin or caveolae-mediated endocytosis (Poincloux et al., 2009).
upport for the idea that MT1-MMP  localization at the Golgi mod-
lates or provides additional MT1-MMP  functions is given by the
ecently reported interactions of MT1-MMP  with other Golgi pro-
eins. In tumor cells the peripheral Golgi matrix protein GRASP55
ssociates with the LLY573 motif in the MT1-MMP  cytoplasmic
omain and favors its furin-dependent activation (Kuo et al., 2000;
oghi et al., 2010). LIM kinase 1 (LIMK1), a modulator of actin
ynamics, also co-localizes and associates with MT1-MMP  at the
olgi vesicles, facilitating its transport to the plasma membrane in
umor cells (Tapia et al., 2011).
More recently, Weiss’s group has uncovered a novel MT1-MMP
unction in macrophages, dependent on its translocation to the
ucleus by an as-yet undeﬁned mechanism (Shimizu-Hirota et al.,
012). MT1-MMP  trafﬁcs to the nucleus and triggers the activation
f the promoter of phosphoinositide 3-kinase  (PI3K), thus acti-
ating the Akt/GSK3  signaling cascade (Fig. 2). This in turn controls
he immunoregulatory Mi-2/NuRD complex of nucleosome remod-
ling enzymes responsible for limiting the transcription of genes
nvolved in the immune response. In this manner, in the absence of
T1-MMP  genes belonging to the Mi-2/NuRD complex like Mi-2ˇ,
DAC2 and MBD3 are down-regulated and genes related to pro-
nﬂammatory responses like Mx1, Mx2, Saa3, CXCL10 and CCL5 are
p-regulated. The mechanism of MT1-MMP  translocation to the
ucleus remains unclear, although transfection with various MT1-
MP  constructs points to a requirement for MT1-MMP  anchorage
o the membrane but not for its cytosolic or hemopexin domains or
or its catalytic activity (Shimizu-Hirota et al., 2012). The possible
ole of MT1-MMP  in ATP production may  also contribute to its tran-
criptional function, since the Mi-2/NuRD axis is an ATP-dependent
ucleosome remodeling complex.
Thus in macrophages, a highly plastic cell type with special
etabolic features, the functional repertoire of MT1-MMP has
xpanded to adapt its functions to cellular responses required for
ptimal cell function during inﬂammation and its resolution.
ite-speciﬁc functions of MT1-MMP  in endothelial cells
During an inﬂammatory response macrophages constitute the
rst-line sensors of damage, producing a number of soluble fac-
ors, including TNF-. TNF- in turn can activate endothelial cells
o engage in an angiogenic program aimed at forming new ves-
els and resolving the inﬂammation. MT1-MMP, in addition to
ts important functions in macrophages, is also a key protease in
ndothelial cells that plays important roles in various steps of theparticulate (P) and soluble (S) fractions, and analyzed by Western blot for p130Cas
and  Rac1 expression. 1 integrin and RhoGDI are included as controls of particulate
and  soluble fractions. A representative blot is shown (n = 5).
angiogenic response. MT1-MMP  proteolytic activity in endothelial
cells is closely linked to its regulated presence at speciﬁc domains
of the plasma membrane, in particular at lamellipodia and ﬁlopo-
dia protrusions in which MT1-MMP  associates with caveolin-1
and integrin v3 and is catalytically active (Galvez et al., 2002,
2004; Fig. 3). Caveolae constitute the main route for MT1-MMP
internalization in endothelial cells but they might also contribute
to its mobilization to invadopodia as reported for tumor cells
(Frittoli et al., 2011; Galvez et al., 2004; Poincloux et al., 2009).
Consistently, MT1-MMP  is expressed in endothelial tip cells, spe-
cialized cells at the nascent vascular sprout that contain many
ﬁlopodia, are highly migratory and invasive and are enriched in
caveolin-1 and v3 integrin expression as shown by recent tran-
scriptomic analysis (Aplin et al., 2009; del Toro et al., 2010; Gerhardt
et al., 2003; Kachgal et al., 2012; Strasser et al., 2010; Yana et al.,
2007).
The possibility that MT1-MMP  might play additional site-
speciﬁc functions in endothelial cells is supported by several
observations. First, MT1-MMP  deﬁciency reduces the targeting of
p130Cas and Rac1 to the plasma membrane, similar to previous
ﬁndings in myeloid progenitors (Fig. 2; Gonzalo et al., 2010). In
endothelial cells, the MT1-MMP/p130Cas/Rac1 complex might con-
tribute to migration, especially in endothelial tip cells, where Rac1
activity has been shown to be relevant (De Smet et al., 2009;
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Fig. 5. Selected biological processes (GO annotations) regulated by MT1-MMP. Transcriptome and degradome analysis of inﬂammatory-activated mouse primary endothelial
cells  identiﬁed genes and proteins positively regulated by MT1-MMP that can affect a number of biological processes related to angiogenesis. Upregulated genes in the
transcriptome analysis were predominantly enriched in processes related to proliferation, vasculature development and adhesion, while proteins identiﬁed in the MT1-MMP
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igs. 3 and 4). This new MT1-MMP  function might also be con-
erved in other cell types; for example, MT1-MMP  has been shown
o associate with a p130Cas/focal adhesion kinase complex upon
rc kinase-dependent Tyr573 phosphorylation, thus favoring degra-
ation of the matrix at focal adhesions in tumor cells (Wang and
cNiven, 2012).
Second, MT1-MMP  could be expected to regulate HIF-1 machin-
ry in endothelial cells. The MT1-MMP/HIF-1 axis is active in
umor cells, which also use ‘aerobic’ glycolysis (the Warburg effect)
Hara et al., 2011), and more recently this axis was reported in
one marrow hematopoietic progenitors exposed to low oxygen
ension (Nishida et al., 2012). Like these cell types, endothelial cells
re equipped with metabolic mechanisms to enable survival in
ighly hypoxic conditions, including deriving most of their energy
naerobically through glycolysis (Fraisl et al., 2009). Moreover, the
IF-1 inhibitor FIH-1 is expressed in certain endothelial cells and
ight inhibit Notch activity, which is critical for endothelial tip
ell fate speciﬁcation. It will be interesting to explore whether
T1-MMP  can also associate with FIH-1/Mint-3 in endothelial tip
ells, thereby modulating FIH-1 availability and regulating HIF-1-
ependent genes such as Dll4 and Notch signaling (Fig. 3).
Finally, bioinformatics analysis of the MT1-MMP  transcriptome
nd degradome (the collection of its substrates) in cytokine-
ctivated primary mouse lung endothelial cells points to a role
f MT1-MMP  in regulating gene transcription in endothelial
ells in a proteolytic-independent manner. Although most of
he Gene Ontology Biological Processes related to angiogenesis,
uch as chemotaxis, motility, migration, adhesion or vasculatureovessel formation (cell motility, adhesion, chemotaxis and vessel morphogenesis).
 only by extracellular processing (degradome) are in red, and processes regulated
development, are enriched in MT1-MMP  degradome or in
both MT1-MMP  degradome and transcriptome, endothelial cell
proliferation was  only enriched in the transcriptome. This
analysis indicates that there is a minor contribution from
non-catalytic MT1-MMP-driven gene regulation to angiogene-
sis (Fig. 5). MT1-MMP  nuclear translocation is not exclusive
of macrophages since it has also been observed in hepato-
cellular carcinoma cells in which caveolin-mediated endocy-
tosis was proposed as the underlying mechanism (Ip et al.,
2007). Moreover, MT1-MMP  can modulate the expression
of components of chromatin remodeling complexes in several cell
types including HMGA2 in tumor cells through ERK signaling and
Mi-2/NuRD in macrophages through the PI3K/Akt/GSK3 path-
way (Dangi-Garimella et al., 2011; Shimizu-Hirota et al., 2012).
Although MT1-MMP  nuclear translocation has not been conﬁrmed
in endothelial cells, we can thus speculate that MT1-MMP  might
directly or indirectly regulate chromatin remodeling, and thereby
gene transcription, in endothelial cells. It will be important to inves-
tigate this point further given the current interest in epigenetic
regulation in vascular biology and angiogenesis (Aurora et al., 2010;
Yan et al., 2010).
Concluding remarks and future perspectivesInterdependence between location and function has been
claimed as a mechanism for diversiﬁcation of protein functions
and improvement of their ability to coordinate extracellu-
lar cues and intracellular responses. MT1-MMP has become a
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rime example of such a site-speciﬁc, multi-task protein, able
o coordinate extracellular proteolytic modiﬁcation with non-
roteolytic-mediated cellular responses including cell motility and
etabolism, ultimately leading to inﬂammatory responses and
ngiogenesis.
Open questions remain about the mechanisms by which cells
nd their metabolic needs regulate the distinct subcellular loca-
ions and functions of MT1-MMP. There are several possibilities;
or example different metabolic or inﬂammatory conditions might
rigger distinct trafﬁc routes of MT1-MMP. Thus, environmental
etabolic needs might change the manner in which MT1-MMP  is
ndocytosed, steering its fate away from degradation to active roles
n the Golgi or other compartments such as the nucleus; alterna-
ively, MT1-MMP  and its partners might meet at the Golgi/TGN
s a result of altered synthesis and secretion. In support of reg-
lated trafﬁc of MT1-MMP  under metabolic stress, in addition to
ranscriptional regulation of MT1-MMP  by HIF-2 in tumor cells
Petrella et al., 2005), hypoxia can also promote the mobilization
f MT1-MMP  from cytosolic storage pools to the plasma mem-
rane involving different molecular mechanisms such as RhoA
ctivation (Li et al., 2012; Munoz-Najar et al., 2006). Interestingly,
hoA activation induced MT1-MMP  location at cell-cell contacts
nd inhibited its caveolae-mediated trafﬁc in endothelial cells
Galvez et al., 2004); it will be interesting to explore whether
ypoxia in a RhoA-dependent or independent manner, can impact
aveolae trafﬁc routes since at least in tumor cells HIF-1 and -
 induce caveolin-1 transcription and caveolae formation (Wang
t al., 2012). Notably, hypoxia also stimulates the formation of
nvadopodia in tumor cells (Lucien et al., 2011; Munoz-Najar et al.,
006) supporting the concept that a decrease in oxygen availability
ight trigger a coordinated cellular response involving increased
T1-MMP  trafﬁc to the plasma membrane together with induc-
ion of caveolae and invadopodia formation resulting in higher
evels of MT1-MMP  at these invasive structures. This response
ight be relevant not only in the tumor context but also in hypoxic
nﬂammatory foci leading to endothelial tip cell and macrophage
nvasion. Moreover, in pathological contexts such as pulmonary
rterial hypertension, hypoxia can also lead to trapping of vesicle
ethers (SNAREs and SNAPs) in the Golgi (Sehgal and Lee, 2011);
t is tempting to speculate that inﬂammatory hypoxic environ-
ents could also regulate Golgi-dependent MT1-MMP  trafﬁc to
ndow cells with appropriate adaptive responses. Understanding
hese new mechanisms of action of MT1-MMP  has the potential
o provide further insights into the complex networks activated
nder stressful inﬂammatory conditions and open new avenues
or therapeutic intervention.
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ABSTRACT The mechanism by which proteolytic
events translate into biological responses is not well
understood. To explore the link of pericellular prote-
olysis to events relevant to capillary sprouting within the
inflammatory context, we aimed at the identification of
the collection of substrates of the protease MT1-MMP
in endothelial tip cells induced by inflammatory stimuli.
We applied quantitative proteomics to endothelial cells
(ECs) derived from wild-type and MT1-MMP-null mice
to identify the substrate repertoire of this protease in
TNF--activated ECs. Bioinformatics analysis revealed
a combinatorial MT1-MMP proteolytic program, in
which combined rather than single substrate processing
would determine biological decisions by activated ECs,
including chemotaxis, cell motility and adhesion, and
vasculature development. MT1-MMP-deficient ECs in-
efficiently processed several of these substrates (TSP1,
CYR61, NID1, and SEM3C), validating the model. This
novel concept of MT1-MMP-driven combinatorial pro-
teolysis in angiogenesis might be extendable to proteo-
lytic actions in other cellular contexts.—Koziol, A.,
Gonzalo, P., Mota, A., Pollán, Á., Lorenzo, C., Colomé,
N., Montaner, D., Dopazo, J., Arribas, J., Canals, F.,
Arroyo, A. G. The protease MT1-MMP drives a combi-
natorial proteolytic program in activated endothelial
cells. FASEB J. 26, 4481–4494 (2012). www.fasebj.org
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Proteolysis governs biological processes such as
angiogenesis, the formation of new vessels from preex-
isting ones; however, the mechanisms by which proteo-
lytic events actually translate into defined cellular re-
sponses remain poorly characterized. Angiogenesis
requires the presence of invasive endothelial tip cells at
the nascent sprout. The endothelial tip cell transcrip-
tome during postnatal retinal vascularization was re-
ported recently (1, 2), but the proteome has not been
characterized. Angiogenesis in adults is often linked to
inflammation, and factors such as tumor necrosis factor
 (TNF-), sphingosine-1-phosphate (S1P), and brady-
kinin induce formation of endothelial tip-like cells in
vitro (3–5). The protease membrane type-1 matrix
metalloproteinase (MT1-MMP) is likely active at the
developing sprout during inflammation, since it is
required for capillary formation induced by nitric oxide
(a downstream effector of bradykinin), prostaglandin
E2 (PGE2), and the chemokine monocyte chemoattrac-
tant protein-1 (MCP-1)/chemokine (C-C motif) ligand
2 (CCL2) (3). Moreover, MT1-MMP is expressed in
endothelial tip cells in vitro (6), and mathematical
models suggest that MT1-MMP contributes to endothe-
lial tip cell guidance (7). Thus, a global analysis of
MT1-MMP proteolytic activity in endothelial tip cells
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should provide deeper understanding of the link be-
tween proteolysis and angiogenesis.
The fingerprint of a protease is its full set of sub-
strates in a given cellular context (also known as the
protease degradome; ref. 8). Shotgun and quantitative
proteomics approaches have significantly advanced this
field. Stable isotope labeling of amino acids in cell
culture (SILAC) is a powerful quantitative proteomics
approach (9), but the need for several cell doublings
limits its use in slowly proliferating primary cells. Bioin-
formatic analysis of identified substrate sets can provide
additional information about protease action in spe-
cific cell contexts. We have used an inflammatory tip
cell model system to integrate SILAC-identified MT1-
MMP substrates in TNF--activated endothelial cells
(ECs) with bioinformatics analysis. This global analysis
reveals a combinatorial MT1-MMP proteolytic program
that governs EC chemotaxis, motility, and adhesion,
ultimately leading to angiogenesis.
MATERIALS AND METHODS
Mice
MT1-MMP-deficient mice were generated as described previ-
ously (10). MT1-MMP heterozygotes on the C57BL/6 back-
ground were crossed, and wild-type (WT) and null littermates
were used for experiments. Mice were kept in the Centro
Nacional de Investigaciones Cardiovasculares (CNIC) Animal
Facility under pathogen-free conditions and according to
institutional guidelines.
Cells
Isolation of mouse lung ECs (MLECs) was described previ-
ously (11). Briefly, lungs from WT or MT1-MMP-null mice
were excised, disaggregated, and digested in 0.1% collage-
nase for 1 h at 37°C. The cell suspension was seeded onto
plates coated with 10 g/ml fibronectin (Sigma, St. Louis,
MO, USA), 10 g/ml collagen I (PureCol; Advanced BioMatrix,
San Diego, CA, USA), and 0.1% gelatin (Sigma). After
attachment, cells were negatively selected with anti-CD16/
CD32 mAb (BD Biosciences, San Jose, CA, USA) coupled to
magnetic beads (Dynal; Invitrogen, Carlsbad, CA, USA), and
then positively selected with anti-intercellular adhesion mol-
ecule 2 (ICAM-2; BD Biosciences) coupled to magnetic beads.
Primary MLECs were immortalized using the polyoma virus
middle T by overnight infection with conditioned medium
from the virus-producing Gpmt cell line supplemented with
antibiotics, 10 mM HEPES, 8 g/ml of polybrene (Sigma),
and 50 g/ml EC growth supplement. The Gpmt cell line
was a kind gift from Dr. Reinhard Fässler (Max Planck
Institute of Biochemistry, Munich, Germany).
Human umbilical vein ECs (HUVECs) from different do-
nors (cultured up to passage 6) were purchased from Lonza
(Basel, Switzerland) or isolated from freshly harvested umbil-
ical cords, as described previously (12). Cells were cultured in
M199 medium (Lonza) supplemented with 20% fetal bovine
serum, 100 U/ml penicillin, 100 g/ml streptomycin, 2.5
g/ml fungizone, 10 UI/ml heparin, and 50 g/ml of EC
growth supplement extracted from bovine brain.
Flow cytometry
Immortalized MLECs were left untreated or treated with 20
ng/ml of the angiogenic factors vascular endothelial growth
factor (VEGF) or TNF- (both from PeproTech, Rocky Hill,
NJ, USA). For surface expression analysis, cells were harvested
using Cell Dissociation Buffer (Gibco, Carlsbad, CA, USA)
and stained with rat anti-mouse vascular cell adhesion mole-
cule 1 (VCAM-1; BD Biosciences), biotinylated hamster anti-
mouse ICAM-1 (BD Biosciences), hamster anti-mouse platelet
EC adhesion molecule 1 (PECAM-1; Millipore, Bedford, MA,
USA), rabbit anti-mouse Jagged 1 (Jag1; Cell Signaling Tech-
nology, Danvers, MA, USA), rabbit anti-mouse VEGF receptor
2 (VEGFR2; Abcam, Cambridge, MA, USA), rabbit anti-
mouse delta-like ligand 4 (Dll4; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), hamster anti-mouse 3 integrin (BD
Bioscience), rat anti-mouse C-X-C chemokine receptor type 4
(CXCR4; BD Biosciences), and rabbit anti-mouse MT1-MMP
(HR; Abcam), followed by incubation with appropriate fluo-
rescent-labeled secondary antibodies. Cell surface expression
was determined in a flow cytometer (FACScanto; Beckton
Dickinson, Franklin Lakes, NJ, USA), and data were analyzed
with FACSDiva software (Beckton Dickinson).
Hierarchical clustering analysis
Regulatory patterns were compared using the platform-inde-
pendent Java suite Genesis (13).
Immunofluorescence staining
MLECs were plated on matrix-coated glass coverslips. Cells
were then fixed with 4% paraformaldehyde (PFA) for 10 min.
After blocking with 2% BSA for 30 min at room temperature,
coverslips were incubated with Texas Red-phalloidin, rabbit
anti-mouse thrombospondin 1 (TSP1; clone 7280; kindly
provided by Dr. M. Luisa Iruela-Arispe, University of Califor-
nia, Los Angeles, CA, USA), goat anti-mouse cysteine-rich
angiogenic inducer 61 (CYR61), goat anti-mouse nidogen 1
(NID1), or goat anti-mouse semaphorin 3C (SEM3C; Santa
Cruz Biotechnology), followed by fluorescent-labeled second-
ary antibodies. Mouse anti-human TSP1 (Thermo Fisher
Scientific, Waltham, MA, USA), rabbit anti-human CYR61,
and rabbit anti-human NID1 or goat anti-human SEM3C
(Santa Cruz Biotechnology) were used for immunostaining of
human ECs. Coverslips were mounted with ProLong Gold
antifade reagent (Invitrogen). Samples were examined under
a Zeiss LSM700 confocal microscope (Plan-Apochromat
631.4 or 401.3 Oil DIC M27; Carl Zeiss, Oberkochen,
Germany) and images were analyzed with ZEN software
(Zeiss).
Three-dimensional (3D) endothelial tip-like cell sprouting
assay
MLECs were plated at confluence in Ibidi angiogenic cham-
bers with Matrigel (BD Biosciences) on top; medium contain-
ing TNF- was then added, and the chamber was kept at 37°C
for 18 h. At the end of incubation, medium was removed,
and the cells were fixed with freshly prepared 4% PFA for 20
min, followed by permeabilization in 0.3% Triton X-100.
Samples were washed with PBS/Triton X-100 and stained
with phalloidin, anti-PECAM-1, anti-TSP1, anti-CYR61, anti-
NID1, or anti-SEM3C antibodies. Samples were examined
under a Zeiss LSM700 confocal microscope, and images were
analyzed with ZEN software.
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SILAC
MLECs were grown in complete SILAC Advance D-MEM F-12
Flex Medium (Invitrogen) supplemented with “light” and
“heavy” amino acids and dialyzed serum to exclude the
possibility of incorporating nonlabeled amino acids. We used
nonlabeled lysine and the 13C6 form of arginine (light
conditions) for cell cultures derived from MT1-MMP-null
mice, and isotopes of lysine (13C6) and arginine (
13C6
15N4)
for cells derived from WT mice (heavy conditions). Cells were
cultured for 7 d, corresponding to 6 doublings, and appro-
priate amounts of isotopic lysine and arginine were used to
optimize isotopic incorporation while minimizing the risk of
arginine to proline conversion. For the last 48 h of culture,
medium was replaced by serum-free medium, to reduce the
serum protein background, and for the last 24 h, cells were
stimulated with 20 ng/ml TNF-. At the end of the 7-d period,
conditioned medium from null and WT cultures was col-
lected, and the cells were harvested with cold PBS and 10 mM
ethylenediaminetetraacetic acid (EDTA). Supernatants from
null (light condition) and WT (heavy condition) were pooled
1:1 after bicinchoninic acid protein determination (BCA
Protein Assay; Pierce, Rockford, IL, USA). The pooled media
were incubated for 3 h at 4°C with wheat germ agglutinin
(WGA)-agarose beads to extract glycoproteins, and the glyco-
proteins were eluted by incubation with 0.5 M N-acetyl-d-
glucosamine. The glycoprotein mixture was concentrated on
a 3-kDa cutoff centrifugal filter (Amicon Ultra-4; Millipore) to
a final volume of 200 l. Urea was added to a final concen-
tration of 8 M (pH 8.5). Proteins were reduced by addition of
50 mM dithiothreitol (DTT; Amersham Biosciences, Piscat-
away, NJ, USA), followed by carbamidomethylation with 125
mM iodoacetamide (Sigma). Finally, the protein mixture was
purified by acetone–trichloroacetic acid precipitation (2D-
CleanUp kit; GE Healthcare, Piscataway, NJ, USA). For mi-
crosomal fraction analysis, cells were detached nonenzyma-
tically with cold PBS and 10 mM EDTA, and equal amounts of
cells from WT and MT1-MMP-null culture were pooled, left in
sucrose buffer, and cracked by sequential passes through a
25-gauge needle. The pooled fraction was spun to pellet
nuclei, and the supernatant was ultracentrifuged for 2 h at
55,000 rpm to separate cytosol from the microsomal fraction.
The microsomal pellet was resuspended in guadininium
chloride (6 M; Sigma). Supernatant and microsomal fractions
were resuspended in loading buffer, and proteins were sepa-
rated by 10% SDS-PAGE.
Mass spectrometry
After separation of glycoproteins by 10% SDS-PAGE, Coomassie-
stained gel was cut into 20 slices, and each one was in-gel
digested with modified porcine trypsin (Promega, Madison, WI,
USA). The digests were dried in a vacuum centrifuge, extracted
with formic acid solution, and analyzed on an Esquire Ultra IT
mass spectrometer (Bruker, Bremen, Germany) coupled to a
nano-HPLC system (Ultimate; LC Packings, Amsterdam, The
Netherlands). Peptide mixtures were first concentrated on a
300-mm i.d. and 1-mm PepMap nanotrapping column and then
loaded onto a 75-mm i.d., 15-cm PepMap nanoseparation col-
umn (LC Packings). Peptides were then eluted with an acetoni-
trile (ACN) gradient (0–60% B in 150 min, where B is 80%
ACN, 0.1% formic acid in water; flow rate 300 nl/min)
through a PicoTip emitter nanospray needle (New Objective,
Woburn, MA, USA) onto the nanospray ionization source of the
IT mass spectrometer. Tandem mass spectrometry (MS/MS)
fragmentation (1.9 s, 100–2800 m/z) was performed on three of
the most intense ions, as determined from a 1.2-s MS survey scan
(310–1500 m/z), using a dynamic exclusion time of 1.2 min for
precursor selection and excluding single-charged ions.
Protein identification and data analysis
Data were processed for protein identification and quantifi-
cation with Protein Scape 2.1 and WARP-LC 1.2 (Bruker), a
software platform that integrates processing of LC-MS run
data, protein identification through database search of
MS/MS spectra, and protein quantification based on the
integration of the chromatographic peaks of MS-extracted
ion chromatograms for each precursor. Proteins were identi-
fied using Mascot (Matrix Science, London, UK) to search
the SwissProt database, restricting the search to mouse pro-
teins. MS/MS spectra were searched with a precursor mass
tolerance of 1.5 Da, fragment tolerance of 0.5 Da, trypsin
specificity with a maximum of 1 missed cleavage, cysteine
carbamidomethylation as a fixed modification, and methio-
nine oxidation and the N-terminal and corresponding Lys
and Arg SILAC labels as variable modifications. A positive
identification criterion was set as an individual Mascot score
for each peptide MS/MS spectrum higher than the corre-
sponding homology threshold score. The false-positive rate
for Mascot protein identification was measured by searching
a randomized decoy database, as described previously (14),
and estimated to be 4%. For protein quantification, heavy/
light (H/L) ratios were calculated by averaging the measured
H/L ratio for the observed peptides, after discarding outliers.
For selected proteins of interest, quantitative data obtained from
Figure 1. Experimental approach to analyze proteolysis in
inflammation-activated ECs. Flow chart depicts experimental
design to identify and analyze the substrate collection of the
protease MT1-MMP in endothelial tip cells stimulated in
inflammatory conditions by quantitative proteomics and
bioinformatics.
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the automated Protein Scape software analysis were manually
reviewed. Further protein analysis was conducted with Protein
Knowledgebase UniProtKB (http://www.uniprot.org) and the
GeneCards database (http://www.genecards.org).
Bioinformatic data analysis with Babelomics
The Babelomics Web tool (http://www.babelomics.org) is a
freely available program suited to analysis of large-scale
experiments (microarrays, proteomics) with functional anno-
tation (15). The FatiGO module (16) was used for enrich-
ment analysis of selected proteins. This functional profiling
was performed by comparing two lists of genes, the first being
the genes encoding the proteins with an H/L ratio  1.5 in
the SILAC analysis unless otherwise stated, and the second
being the rest of the genome.
Overlap analysis
Overlap analysis and generation of Venn diagrams was per-
formed using an online application (http://www.pangloss.com/
seidel/Protocols/venn4.cgi).
Microarrays
Primary MLECs were treated with 20 ng/ml MCP-1 for 6 h.
The experiments were conducted using 1-color mouse whole-
genome oligomicroarrays (Applied Biosystems, Foster City,
CA, USA), and differential expression analyses was performed
using the linear modeling features of the Limma package
(Bioconductor; http://www.bioconductor.org/).
RT-PCR
For relative quantitation of expression, quantitative real-time
PCR analysis was performed using the AB7900 FAST 384
Detection System (Applied Biosystems), according to the
manufacturer’s instructions. Total cellular RNA was extracted
from cultured confluent MLECs using TRIzol reagent (Invit-
rogen), according to the manufacturer’s protocol, and quan-
tified using a Nanodrop ND-1000 (Thermo Fisher Scientific).
cDNA synthesis was performed with 1 g of total RNA using
an RNA synthesis kit (RNeasy Plus mini kit; Qiagen, Valencia,
CA, USA). Predesigned qPCR primers for mouse Mmp14,
Thbs1, Cyr61, Nid1, Sema3c, Tbp, and Hrpt1 were selected
from TaqMan Gene Expression Assay database (Applied
Biosystems). Relative quantitation of each target gene was
performed using comparative threshold multiplex PCR in
gene expression relative to the Tbp and Hrpt1. The data were
analyzed by the qBASE program (http://www.biogazelle.
com), obtaining the Ct of the amplification products.
For HUVECs, after RNA extraction, cDNA synthesis was
also performed with 1 g of total RNA using an RNA synthesis
kit (RNeasy Plus mini kit; Qiagen). cDNAs were subjected to
PCR amplification using the following primer pairs for hu-
man MT1-MMP: 5=-CGCTACGCCATCCAGGGTCTC-3= and
5=-CGGTCATCATCGGGCAGCACAAAA-3= (Isogen Biosci-
ence, Maarssen, The Netherlands). The PCR products were
visualized using ethidium bromide in 1% agarose gel.
Western blot
Cells were lysed in RIPA buffer containing protease inhibi-
tors, and culture supernatants (CSUPs) were collected and
enriched for glycoproteins as described above. Culture (50
g) supernatant and 20 g of total cell lysate were loaded and
separated by SDS-PAGE, and proteins were transferred to
nitrocellulose membrane; protein loading of CSUPs was
checked by Ponceau red staining of the blotted membrane.
Blots were incubated with anti-mouse or anti-human antibod-
ies overnight at 4°C, washed, and followed by secondary
HRP-conjugated antibody. Signal was detected by chemilumi-
nescence (Amersham ECL Signal Detection Reagent; GE
Healthcare) or enhanced chemiluminescence (Immobilon
Western, Chemiluminescent HRP Substrate; Millipore). Pro-
tein amount in the supernatants was quantified by densitom-
etry using ImageJ software (U.S. National Institutes of Health,
Bethesda, MD, USA). All the experiments were performed at
Figure 2. iMLECs respond similarly to pMLECs to TNF- stimulation. A) Morphology of pMLECs and iMLECs (left panels); levels of
PECAM-1 and MT1-MMP in pMLECs and iMLECs assessed by flow cytometry (middle panels) and immunostaining (right panels). B)
iMLECs were left untreated (0 h) or treated with 20 ng/ml of VEGF or TNF-, and the expression of the tip cell markers VEGFR2, Jag1,
Dll4, MT1-MMP, integrin3, and CXCR4 was analyzed at the cell surface by flow cytometry at 4, 24, and 48 h (n3). Left panel: hierarchical
schemes were obtained. Right panel: average percentages of positive population for each marker and condition were analyzed by the
high-content analysis software Genesis on normalization of data. C) Cell surface levels of ICAM-1 and VCAM-1 were assessed by flow
cytometry in pMLECs and iMLECs left untreated or treated with 20 ng/ml TNF- for 24h; D) TNF--stimulated pMLECs or iMLECs were
cultured in 2D or 3D conditions and stained with phalloidin or anti-PECAM-1 antibody, respectively.
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least in triplicate. Data are represented as means 	 se, and
unpaired Student’s t test was applied. Differences were con-
sidered significant at values of P  0.05.
Whole-mount retina staining
Eyes from postnatal day 6–8 (P6–P8) mice were removed and
fixed with 4% PFA at 4°C. Fixed retinas were flat-mounted and
blocked in 2% BSA, PBS, and 0.3% Triton X-100, followed by
overnight incubation with primary antibodies (anti-CYR61 or rat
anti-mouse NID1; Abcam) and isolectin IB4 (Sigma) to visualize
vasculature. The next day, retinas were extensively washed and
incubated with fluorescent-conjugated secondary antibodies.
Images were acquired with a Zeiss LSM700 confocal microscope
(Plan-Apochromat 631.4 Oil DIC M27), and images were
analyzed with ZEN software.
Transfection of small interfering RNA (siRNA)
Silencer siRNA constructs were purchased from Ambion
(Applied Biosystems). Specific oligonucleotide sequences tar-
geting human MT1-MMP were as follows: 5=-CAUCUGU-
GACGGGAACUUU-3= and 5=-GGAAUGAGGAUCUGAAUGG-3=
and a nontargeting siRNA control, which bears no homology
with relevant human genes. For siRNA transfection, cells were
seeded in 6-well plates at 2.5  105 cells/well and grown to
reach 60–70% confluence. The different amounts of siRNAs
and Oligofectamine reagent (Invitrogen) were diluted in
Opti-MEM I (Gibco; Invitrogen). The diluted siRNA-lipo-
some complex was added to cells and incubated for 4 h.
Following the transfection, fresh Opti-MEM I containing 30%
FBS was added, and cells were grown for 24 h. After that, cells
were rinsed with fresh M199 medium and cultured with
TNF- for 24 h for analysis.
RESULTS
Pericellular proteolysis in inflammation-induced
endothelial tip cells
To understand the link of pericellular proteolysis to
events relevant to capillary sprouting within the
Figure 3. SILAC in TNF--stimulated iMLECs. A) SILAC strategy for comparing the supernatant proteome of WT (MT1
/
) and
MT1-MMP-null (MT1/) iMLECs stimulated with TNF- (20 ng/ml) for 24 h. B) Peptide mass spectra for NID1 and TSP1, with
relative abundance of heavy and light labeled forms. C) Venn diagram showing proteins identified in both microsomal
proteome and supernatant glycoproteome. D) Normal distribution of H/L ratios of labeled peptides in microsomal proteome
and supernatant glycoproteome. Histogram shows the percentage of quantified proteins with H/L ratio  1, and 1.5- or
1.5-fold change in the microsomal proteome and the supernatant glycoproteome.
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TABLE 1. MT1-MMP degradome glycoproteins grouped in relation to their reported function in angiogenesis
Protein Name Function
H/L
ratio
Processed by MMP/ADAM
proteases
Angiogenesis related
ITPR1 Inositol 1,4,5-trisphosphate
receptor type 1
Calcium signaling pathway 18.04 
TSP2 Thrombospondin-2 Cell adhesion, ECM-receptor
interaction
8.68 ADAMTS1, MMP-2, MMP-9
MMP3 Stromelysin-1 Proteolysis 6.04 
LYOX Protein-lysine 6-oxidase Vasculature development,
extracellular matrix
organization
5.68 
PCOC1 Procollagen C-endopeptidase
enhancer 1
Proteolysis 5.53 MMP-2
TRPM2 Transient receptor potential
cation channel subfamily M
member 2
Ion transport 5.33 
EGFR Epidermal growth factor receptor Proliferation, protein
interaction
4.60 
SODE Extracellular superoxide
dismutase [Cu-Zn]
Oxygen metabolism 4.37 
PTX3 Pentraxin-related protein PTX3 Membrane organization,
endocytosis
4.20 MT1-MMP
PR2C2 Prolactin-2C2 Vascular development, cell
migration
4.14 
IC1 Plasma protease C1 inhibitor Immune response 3.70 
CNTN1 Contactin-1 Cell adhesion 3.67 
STC1 Stanniocalcin-1 Cellular ion homeostasis 3.59 MT1-MMP
SFRP1 Secreted frizzled-related protein 1 Development, differentiation 3.34 
TIMP1 Metalloproteinase inhibitor 1 Enzyme inhibitor activity 3.14 MMP-9
SEM3C Semaphorin-3C Vasculature development,
axon guidance
2.94 ADAMTS1, ADAMTS13
CO6A1 Collagen -1(VI) chain Cell adhesion 2.88 MMP-9, MMP-13
FBN1 Fibrillin-1 Metal ion binding 2.76 MT1-MMP, MMP-2, MMP-3,
MMP-7, MMP-9, MMP-12,
MMP-13
SLIT3 Slit homolog 3 protein Axon guidance 2.51 
LIF Leukemia inhibitory factor Receptor interaction, Jak-
STAT signaling pathway
2.37 MMP-9
CERU Ceruloplasmin Metal ion binding 2.29 
NID1 Nidogen-1 Cell adhesion, binding 2.26 MT1-MMP, ADAMTS1,
MMP-15, MMP-19
NGAL Neutrophil gelatinase-associated
lipocain
Response to virus 2.11 
MMP19 Matrix metalloproteinase-19 Vascular development,
differentiation
2.10 
CSF1 Macrophage colony-stimulating
factor 1
Cytokine-cytokine receptor
interaction
2.06 
GELS Gelsolin Cytoskeleton organization 2.06 MT1-MMP
TENA Tenascin Focal adhesion, ECM-receptor
interaction
2.04 MT1-MMP
FBLN2 Fibulin-2 Cell adhesion, matrix binding 2.04 
CO3 Complement C3 Immune response, ECM-
receptor interaction
1.96 MT1-MMP
CCL2 C-C motif chemokine 2 Proliferation. Immune
response, chemotaxis
1.86 
TIMP3 Metalloproteinase inhibitor 3 Enzyme inhibitory activity 1.80 
SLIT2 Slit homolog 2 protein Axon guidance, cell motion 1.73 
TSP1 Thrombospondin-1 Migration, cell adhesion,
immune response
1.68 MT1-MMP, ADAMTS1,
ADAMTS13
CYR61 Protein CYR61 Vasculature development,
adhesion, proliferation
1.68 MT1-MMP, 
CO3A1 Collagen -1(III) chain Vasculature development 1.67 MT1-MMP
TIMP2 Metalloproteinase inhibitor 2 Enzyme inhibitory activity 1.67 
(continued on next page)
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inflammatory context, we aimed at the identification
of the collection of MT1-MMP substrates in endothe-
lial tip cells induced by inflammatory stimuli. Figure 1
outlines the experimental design undertaken in this
study.
We first compared the behavior of primary MLECs
(pMLECs; ref. 17) vs. polyoma virus middle T-immor-
talized MLECs (iMLECs) from WT mice. iMLECs main-
tained EC morphology and similar expression of
PECAM-1 (95% in both iMLECs and pMLECs); MT1-
MMP cell surface levels were slightly higher in iMLECs
(Fig. 2A). To choose the appropriate inflammatory
stimulus for inducing endothelial tip cells, we evaluated
the effect of the main angiogenic factor VEGF and of
the proangiogenic cytokine TNF- on the expression
of the endothelial tip cell markers Jag1, VEGFR2, Dll4,
MT1-MMP, integrin 3, and CXCR4 in iMLECs (Fig.
2B). Hierarchical clustering analysis of these data per-
formed with Genesis (13) showed that TNF- regulated
the expression of the tip cell markers Dll4
MT1-MMP
and Jag1 
 CXCR4 but in a different manner than
VEGF, which mainly regulated Dll4 
 VEGFR2, as
reported previously (5). This analysis confirmed TNF-
as an inflammatory inducer of endothelial tip cells (4).
TNF- induced a similar increase of the endothelial
activation markers ICAM-1 and VCAM-1 and enhanced
MT1-MMP expression in both pMLECs and iMLECs
(Fig. 2C and not shown). TNF- stimulation also re-
sulted in similar elongation and induction of filopodia-
like membrane protrusions in both pMLECs and
iMLECs cultured in 2D or 3D conditions (Fig. 2D).
Since iMLECs responded similarly to TNF- and dis-
played higher MT1-MMP levels and proliferative capac-
ity than pMLECs, iMLECs were chosen as the proper
cellular model to perform quantitative proteomics of
MT1-MMP activity in inflammation-activated ECs.
SILAC identification of MT1-MMP degradome in
TNF--induced endothelial tip cells
Proteolysis by transmembrane proteases mainly affects
other transmembrane or secreted glycoproteins (18).
We therefore used SILAC to analyze lectin-enriched
glycoproteins in mixed supernatants of TNF--activated
WT (labeled with heavy amino acids) and MT1-MMP-
null iMLECs (labeled with light isotopes). Proteins in
mixed microsomal fractions were also analyzed; for
details of the SILAC procedure and examples of mass
spectra, see Fig. 3A, B and Materials and Methods.
Totals of 157 glycoproteins in conditioned medium and
797 proteins in the microsomal fraction were identified
and quantified (relative H/L ratios; complete list of proteins
available at http://www.cnic.es/doc/metaloproteinasas/
SILACproteinlist.pdf), with only 28 proteins found in
both proteomes (Fig. 3C). Interpretation of H/L ratios
in the supernatant glycoproteome is complex; a trans-
membrane protein or a matrix-bound secreted protein
shed by MT1-MMP will yield an H/L ratio 1, but
degraded secreted proteins might give H/L ratios 1
or 1 (ref. 8 and Supplemental Fig. S1). Peptide H/L
ratio frequencies show a gaussian distribution, with a
peak at log H/L  0, indicating equivalent labeling of
WT and MT1-MMP-null cells (Fig. 3D). Notably, lack of
MT1-MMP altered H/L ratios more in the supernatant
glycoproteome than in the microsomal proteome
(31.85 vs. 17.02% H/L1.5; Fig. 3D). Since H/L  1 is
the more likely outcome for protease action on the
supernatant glycoproteome (Supplemental Fig. S1), we
defined the MT1-MMP endothelial degradome as the
set of glycoproteins with H/L  1.5 (Fig. 3D). Catego-
rization of these identified proteins based on their
generic assigned function [Database for Annotation,
Visualization, and Integrated Discovery (DAVID); ref.
19) and PubMed search defined a group of angiogen-
TABLE 1. (continued)
Protein Name Function
H/L
ratio
Processed by MMP/ADAM
proteases
Unrelated to angiogenesis
KLRA4 Killer cell lectin-like receptor 4 Cell adhesion, NK mediated
cytotoxicity
14.90 
KPBB Phosphorylase b kinase
regulatory subunit 
Calcium signaling pathway 11.58 
SNED1 Sushi, nidogen and EGF-like
domain-containing protein 1
Cell adhesion 7.05 
CPXM1 Probable carboxypeptidase X1 Adhesion, proteolysis 6.12 
IGS10 Immunoglobulin superfamily
member 10
Receptor signaling 5.85 
GDN Glia-derived nexin Enzyme inhibitory activity,
developmental protein
1.95 
AEBP1 Adipocyte enhancer-binding
protein 1
Regulation of transcription,
cell adhesion
1.77 
LOXL3 Lysyl oxidase homolog 3 Oxidoreductase activity 1.73 
Information about reported protein function was obtained from the DAVID annotation database and PubMed (search keywords: protein
or gene name AND angiogenesis, vasculogenesis, endothelial cell migration, endothelial cell adhesion OR endothelial cell proliferation).
Reported processing of each protein by MT1-MMP or other MMP/ADAM proteases is indicated. Asterisks indicate proteins reported to be
processed by other protease families (serine proteases, etc.).
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esis-related proteins and a smaller group of unrelated
proteins (Table 1). Most identified proteins are exclu-
sively MT1-MMP substrates, including extracellular ma-
trix (ECM)/matricellular proteins (CYR61, FBLN2,
SNED1), and non-ECM proteins (PR2C2, SLIT2,
EGFR, SFRP1) (Table 1). Nonexclusive substrates in-
clude TSP1, NID1, and SEM3C.
Bioinformatic analysis reveals a combinatorial
MT1-MMP proteolytic program in angiogenesis
Gene Ontology (GO) enrichment analysis of the MT1-
MMP endothelial degradome (H/L1.5) was carried
out with the FatiGO module (16) in the open-source
bioinformatics Web tool Babelomics (15), which com-
pares genes of interest with the rest of the mouse
genome. This set of proteins was enriched in cellular
components of extracellular and matrix-related com-
partments (Fig. 4A) correlating with exposure of
these proteins to the protease. The MT1-MMP endo-
thelial degradome was also enriched in molecular
functions related to binding, particularly matrix
binding, and enzyme activity (Fig. 4B) and was
highly-enriched in biological processes (BPs) related
to cellular adhesion, motility, and chemotaxis, key
steps in endothelial tip cell function, and to vascula-
ture development (Fig. 4C).
Several substrates appeared in more than one BP
(Supplemental Table S1). Overlap analysis and Venn
diagrams of proteins annotated in these BPs revealed a
proteolytic program of 14 substrates, in which com-
bined rather than single substrate processing by MT1-
MMP would control key steps of the angiogenic re-
sponse, in particular cell motility, chemotaxis, cell
adhesion, and vasculature development (Fig. 4D). In
this combinatorial program, processing of TSP1 is
common to these 4 BPs; CYR61 processing is the
second branch point, excluding motility and steering
toward one of the other fates. Processing of TSP1 and
CYR61, combined with CCL2 and SLIT2, determines
chemotaxis. Within the MT1-MMP-combinatorial pro-
gram, adhesion and vasculature development would be
more closely related, with motility showing the least
overlap, being determined by combined processing of
TSP1, SEM3C, EGFR, PR2C2, and CSF1.
The SILAC-analyzed microsomal fraction lacked
most MT1-MMP substrates (Fig. 3C). However, the 24 h
of iMLEC TNF- stimulation is enough for transcrip-
Figure 4. GO terms (Babelomics
and FatiGO) reveal a combinato-
rial MT1-MMP proteolytic pro-
gram in angiogenesis. Identified
MT1-MMP substrates with H/L
1.5 were analyzed for GO terms.
A, B) Percentages of total identi-
fied GO cellular components and
molecular functions terms. C)
Logarithmic P values for enrich-
ment in GO BP terms. D) Overlap
analysis of identified MT1-MMP
substrates included in the four
general GO BPs relevant to angio-
genesis: cell motility, chemotaxis,
cell adhesion, and vasculature de-
velopment (Supplemental Table
S1). Venn diagram shows ub-
strates shared between BPs, indi-
cating combinatorial rather than
single processing of substrates.
Colored lines demark the four
GO BPs.
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tional regulation to occur, and genes encoding 4 of the
14 proteins in the combinatorial model (CO3A1,
FBLN2, protein-lysine 6-oxidase and MMP19) are
found up-regulated in MCP-1-stimulated WT but not
MT1-MMP-null pMLECs (Supplemental Table S2 and
Supplemental Fig. S2); thus, their H/L  1 in iMLEC
supernatant might partly reflect transcriptional regula-
tion.
Biological validation of MT1-MMP combinatorial
proteolysis in TNF--stimulated primary ECs
For further validation, we selected substrates within
each of the 4 main BPs. In vitro digestion assays had
previously shown the ability of MT1-MMP to cleave
TSP1, CYR61, and NID1 (20, 21), and we further
confirmed by in silico analysis that TSP1, CYR61, and
NID1 and also SEM3C contain putative MT1-MMP
cleavage sequences [R(F/K)-nonP-X(polar)-X(hydro-
phobic); ref. 22] at positions that predict the peptides
identified by SILAC (Supplemental Fig. S3).
Based on the SILAC analysis performed in CSUPs
and on the ability of the identified proteins TSP1,
CYR61, NID1, and SEM3C to bind the ECM and/or the
basement membrane, we next hypothesized that the
absence of MT1-MMP might affect cleavage of these
proteins from the ECM and therefore their release to
the supernatant and their cellular distribution. No
major differences were observed in mRNA and protein
levels of TSP1, CYR61, NID1, and SEM3C in total lysates
of WT and MT1-MMP-null pMLECs treated with TNF-
(24 h), pointing to similar abundance of these sub-
strates (Fig. 5A, B). In accordance with SILAC data,
lower levels of TSP1, NID1, and SEM3C were detected
in the supernatants of MT1-MMP-null MLECs, indicat-
ing that MT1-MMP proteolytic action releases TSP1,
NID1, and SEM3C from the ECM; consistent with
cleavage of NID1 at the N or C terminus, the molecular
mass of NID1 in supernatants from WT MLECs was
slightly smaller (Fig. 5A). Higher levels of CYR61 were,
however, found in supernatants from MT1-MMP-defi-
cient pMLECs, correlating with a more complex SILAC
peptide profile and pointing to an active processing of
the intact soluble form of CYR61 by MT1-MMP. Im-
paired processing in the absence of MT1-MMP led to
accumulation of TSP1, CYR61, NID1, and SEM3C in
Figure 5. Impaired processing of TSP1, CYR61, NID1, and SEM3C in MT1-MMP-null pMLECs. A) Bar charts show mRNA levels
of Thbs1, Cyr61, Nid1, and Sema3c in TNF--stimulated WT (MT1
/
) and null (MT1/) pMLECs analyzed by quantitative
PCR (n5). B) Immunoblots show detection of TSP1, CYR61, NID1, and SEM3C in total lysates (TL) and CSUPs of
TNF--stimulated WT (MT1
/
) and null (MT1/) pMLECs; bar charts show densitometric quantification of proteins in
supernatants (n3). C) Confocal microscopy analysis was performed in TNF--stimulated WT and MT1-MMP-null pMLECs
immunostained for TSP1, CYR61, NID1, or SEM3C; representative maximal projections are shown (n5). D) Confocal
immunofluorescence of TSP1, CYR61, NID1, or SEM3C in TNF--stimulated WT and null pMLECs grown in Ibidi chambers
covered by 3D-Matrigel; representative maximal projections are shown (n5). Insets: F-actin staining.
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pericellular clusters in contact with the matrix and/or
adhesion sites in MT1-MMP-null pMLECs (Fig. 5C).
TSP1, CYR61, NID1, and SEM3C have been related
to angiogenesis and vascular development (23–26), and
we therefore analyzed the effect of MT1-MMP-medi-
ated processing of these substrates in models better
mimicking vascular development, such as 3D-Matrigel
MLEC cultures and retina postnatal vascularization.
Although no major differences were observed in TSP1,
CYR61, NID1, and SEM3C signal along EC 3D tubes,
enrichment and/or pericellular clusters of these sub-
strates, especially of CYR61 and NID1, were observed
along the endothelial tip cells formed by MT1-MMP-
null pMLECs compared with WT (Fig. 5D). Accord-
ingly, accumulation of CYR61 and NID1 was also de-
tected along endothelial tip cells at the vascular front of
retinas from MT1-MMP-null neonates, but not their
WT counterparts, indicating that this newly identified
MT1-MMP processing axis is also relevant to in vivo
angiogenesis (Fig. 6). SEM3C and TSP1 were undetect-
able in the vasculature of mouse neonate retinas (not
shown).
We next investigated whether the MT1-MMP proteo-
lytic program identified in mouse ECs could be extend-
able to the human model. To this purpose, MT1-MMP
expression was inhibited by two independent siRNA
oligonucleotides in HUVECs; the efficiency of MT1-
MMP interference was 70% assessed by RT-PCR
and Western blot (Fig. 7A). TSP1, CYR61, NID1, and
SEM3C levels in total lysates from negative siRNA and
MT1-MMP-inhibited HUVECs were similar (not shown).
Lower levels of TSP1, CYR61, and NID1 were, however,
found in supernatants from MT1-MMP-inhibited com-
pared with negative siRNA-inhibited HUVECs, pointing
to decreased processing of these substrates in cells with
reduced levels of MT1-MMP (Fig. 7B). No differences
could be detected in supernatant levels of SEM3C (Fig.
7B). In a complementary approach, we compared sub-
strate subcellular distribution in MT1-MMP-inhibited
HUVECs. As shown in Fig. 7C, the subcellular distribu-
tion of TSP1, CYR61, NID1, and SEM3C was changed in
HUVECs with reduced expression of MT1-MMP; in
particular, CYR61 and SEM3C appeared more intense
and NID1 formed pericellular clusters in HUVECs with
lower expression of MT1-MMP. These data support the
hypothesis that the identified MT1-MMP combinatorial
program is also operative in human ECs.
DISCUSSION
SILAC performed in TNF--activated primary ECs has
provided an integrated view of the contribution of the
protease MT1-MMP to inflammatory capillary sprout-
ing through combinatorial cleavage of defined sets of
substrates and a mechanistic link between proteolytic
events and biological responses by ECs during angio-
genesis (Fig. 8).
Largely known for a long time, the link between
angiogenesis and inflammation is not well understood.
TNF- is an early tissue-damage signal for angiogenesis
and can induce morphological and molecular changes
compatible with induction of the endothelial tip cell
phenotype (4, 27); we confirmed this ability in iMLECs.
Endothelial tip cells are crucial to initiate an efficient
angiogenic response (5). The molecular fingerprint of
these tip cells has started to be elucidated by recent
transcriptomics analysis in retinal tip cells; matrix and
matrix-related genes as well as secreted proteins, such
as apelin, seemed to be particularly represented (2).
MT1-MMP gene was not found to be enriched in the
microarray assays performed in retinal tip cells (1, 2);
low levels of MT1-MMP might have been missed, or
MT1-MMP might be especially relevant in inflammatory
angiogenesis. We then hypothesized that identification
of MT1-MMP collection of substrates in inflammatory
tip cells will provide insights into their function and
into the link between proteolytic events and biological
responses during angiogenesis.
We have circumvented SILAC limited use in primary
cells by immortalizing mouse lung ECs, allowing us to
perform this approach for the first time in ECs ob-
tained from genetically modified mice. Our results
showed larger variations in the supernatant glycopro-
teome than in the microsomal proteome in the absence
of MT1-MMP; this highlights the power of performing
Figure 6. Accumulation of CYR61 and NID1 in
endothelial tip cells of retinas from MT1-MMP-
null mouse neonates. Whole-mount confocal
immunofluorescence of CYR61 or NID1 (red)
and isolectin B4 (green) in retinas of P6 WT
(MT1-MMP
/
) and null (MT1-MMP/)
mice; representative maximal projections are
shown (n4).
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SILAC in CSUPs for protease analysis, since catalytic
activity mostly affects secreted glycoproteins that are a
small fraction of the total proteome (28). A few SILAC
MT1-MMP substrates were identified previously by iso-
baric tags for relative and absolute quantitation-
(iTRAQ)/isotope-coded affinity tag (ICAT) in tumor
cells (29) and by differential gel electrophoresis
(DIGE) in human plasma incubated with the MT1-
MMP catalytic domain (30), supporting the robustness
of these techniques and pointing to MT1-MMP cleav-
age of a given substrate in different contexts. MT1-
MMP can affect angiogenesis through the processing of
matrix components (31) but also of transmembrane
molecules such as semaphorin 4D and endoglin (32,
33). Although we used SILAC to identify transmem-
brane glycoproteins, most of the identified MT1-MMP
substrates in inflammatory endothelial tip cells are
ECM and secreted proteins, in accordance with re-
ported retinal endothelial tip cell transcriptome (2),
and reinforcing the idea that matrix and its remodeling
are essential for modulating endothelial tip cells. Fur-
ther optimization of cell surface protein labeling (34)
might still expand MT1-MMP repertoire to include
endothelial transmembrane proteins. SILAC also pro-
vided insight into redundancy vs. specificity of substrate
cleavage by MMP/a disintegrin and metalloproteinase
(ADAM) family members. MT1-MMP mainly shares
substrates such as TSP1, NID1, and SEM3C with ADAM
with thrombospondin motifs 1 (ADAMTS1), suggesting
cooperation among these proteolytic pathways in an-
giogenesis. Accordingly, ADAMTS1 is up-regulated in
the transcriptome of retinal endothelial tip cells (2)
and down-regulated in MCP-1-stimulated MT1-MMP-
null pMLECs (Supplemental Table S2).
One of the most novel aspects of our study involves
the identification of a combinatorial proteolytic pro-
gram by overlap analysis and Venn diagram represen-
tation of the MT1-MMP endothelial degradome. In this
combinatorial program, TSP1 and/or CYR61 process-
ing is central to processes such as cell adhesion, motil-
ity, chemotaxis, and vasculature development (35).
Matricellular proteins, such as TSP1 and CYR61, are
interesting because they act as a bridge between cells
and the ECM, thus modulating cell behavior; therefore,
it is not unexpected that MT1-MMP action relies mainly
on processing of members of this family. Outcome of
angiogenesis will then depend on combined rather
than individual processing of substrates, whose frag-
ments might act in a competitive, synergistic, or sequen-
tial manner to fine-tune the angiogenic response; for
example, TSP1 and CYR61 share domains that directly
or indirectly bind integrin v3, an adhesion receptor
expressed in endothelial tip cells that cooperates with
endothelial MT1-MMP (2, 12). Overlap analysis also
showed that EC adhesion and vasculature development
are molecularly closer and that cell motility is the most
unique in the combination of processed substrates.
Increased abundance of a given protein in the super-
natant of WT cells might also be related to higher
expression of the protein. Although no major changes
were found in the microsomal fraction, 4 of the 14
genes encoding for proteins represented in the combi-
natorial proteolytic program were up-regulated in
MCP-1-stimulated pMLECs expressing MT1-MMP vs.
Figure 7. Impaired processing of TSP1, CYR61, NID1 and
SEM3C in MT1-MMP-inhibited human ECs. A) MT1-MMP
expression was inhibited by siRNA transfection of two differ-
ent MT1-MMP siRNA oligonucleotides (siMT1 #1 and siMT1
#2) or a negative siRNA (siNT) in HUVECs; MT1-MMP
mRNA and protein levels were assessed by RT-PCR and
Western blot, respectively. B) Immunoblots show detection of
TSP1, CYR61, NID1, and SEM3C in CSUPs of TNF--stimu-
lated HUVECs transfected with siNT or siMT1 #1 and #2; bar
charts show densitometric quantification of proteins in super-
natants (n4–6). C) Confocal microscopy analysis was per-
formed in TNF--stimulated MT1-MMP-siRNA HUVECs im-
munostained for MT1-MMP and TSP1, CYR61, NID1, or
SEM3C; representative maximal projections are shown
(n4); arrows indicate NID1 pericellular deposits.
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null cells; in particular, genes and proteins related to
cell adhesion and vasculature development, complex
responses that likely require activation of a given tran-
scriptional program. These data indicate a bimodal
contribution of MT1-MMP to inflammatory angiogen-
esis, including regulation of a restricted gene set but
dominated by combinatorial processing of defined
substrates related to motility, chemotaxis, and adhe-
sion.
We next biologically validated the processing of
selected substrates involved in the four main BPs, cell
motility, chemotaxis, cell adhesion, and vasculature
development (TSP1, CYR61, NID1, and SEM3C), whose
cleavage would likely occur within the same time frame,
cooperating in driving cellular responses leading to
inflammatory capillary sprouting. Conversely, as we
demonstrated in TNF--stimulated MT1-MMP-null
pMLECs, in the absence of MT1-MMP simultaneous
accumulation of these substrates in ECs might contrib-
ute to defective angiogenesis (10, 17). Whether the
proteolytic effect of MT1-MMP on the identified sub-
strates in cells is only due to direct processing or to
additional indirect effects, for instance, through the
combined action of other proteases, such as ADAMTS1,
remains to be defined. Notably, we have also confirmed
that the combinatorial program driven by MT1-MMP
identified in mouse cells is also acting in human ECs,
since decreasing MT1-MMP expression affects on the
processing and subcellular distribution of TSP1,
CYR61, NID1, and SEM3C in HUVECs; however,
milder effects were observed and were likely related to
the experimental approach and possibly to a different
repertoire of proteases expressed by human ECs. The
multidomain structure of matricellular proteins con-
tributes to their pleiotropic functions in angiogenesis.
Thus, TSP1 effects on angiogenesis largely depend on
whether it is soluble or matrix-bound (23); during
inflammatory angiogenesis, MT1-MMP could modulate
these angiogenic properties by cooperating with ADAMTS1
(35) or acting at a different cleavage site and possibly
affecting interaction with integrin v3. Matrix-bound
TSP1 accumulation in the absence of MT1-MMP might
contribute to the reduced angiogenesis reported in
MT1-MMP-null cells (11, 17). Moreover, accumulation
of CYR61/CCN1 might impair its induction of EC
adhesion, migration, and proliferation (24) likely by
altering its binding to integrins 61 or v3 (36).
CYR61 was also accumulated in MT1-MMP-deficient
retinas pointing to a key role for MT1-MMP in CYR61
processing in vivo and suggesting that loss of this
processing might mimic vascular defects observed in
the absence of CYR61 (24). However, since CYR61 can
play dual roles in physiological and pathological vascu-
larization in the retina (37), functional consequences
of CYR61 processing would deserve further investiga-
tion. Likewise, pericellular deposits of NID1, a protein
normally associated to laminin and fibulin at the base-
ment membrane (25) might confer basement mem-
brane-like “quiescence” signals hindering EC active
sprouting. We also observed NID1 deposition along the
filopodia of endothelial tip cells at the retinal vascular
front of MT1-MMP-null neonates in contrast to the
restricted distribution of NID1 to the posterior pole of
retinal tip cells in WT (2); this points to an active role
of MT1-MMP in NID1 processing during vascular
sprouting also in vivo. Finally, SEM3C processing by
ADAMTS1 can contribute to tumor cell migration (26),
and therefore we can envision that MT1-MMP-process-
ing of SEM3C might affect EC migration required for
capillary sprouting; in the absence of this processing,
impaired migration might lead to defective angiogene-
sis. In sum, TSP1, CYR61, NID1, and SEM3C can
modulate EC adhesive and migratory behavior through
complementary mechanisms including binding to in-
tegrins; the synergistic or competitive action of these
accumulated substrates in the absence of MT1-MMP
would impair migration and adhesion, yielding a more
quiescent endothelial state and defective angiogenesis
(ref. 17 and Fig. 8).
We have established a valid cell model system for
studying the mechanistic link between proteolysis and
biological responses in the context of inflammation-
activated ECs. SILAC-based proteomics identified the
supernatant glycoproteome as the main protein set
targeted by the protease MT1-MMP. Combination of
SILAC with bioinformatics revealed that the main con-
Figure 8. MT1-MMP combined substrate pro-
cessing in inflammatory angiogenesis. Com-
bined processing of TSP1, CYR61, NID1,
SEM3C, and other substrates by MT1-MMP has
a major effect on the regulation of EC adhesion
and motility and chemotaxis, ultimately leading
to vasculature development. This proteolytic
program is activated by inflammatory stimuli,
such as TNF-. The absence of MT1-MMP in
stimulated ECs results in impaired processing
and accumulation of the identified substrates
dampening the capillary sprouting process and
favoring quiescence of the vasculature.
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tribution of MT1-MMP to inflammatory angiogenesis is
a combinatorial processing of defined substrates im-
pacting early and rapid responses such as motility,
chemotaxis, and adhesion, finally leading to new vessel
formation. Profiling of MT1-MMP-processed substrates
in plasma could be used as a surrogate marker of
angiogenic activity in chronic inflammatory disease
such as rheumatoid arthritis, inflammatory bowel dis-
ease, psoriasis, and atherosclerosis, potentially identify-
ing patients who might benefit from antiangiogenic
therapies.
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